

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Express Mail No.	
DECLARATION FOR UTILITY, DESIGN, DIVISIONAL AND CONTINUATION-IN-PART PATENT APPLICATIONS (37 CFR 1.63)	Attorney Docket Number	41946/32854
	First Named Inventor	MEESE, Claus
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing	COMPLETE IF KNOWN	
<input type="checkbox"/> Supplemental Declaration Submitted	Application Number	To be assigned
<input type="checkbox"/> Declaration Submitted for Continuation-In-Part Filing	Filing Date	To be assigned
<input type="checkbox"/> Declaration Submitted for Divisional Filing	Group Art Unit	To be assigned
	Examiner Name	To be assigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-PHENYLPROPYLAMINES

(Title of the Invention)

the specification of which

is attached hereto

OR

was filed on (MM/DD/YYYY) 11/15/2000 as United States Application Number or PCT International

Application Number PCT/EP00/11309 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
DE 199 55 190.1	Germany	11/16/1999	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: SCHWARZ PHARMA AG

Application No./Patent No.: _____ Filed/Issue Date: _____

Entitled: STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

SCHWARZ PHARMA AG, a CORPORATION
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- 1. the assignee of the entire right, title, and interest; or
- 2. an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

- 1. From _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- 2. From _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- 3. From _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

2 May 2002
Date

ppa. K. D. Hommerich i.V. D.W. Schacht
Typed or printed name

[Signature]
Signature

Authorized Officer Assistant Manager
Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/01 (02-01)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	
Filing Date	
First Named Inventor	MEESE, Claus
Title	STABLE SALTS OF et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	41946/32854

I hereby appoint:

Practitioners at Customer Number **021888**

Practitioner(s) named below:



PATENT TRADEMARK OFFICE

Name	Registration Number


as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

The above-mentioned Customer Number

OR

Practitioners at Customer Number **021888**



PATENT TRADEMARK OFFICE

<input checked="" type="checkbox"/> Firm or Individual Name	Paul A. Lesko				
Address	Thompson Coburn LLP				
Address	One US Bank Plaza				
City	St. Louis	State	MO	Zip	63101
Country	USA				
Telephone	314-552-6443	Fax	314-552-7000		

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).


SIGNATURE of Applicant or Assignee of Record

Name	ppa. K.-D. Hommerich i.V. D.W. Schacht
Signature	
Date	2 May 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of _____ forms are submitted.

Burden Hour Statement This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: Customer Number or Bar Code Label 021888 OR Correspondence address below

Name Paul A. Lesko, Esq.

Address Thompson Coburn LLP
One U.S. Bank Plaza, Suite 3500

City St. Louis **State** MO **ZIP** 63101

Country USA **Telephone** 314-552-6443 **Fax** 314-552-7443

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR : A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Claus **Family Name or Surname** MEESE

Inventor's Signature *Claus D. Meese* **Date** 2 May 2002

Residence: City Monheim **State** DEX **Country** Germany **Citizenship** Germany

Mailing Address Kreuzbergerstrasse 50

City 40789 Monheim **State** **ZIP** **Country** GERMANY

NAME OF SECOND INVENTOR : A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) **Family Name or Surname**

Inventor's Signature **Date**

Residence: City **State** **Country** **Citizenship**

Mailing Address

City **State** **ZIP** **Country**

Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER
41946/32854

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

New **10/130274**

INTERNATIONAL APPLICATION NO.
PCT/EP00/11309

INTERNATIONAL FILING DATE
15 NOVEMBER 2000

PRIORITY DATE CLAIMED
16 NOVEMBER 1999

TITLE OF INVENTION

STABLE SALTS OF NOVEL DERIVATIVES OF 3,3,-DIPHENYLPROPYLAMINES

APPLICANT(S) FOR DO/EO/US

MEESE, Claus

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154 (d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
14. A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. A substitute specification.
16. A change of power of attorney and/or address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information: Certificate of Express Mailing;
Postcard
Statement Under 37 CFR 3.73(b)

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) New 10/130214	INTERNATIONAL APPLICATION NO. PCT/EP00/11309	ATTORNEY'S DOCKET NUMBER 41946/32854	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	860.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	30- 20 =	10	x \$18.00
Independent claims	10- 3 =	7	x \$80.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00
TOTAL OF ABOVE CALCULATIONS =			\$
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+	\$
SUBTOTAL =			\$
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
TOTAL NATIONAL FEE =			\$
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+	\$ 40.00
TOTAL FEES ENCLOSED =			\$ 1910.00
		Amount to be refunded:	\$
		charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1910.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>20-0823</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to review (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: Paul A. Lesko, Esq. Thompson Coburn LLP One U.S. Bank Plaza St. Louis, MO 63101 Telephone No.: 314.552.6443 Facsimile No.: 314.552.7000			
		_____ Signature	
		_____ Paul A. Lesko Name	
		_____ 45,364 Registration Number	

EXPRESS MAIL CERTIFICATE OF MAILING (37 CFR 1.10) Express Mail No. EL94273160	Docket No. 41946/32854
--	---------------------------

In Re Application Of:
 MEESE, Claus

Serial No. New 10/130274	Filing Date Herewith	Examiner Not assigned	Group Art Unit Not assigned
---------------------------------------	-------------------------	--------------------------	--------------------------------

Title:
 STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES


TO THE COMMISSIONER OF PATENTS AND TRADEMARKS

Transmitted herewith is:

- Transmittal Letter to the United States Designated/Elected Office (DE/EO/US) Concerning a Filing under 35 U.S.C. 371
- Declaration
- English Translation of the International Application as filed
- Preliminary Amendment
- Information Disclosure Statement
- Assignment and Recordation Form Cover Sheet
- Statement Under 37 CFR 3.73(b)
- Power of Attorney
- Check number 446161
- Postcard

Paul A. Lesko, Reg. No. 45,364
 Thompson Coburn LLP
 One U.S. Bank Plaza, Suite 3500
 St. Louis, Missouri 63101
 314-552-6443
 314-552-7000 FAX

Customer No. 021888

I certify that the document and fee is being deposited on <u>May 14, 2002</u> with the U.S. Postal Service as Express Mail under 37 C.F.R. 1.10 and is addressed to the Commissioner for Patents, Box PCT, Washington, D.C. 20231.
Express Mail No. EL942731601US
 _____ Signature of Person Mailing Correspondence
Paul A. Lesko _____ Typed or Printed Name of Person Mailing Correspondence

ISSUE SLIP STAPLE AREA (for additional cross-references)

ORIGINAL		CROSS REFERENCE(S)					
CLASS	SUBCLASS	CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)				
INTERNATIONAL CLASSIFICATION							
	/						
	/						
	/						
	/						
	/						

^ Continued on Issue Slip Inside File Jacket

INDEX OF CLAIMS

..... Rejected - (Through numeral) ... Canceled N Non-elected A Appeal
 Allowed + Restricted I Interference O Objected

Claim	Date
1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	

Claim	Date
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	
97	
98	
99	
100	

Claim	Date
101	
102	
103	
104	
105	
106	
107	
108	
109	
110	
111	
112	
113	
114	
115	
116	
117	
118	
119	
120	
121	
122	
123	
124	
125	
126	
127	
128	
129	
130	
131	
132	
133	
134	
135	
136	
137	
138	
139	
140	
141	
142	
143	
144	
145	
146	
147	
148	
149	
150	

If more than 150 claims or 9 actions staple additional sheet here

10/130214

FILED UNDER 35 U.S.C. 371

PATENT NUMBER and
ISSUE DATE

U.S. UTILITY Patent Application

APPL NUM 10130214	FILING DATE 05/14/2002	CLASS 514 510	SUBCLASS 539 19	CLASS 1014	EXAMINER TUCKER Z
----------------------	---------------------------	---------------------	-----------------------	---------------	----------------------

**APPLICANT'S: Meese Claus;

**CONTINUING DATA VERIFIED:
THIS APPLICATION IS A 371 OF PCT/EP00/11399 11/15/2000

** FOREIGN APPLICATIONS VERIFIED:
GERMANY 199 55 190.1 11/16/1999

PG-PUB	DO NOT PUBLISH <input type="checkbox"/>	RESCIND <input type="checkbox"/>	ATTORNEY DOCKET NO 41946/32854
Foreign priority claimed 35 USC 119 conditions met		<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> yes <input type="checkbox"/> no	
Verified and Acknowledged Examiners's initials			
TITLE : Stable salts of novel derivatives of 3,3-diphenylpropylamines			

U.S. DEPT. OF COMM. / PAT. & TM. PTO-436L (Rev. 12-94)

NOTICE OF ALLOWANCE MAILED		CLAIMS ALLOWED	
Assistant Examiner		Total Claims	Print Claim for 0.6
ISSUE FEE		DRAWING	
Amount Due	Date Paid	Sheets Drawn	Figs. Drawn
Primary Examiner		Print Fig.	
<input type="checkbox"/> TERMINAL DISCLAIMER		Application Examiner	
PREPARED FOR ISSUE			
WARNING: The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368, Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.			

FILED WITH: DISK (CRF) CD-ROM
(Attached in pocket on right inside flap)

SEARCH

Class	Sub.	Date	Exmr.
560	37, 18 42, 140, 142	} 7/30/02	ZT
564	319		

INTERFERENCE SEARCHED			
Class	Sub.	Date	Exmr.

SEARCH NOTES

(List databases searched. Attach search strategy inside.)

	Date	Exmr.
<u>PALM</u> INVENTOR NAME SEARCHED	7/30/03	ZT
<u>STN</u> REGISTRY, CAPLUS STRUCTURES SEARCHED IN REGISTRY + 'D W/ CAPLUS. (TRANSCRIPT ATTACHED)	7/30/03	ZT

PATENT APPLICATION FEE DETERMINATION RECORD
Effective October 1, 2001

Application or Docket Number

10/130214

CLAIMS AS FILED - PART I

SMALL ENTITY TYPE OR

OTHER THAN SMALL ENTITY

RATE	FEE
BASIC FEE	370.00
X\$ 9=	
X42=	
+140=	
TOTAL	

RATE	FEE
BASIC FEE	740.00 890
X\$18=	486
X84=	588
+280=	280
TOTAL	

	(Column 1)	(Column 2)
TOTAL CLAIMS	30	
FOR	NUMBER FILED	NUMBER EXTRA
TOTAL CHARGEABLE CLAIMS	47 minus 20=	* 27
INDEPENDENT CLAIMS	10 minus 3 =	* 7
MULTIPLE DEPENDENT CLAIM PRESENT <input checked="" type="checkbox"/>		

* If the difference in column 1 is less than zero, enter "0" in column 2

CLAIMS AS AMENDED - PART II

SMALL ENTITY OR

OTHER THAN SMALL ENTITY

RATE	ADDITIONAL FEE
X\$ 9=	
X42=	
+140=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X84=	
+280=	
TOTAL ADDIT. FEE	

AMENDMENT A	(Column 1)	(Column 2)	(Column 3)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus **	=
Independent	*	Minus ***	=
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

AMENDMENT B	(Column 1)	(Column 2)	(Column 3)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus **	=
Independent	*	Minus ***	=
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

RATE	ADDITIONAL FEE
X\$ 9=	
X42=	
+140=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X84=	
+280=	
TOTAL ADDIT. FEE	

AMENDMENT C	(Column 1)	(Column 2)	(Column 3)
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus **	=
Independent	*	Minus ***	=
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

RATE	ADDITIONAL FEE
X\$ 9=	
X42=	
+140=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X84=	
+280=	
TOTAL ADDIT. FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20."

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3."

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

PATENT APPLICATION SERIAL NO. 10/130214

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

05/22/2002 GFREY1 00000027 10130214

01 FC:970	890.00	OP
02 FC:966	180.00	OP
03 FC:964	588.00	OP

05/22/2002 GFREY1 00000027 10130214

05 FC:198	212.00	OP
----------------------	-------------------	---------------

Adjustment date: 08/02/2002 BCAMPBEL
05/22/2002 GFREY1 00000027 10130214
05 FC:198
-212.00 OP

08/02/2002 BCAMPBEL 00000005 200023 10130214

01 FC:968	60.00	CH	212.00	OP
02 FC:966	306.00	CH		

PTO-1556
(5/87)

MULTIPLE DEPENDENT CLAIM FEE CALCULATION SHEET
(FOR USE WITH FORM PTO-875)

SERIAL NO.

10/130214

FILING DATE

APPLICANT(S)

CLAIMS

	AS FILED		AFTER 1st AMENDMENT		AFTER 2nd AMENDMENT	
	IND.	DEP.	IND.	DEP.	IND.	DEP.
1	1		1			
2		1		1		
3		①		①		
4		1		1		
5		①		①		
6		①		①		
7		①		①		
8	1		1			
9		1		1		
10	1		1			
11		1		1		
12		4		4		
13		4		4		
14		4		4		
15		①		①		
16		①		①		
17		①		①		
18	1		1			
19	1		1			
20	1		1			
21		3		①		
22		3		3		
23	1		1			
24	1		1			
25	1		1			
26	1		1			
27		4		①		
28		4		4		
29		①		①		
30		4		4		
31						
32						
33						
34						
35						
36						
37						
38						
39						
40						
41						
42						
43						
44						
45						
46						
47						
48						
49						
50						
TOTAL IND.			10			
TOTAL DEP.			37			
TOTAL CLAIMS			47			

	☆		☆		☆	
	IND.	DEP.	IND.	DEP.	IND.	DEP.
51						
52						
53						
54						
55						
56						
57						
58						
59						
60						
61						
62						
63						
64						
65						
66						
67						
68						
69						
70						
71						
72						
73						
74						
75						
76						
77						
78						
79						
80						
81						
82						
83						
84						
85						
86						
87						
88						
89						
90						
91						
92						
93						
94						
95						
96						
97						
98						
99						
100						
TOTAL IND.						
TOTAL DEP.						
TOTAL CLAIMS						

* MAY BE USED FOR ADDITIONAL CLAIMS OR ADMENDMENTS

Patent Center
National Stage Processing
(703) 305-3391

#4/a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: MEESE, Claus et al.)	Examiner: To be assigned
)	
Application No.: To be assigned)	Group Art Unit: To be assigned
)	
Filed: Herewith)	
)	
Title: STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES)	Docket No.: 41946/32854
)	

Commissioner for Patents
Box PCT
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the filing fee and examination on the merits, kindly amend the above-identified patent application per the following instructions.

Kindly amend the specification at page one after the title and before the first line of text, by inserting at that point the following sentence --


a' This patent application claims the benefit of priority under 35 U.S.C. § 119 of German Patent Application No. 199 55 190.1, filed November 16, 1999. German Patent Application No. 199 55 190.1 is incorporated herein in its entirety by reference.--

The amendments to claims 18-21, 23-25, 27, and 28 are pursuant to an Article 34 amendment made to the PCT application on October 5, 2001.

IN THE CLAIMS

At page 56, amend claims 18-21, 23-25, 27, and 28 as follows:


18. (once amended) Compound of formula III



Formula III

in highly pure, crystalline and stable form.


19. (once amended) Compound of formula V



Formula V

in highly pure, crystalline and stable form.

20. (once amended) Compound of formula VI




Formula VI

in highly pure, crystalline and stable form.

21. (once amended) Use of a compound in accordance with claims 18 to 20 as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds of formula 1 in accordance with claim 1.


23. (once amended) Compound of formula 3



Formula 3

in highly pure, crystalline and stable form.


24. (once amended) Compound of formula 5



Formula 5

in highly pure, crystalline and stable form.


25. (once amended) Compound of formula 6



Formula 6

in highly pure, crystalline and stable form.

27. (once amended) Use of a compound in accordance with claims 23 to 26 as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds of formula 2 in accordance with claim 3.
28. (once amended) Use of a compound in accordance with claims 23 to 26 as an intermediate product in the manufacture of phenolic monoesters of general formula 1



in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl or unsubstituted or substituted phenyl.

Kindly consider this preliminary amendment and enter it into the record of this application. Attached is a clean copy of the claims. All correspondence should to be directed to Paul A. Lesko, Thompson Coburn LLP, One U.S. Bank Plaza, St. Louis, MO 63101, Telephone No.: 314.552.6443, Facsimile No.: 314.552.7000.

Respectfully submitted,



Paul A. Lesko
Registration No. 45,364
Thompson Coburn LLP
One U.S. Bank Plaza
St. Louis, MO 63101
Telephone: 314.552.6443
Facsimile: 314.552.7000


CLEAN COPY OF PARAGRAPH TO BE INSERTED INTO SPECIFICATION

-- This patent application claims the benefit of priority under 35 U.S.C. § 119 of German Patent Application No. 199 55 190.1, filed November 16, 1999. German Patent Application No. 199 55 190.1 is incorporated herein in its entirety by reference.--

Claims

18. Compound of formula III


a²



Formula III

in highly pure, crystalline and stable form.

19. Compound of formula V




Formula V

in highly pure, crystalline and stable form.

20. Compound of formula VI

Q²




Formula VI

in highly pure, crystalline and stable form.

21. Use of a compound in accordance with claims 18 to 20 as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds of formula 1 in accordance with claim 1.

23. Compound of formula 3

Q³




Formula 3

in highly pure, crystalline and stable form.

24. Compound of formula 5


a³



Formula 5

in highly pure, crystalline and stable form.

25. Compound of formula 6



Formula 6


in highly pure, crystalline and stable form.

a⁴

27. Use of a compound in accordance with claims 23 to 26 as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds of formula 2 in accordance with claim 3.

28. Use of a compound in accordance with claims 23 to 26 as an intermediate product in the manufacture of phenolic monoesters of general formula 1

Q 7




in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl or unsubstituted or substituted phenyl.

Figure 1

Reaction diagram 1

(i), (ii), (iii), (iv), (v) stand for: (i), LiAlH_4 , (ii), Raney nickel/ H_2 , (iii), $\text{Me}_2\text{CH}-\text{CoCl}$, Et_3N , (iv), fumaric acid, (v), hydrochloric acids; R stands for isopropyl (iPr)



1/p rts

-1-

SPECIFICATIONStable salts of novel derivatives of
3,3-diphenylpropylaminesms
a'


The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for manufacturing these and highly pure, stable, intermediate products.

From document PCT/EP99/03212 novel derivatives of 3,3-diphenylpropylamines are known.

These are valuable prodrugs for the treatment of urinary incontinence and other spasmodic complaints, which overcome the disadvantage of the active substances available to date, namely inadequate absorption of the active substance by biological membranes or the unfavourable metabolism of these.

Furthermore these novel prodrugs have improved pharmacokinetic characteristics compared with Oxybutynin and Tolterodin.

Preferred compounds from the group of these novel derivatives of 3,3-diphenylpropylamines are esters of aliphatic or aromatic carboxylic acids with the general formula A referred to below



Formula A

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl or unsubstituted or substituted phenyl. These can occur in their optical isomers form as racemic mixtures and in the form of their individual enantiomers.

Compounds with the structure of formula A do, however, have low solubility in water. This restricts their oral bioavailability.


Finally, monoesters of the structure, as shown in formula A, have a tendency towards intermolecular transesterification.

During long periods of storage, therefore, as the content of the compounds with the structure of general formula A drops an increase in diesters and free diol can be detected.

Basically salts of the compounds of general formula A can be obtained if solutions of the compounds of formula A (base component) are purified with solutions of acids in suitable solvents, but the salts obtained in the form of solid matter can prove to be altogether amorphous and/or hygroscopic and cannot be directly crystallized from the normal solvents either. Such salts have inadequate chemical stability to be galenically processed as valuable pharmaceutically active substances.

Surprisingly, it has now been found that the abovementioned disadvantages can be avoided if compounds with the structure of general formula A, once they have been prepared under a special reaction process, are converted with a physiologically compatible inorganic or organic acid with general formula H-X, in which X represents the respective

acid residue, into their respective salt with general formula I.




Formula I

The problem for the present invention is therefore to provide highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, that avoid the stated disadvantages and are well suited to use in pharmaceutical-technical formulations and can be processed into these.

A further problem for the present invention is to provide a method for manufacturing such highly pure, crystalline, stable compounds in the form of their salts, as well as highly pure, stable intermediate products.

The final problem for the invention is to provide a method for manufacturing the abovementioned compounds with which a high yield of the products of the process and the respective intermediate products can be obtained chemo- or regioselectively.

This problem is solved in that highly pure, crystalline, stable compounds of the 3,3-diphenylpropylamines in the form of their salts with general formula I are provided,



Formula I


in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

In accordance with a design of the invention the salts of general formula I can contain the respective acid residue X⁻ of the acids mentioned below:

hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetyl-glycine), phloretinic acid

(3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.

In accordance with a further design form of the invention R-configured compounds with general formula 2 are provided



Formula 2

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

In accordance with an advantageous design form of the invention the compounds in the form of their salts of general formula 2 can contain the respective acid residue X⁻ of the acids mentioned below:

hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-

glycine), aceturic acid (N-aetylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.

Preferred compounds of the present invention are the salts

- R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate
- and
- R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate.

Furthermore, compounds are preferred in which R stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-(1-cyclopropyl-methanoyloxy)-phenyl, 4-(1-cyclobutyl-methanoyloxy)-phenyl, 4-(1-cyclohexyl-methanoyloxy)-phenyl or 4-(2,2-dimethyl-propanoyloxy)-phenyl and X⁻ denotes chloride.

Particular preference is for [(R)-3-(2-{1-[4-(1-cyclopropyl-methanoyloxy)-phenyl]-methanoyloxy}-5-hydroxymethyl-phenyl)-3-phenylpropyl]-diisopropyl-ammonium chloride, [(R)-3-(2-{1-[4-(1-cyclobutyl-methanoyloxy)-phenyl]-methanoyloxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-ammonium chloride, [(R)-3-(2-{1-[4-(1-cyclohexyl-methanoyloxy)-phenyl]-methanoyloxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-ammonium chloride, [(R)-3-(2-{1-[4-(2,2-dimethyl-propanoyloxy)-phenyl]-methanoyloxy}-5-hydroxymethyl-phenyl)-3-phenyl-propyl]-diisopropyl-ammonium chloride, [(R)-3-[2-(1-cyclopropyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl]-diisopropyl-ammonium chloride, [(R)-3-[2-(1-cyclobutyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-

propyl}-diisopropyl-ammonium chloride, {(R)-3-[2-(1-cyclopentyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl}-diisopropyl-ammonium chloride and {(R)-3-[2-(1-cyclohexyl-methanoyloxy)-5-hydroxymethyl-phenyl]-3-phenyl-propyl}-diisopropyl-ammonium chloride.


In the compounds of the present invention the expression "alkyl" preferably stands for a straight-chain or branched-chain hydrogen group with between 1 and 6 C-atoms. Special preference is for methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl and hexyl. The expression "cycloalkyl" designates cyclical hydrogen groups, that have between 3 and 10 hydrogen atoms, that may also contain suitable substitutes in place of the hydrogen atoms.

The expression "phenyl" designates a -C₆H₅-group that may be substituted or unsubstituted. Suitable substitutes can be, for example, alkyl, alkoxy, halogen, nitro and amine. The expression "alkoxy" has, with respect to the alkyl component, the same meaning as already given above for "alkyl". Suitable halogens are fluorine, chlorine, bromine and iodine atoms

The present invention also includes methods for manufacturing the compounds in accordance with the invention of general formula I as well as valuable intermediate products.

The method is characterised by chemo- and regioselectivity.

Compounds of general formula I




Formula I

X⁻


in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid, are manufactured in that

a) a compound of formula III



Formula III


is split with a hydrogenation agent to form a compound of formula V



Formula V


whereupon

- b) the compound of formula V so obtained is converted with a reducing agent, in order to give a compound of formula VI




which

- c) is converted with an acylation agent, in order to obtain a compound of formula A



in which R has the significance stated above, which

- d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula I




Formula I

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, unsubstituted or substituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

In accordance with the invention, for the manufacture of the compounds of general formula I hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetylglycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.

In accordance with an advantageous further development of the invention a method for the manufacture of R-configured compounds of the general formula 2 is described,




Formula 2

X⁻


in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid, in that

a) a compound of formula 3



Formula 3


is split with a hydrogenation agent to form a compound of formula 5



Formula 5


whereupon

- b) the compound of formula 5 so obtained is converted with a reducing agent, in order to give a compound of formula 6




which

- c) is converted with an acylation agent, in order to obtain a compound of formula 1



in which R has the significance stated above, which

- d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula 2



Formula 2


in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, unsubstituted or substituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

Advantageously in order to obtain compounds of general formula 2, in accordance with the method hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetyl-glycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.

Particular advantageously, on the basis of the crystalline R-(-)-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)benzoic acid methyl ester, the highly pure,

crystalline intermediate product *R*-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester is prepared, which is reduced to *R*(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol, is finally acylated in a suitable manner and is then converted with a physiologically compatible inorganic or organic acid under spontaneous crystallisation to the respective highly pure, crystalline, stable salt.

Depending on the acid chloride used, compounds of general formula 1 are obtained,



Formula 1

in which R denotes C₁-C₆-alkyl, in particular isopropyl, C₃-C₁₀-cycloalkyl or unsubstituted or substituted phenyl.

In order to obtain the compounds in accordance with the invention in the form of their salts the special reaction process via particular intermediate stages and individually identifiable intermediate products is crucial.

This is explained using reaction diagram 1 (see Figure 1), in which the conversions with *R*-configured compounds are described, but without this being restrictive.

In this:

- 3 = R-(-)-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-benzoic acid-methyl ester
- 4 = R-(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanol
- 5 = R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester
- 6 = R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol
- 1 = R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl-isobutyrate ester
- 2a = R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methylphenyl-isobutyrate ester hydrogen fumarate
- 2b = R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl-isobutyrate ester hydrochloride hydrate

In accordance with the reaction process explained in the embodiment the preliminary stage 3 (R-(-)-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-benzoic acid-methylester) is prepared in crystalline, pure form.

Using normal methods - such as BBr_3 , AlCl_3 - but preferably by means of hydrogen gas via Raney nickel in methanol as the solvent at room temperature (RT), preliminary stage 3 is split into 5 (R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methylester. This develops in highly pure, crystalline form (melting point 143.7 °C).

Finally, using a suitable reducing agent - such as $\text{NaBH}_4/\text{EtOH}$ - preferably LiAlH_4 5 is reduced into an inert solvent at low

temperature (-78°C to + 10°C) and the compound 6 (*R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol) is obtained. The compound 6 is obtained in a highly pure state and can be crystallised from a suitable solvent such as ethyl acetate. The colourless, compact grained material has a melting point of 102.3°C. This is surprising in that the compound 6 in the state of the art is described as an amorphous solid.

Compound 6 is now acylated with very good yield and regio- and chemoselectivity, into a phenolic ester. This reaction is performed at RT or low temperatures with an equivalent acid chloride in the presence of a base in a suitable solvent. Suitable solvents are ethyl acetate, dichloromethane, tetrahydrofuran, acetonitrile or toluene.

The reaction is preferably performed with isobutyrylchloride as the acid chloride and triethylamine as the base at the abovementioned temperatures. The 1 (*R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester) then obtained, occurs with such purity that with solutions of the fumaric acid in suitable solvents spontaneous crystallisation starts with the formation of the hydrogen fumarate salt 2a.

This salt has a high melting point of 103°C, is stable at RT, is non-hygroscopic and does not contain crystalline agents. It can be recrystallised as often as desired.

If instead of fumaric acid anhydrous hydrochloric acid is used - for example as an ethereal solution - salt formation also takes place with the crystalline product 2b (*R*-(+)-2-(3-

diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl-isobutyrate ester hydrochloride hydrate being obtained.

Following a further recrystallisation the product 2b has a melting point range of 97 - 106°C.

Finally the product 2b can particularly advantageously be obtained by the following variants of the inverse reaction process, starting with the compound 6 of reaction diagram 1. The product 2b can thus be obtained without the addition of an external acid-intercepting base, as explained in the following.


Solutions of 6 (*R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol) are dripped into solutions of isobutyrate chloride, so that under suitable polarity conditions the anhydrous product 2b rapidly crystallises out. 2b is very hygroscopic.

If the abovementioned reaction is carried out in a humid solvent, that contains at least one mole equivalent of water, a stable and crystalline, hydrate-containing product 2b is obtained, that has the abovementioned melting characteristics.

The compounds in accordance with the invention of general formulae 1 and 2 are suited to bulk material.


Of particular advantage are the highly pure compounds of general formulas III, V, VI, 3, 5, 6 and 7 which can be obtained.

Compound of formula III




Formula III

Compound of formula V




Formula V

Compound of formula VI



Formula VI

Compound of formula 7



[(R)-3-(2-{1-[4-(2,2-dimethyl-propanoyloxy)-phenyl]-methane-oxo}-5-{1-[4-(2,2-dimethyl-propanoyloxy)-phenyl]-methane-oxymethyl}-phenyl)-3-phenyl-propyl]-diisopropyl-ammonium-chloride

The abovementioned compounds III, V, VI, 3, 5, 6 and 7 are particularly suited to use in each case as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds.

Of particular advantage are compounds for use as an intermediate product in the manufacture of R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate.

Finally, the method can be carried out in a particularly advantageous way by converting a compound of general formula 6 (see reaction diagram 1) with an equivalent isobutyryl

chloride in the presence of triethylamine using one of the respective solvents ethylacetate, dichloromethane, tetrahydrofurane, acetonitrile or toluene regio- and chemoselectively into R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester.

In accordance with the invention R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester is particularly suited to conversion with fumaric acid or hydrochloric acid with the formation of the respective salt.

The following embodiments explain the invention.

Experimental

I. General

All compounds have been fully characterised by ^1H and ^{13}C NMR-spectroscopy (Bruker DPX 200). The stated chemical displacements in the ^{13}C -NMR-spectra (50 MHz, ppm values stated) refer to the solvent resonances of CDCl_3 (77.10 ppm). ^1H NMR data (CDCl_3 ; 200 MHz, ppm) refer to internal tetramethylsilane).

Thin layer chromatography (DC, R_f given) was carried out on 5x10 cm E. Merck silica gel films (60F254), and the stains were revealed by fluorescence erasure or by spraying with alkaline potassium permanganate solution.

Absorbent systems were: (1), n-hexane / acetone / triethylamine (70/20/10, v/v-%); (2), toluene / acetone / methanol / acetic acid (70/5/20/5, v/v-%).

The optical rotations were measured at a wavelength of 589.3 nm (sodium D-line), at room temperature using ethanol as a solvent (apparatus: Perkin Elmer Polarimeter Type 241), melting points (in °C) are uncorrected and were determined on the Mettler FP apparatus, or by differential thermoanalysis (DSC) on the Perkin Elmer Model DSC7, using "Pyris" evaluation software.

UV/VIS measurements were carried out on the spectrophotometer model Lambda 7 (Perkin-Elmer) with a layer thickness of 1 cm. The specific absorption stated is for a 1% solution ($A^{1\%}_{1\text{ cm}}$).

IR spectra were recorded on a Perkin-Elmer FTIR spectrometer Series 1610 (resolution 4 cm^{-1}).

Gas chromatography mass spectrometry (GC-MS, m/z values and relative intensity with reference to the base ion (%)) was carried out with a Finnigan TSQ 700 Triple Mass Spectrometer in positive (P-CI) or negative (N-CI) chemical ionisation measurement mode with methane or ammonium as a reactant gas or via electron impact ionisation. Hydroxy compounds were measured as trimethylsilylether-derivatives.


Coupled liquid chromatography-mass spectrometry (LC-MS): Waters Integrity System, Thermabeam Mass Detector (EI, 70 eV), m/z-values and relative intensity (%) are given over a quantity range of 50-500 a.m.u.

II. Embodiments

The Arabic numerals in brackets (3), (4), (5), (6) refer to the identical designations in reaction diagram 1.

1. Preparation of

R-(-)-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-benzoic acid methylester (3)



A solution of *R*-(-)-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-benzoic acid hydrochloride (2.30 kg, 4.77 Mol) in 26.4 litres of methanol and 0.25 litre of concentrated sulphuric acid is heated for 16 hours with recycling. Then a third of the solvent is distilled off, cooled and under agitation mixed with 5 kg ice and 2.5 litres 25% aqueous sodium carbonate solution. The deposit is first extracted with 15 litres and then again with 5 litres of dichloromethane. The organic phases are purified and concentrated on the rotary evaporator until dry. 1.99 kg (90.7% of theoretical) dark yellow oil with a purity of approximately 90% (DC, NMR) are obtained.

DC (1): 0.58


^{13}C -NMR (CDCl_3): 20.55, 20.65, 36.83, 41.84, 43.83, 51.82, 70.12, 111.09, 122.46, 125.28, 127.49, 128.02, 128.35, 128.50, 129.22, 129.49, 133.20, 136.39, 144.51, 159.87, 167.09.

Recrystallisation

69.0 oily raw material is dissolved in 150 ml boiling methanol. Following the addition of 15 ml distilled water it is left at 0°C , whereupon colourless crystals precipitate. These are filtered off, washed with a little cold methanol and vacuum-dried. Yield: 41.8 g (60.6 % of theoretical) colourless crystals, melting point 89.8°C ; $[\text{I}]_{\text{D}}^{20} = -30.7$ ($c = 1.0$, ethanol).

2. Preparation of

R-(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanol (4)



Raw product (3) (28 g) is dissolved in 230 ml pure diethylether and under agitation is dripped into a suspension of 1.8 g lithium-aluminium hydride in diethylether (140 ml). After 18 hours of agitation at room temperature, 4.7 ml of water are added in drop form. The organic phase is separated


off, dried with anhydrous sodium sulphate, filtered and concentrated on the rotary evaporator until dry. 26 g (98.9% of theoretical) *R*-(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanol (4) are obtained as a colourless oil.

DC (2): 0.32; $[I]_D^{20} = + 6.3$ ($c = 1.0$, ethanol).

^{13}C -NMR (CDCl_3): 20.53, 20.61, 36.87, 41.65, 44.14, 48.82, 65.12, 70.09, 111.80, 125.77, 125.97, 126.94, 127.55, 128.08, 128.37, 128.44, 133.27, 134.05, 134.27, 137.21, 144.84.

3. Preparation of

R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester (5)



To an agitated suspension of 5g Raney nickel (washed with water, then with methanol) in 200 ml methanol, 10 g (21.8 mmol) *R*-(-)-4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-benzoic acid methyl ester (3) are added. Following brief heating, in order to dissolve all (3) completely, the apparatus is placed under a hydrogen gas atmosphere. After three hours of agitation at normal pressure and room temperature, the thin layer chromatography demonstrates

complete conversion. The deposit is rinsed with nitrogen gas and following addition of some active charcoal is filtered. Following concentration of the methanolic solution on the rotary evaporator 6.0 g (75% of theoretical) *R*-(-)-3-(3-diisopropylaminophenyl-propyl)-4-hydroxy-benzoic acid methyl ester (5) remains in the form of colourless crystals with a purity of 99.6 % (HPLC).


Melting point 143.7 °C; DSC 144.7°C

$[I]_D^{20} = -26.6$ ($c = 0.93$, ethanol).

^{13}C -NMR (CDCl_3): 18.74, 19.21, 19.62, 33.12, 39.68, 42.36, 48.64, 51.42, 117.99, 120.32, 126.23, 127.81, 128.85, 129.39, 130.26, 132.21, 144.06, 162.43, 167.35.

4. Preparation of

R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (6)



a) Starting from the intermediate stage (4), *R*-(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanol

R-(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanol (19.7 g, 45.7 mmol) are dissolved in 220 ml methanol and Raney nickel (5 g). The apparatus is rinsed with hydrogen gas and the deposit is agitated for two days at room

temperature. Following the addition of a further 5 g Raney nickel, agitation for a further two days at room temperature takes place under a hydrogen gas atmosphere, followed by filtration off from the catalyser and concentration until dry on the rotary evaporator. The oily, pale yellow residue is dissolved in 100 ml diethylether, washed twice with 100 ml water each time, dried via sodium sulphate, filtered and concentrated until dry. 14.1 g (90.4% of theoretical) R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol are obtained in the form of a cream-coloured, amorphous solid. For recrystallisation see under c).

b) Starting from the intermediate stage (5); R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester

A solution of 370 mg (1.0 mmol) R-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester in 20 ml anhydrous tetrahydrofurane is slowly and at room temperature dropped into an agitated mixture of dried tetrahydrofurane (10 ml) and a 1M solution of lithium-aluminium hydride in tetrahydrofurane (3 ml) (under a nitrogen protective gas atmosphere). Excess hydride is decomposed by the dropped addition of a saturated sodium carbonate solution. Following separation of the organic phase this is concentrated on the rotary evaporator and then dried in the high-vacuum. 274 mg (74% of theoretical) pale yellow oil is obtained, that slowly solidifies into an amorphous mass.

c) Recrystallisation:

Raw product 6 (1.0 g) is dissolved in ethyl acetate and again concentrated on the rotary evaporator. The diol released in

this way from foreign solvents (diethyl ether or tetrahydrofuran, see above) has 1.5 ml ethyl acetate added with slight heating. Agitation takes place until a clear solution results, followed by cooling at room temperature and addition of a few seed crystals. These are obtained by purifying raw 6 via HPLC, collecting the main fraction, concentrating this and drying the residue for a number of hours in the high-vacuum. Once clear crystallisation has definitely started, it is left at - 10°C. The crystals are sucked off in the cold and dried in the vacuum. Colourless crystals with a yield of 84% are obtained.

Melting point 102.3 °C


DC (1): 0.57

$[I]_D^{20} = +21.3$ (c = 1.0, ethanol).

$^{13}\text{C-NMR}$ (CDCl_3): 19.58, 19.96, 33.30, 39.52, 42.10, 48.00, 65.40, 118.58, 126.31, 126.57, 127.16, 127.54, 128.57, 132.63, 132.83, 144.55, 155.52.

5. Preparation of

R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenolisobutyrate ester (1)




A solution of *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (6) (65.0 g, 190.3 mmol) and triethylamine (20.4 g, 201.7 mmol) in 750 ml dichloromethane has a solution of isobutyrate chloride (23.4 g, 201.7 mmol) in 250 ml dichloromethane added under agitation and cooling. Following addition agitation takes place for a further 15 minutes at 0°C, then for 30 minutes at room temperature and then one after another washing with water (250 ml) and 5% aqueous sodium hydrogen carbonate solution. The organic phase is separated and concentrated on the rotary evaporator until dry. The ester *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester is obtained as a colourless, viscous oil; yield: 77.1 g (98.4 % of theoretical).

DC (1): 0.26; $[I]_D^{22} = + 2.7$ (c = 1.0, ethanol).

^{13}C -NMR (CDCl_3): 19.01, 19.95, 20.59, 21.12, 34.28, 36.89, 41.88, 42.32, 43.90, 48.78, 64.68, 122.57, 125.59, 126.16, 126.86, 127.96, 128.54, 136.88, 138.82, 143.92, 147.90, 175.96.

6. Preparation of

R-(+)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate.



A solution of 41.87 g (102 mmol) R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester in 90 ml 2-butanone has fumaric acid (11.81 g, 102 mmol) added while heating. Following dissolution of the acid, cyclohexane (20-30 ml) is slowly added under agitation until the onset of turbidity. The colourless, homogenous deposit is initially left for 18 hours at room temperature, and then for several hours at 0°C. The colourless crystals that have precipitated are sucked off, washed with a little cyclohexane/2-butanone (90:10, vol.-%) and dried in the vacuum at 30°C. 44.6 g (83.1 % of theoretical) hydrogen furate salt of R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester in the form of colourless flakes are obtained.

Melting point 98.8°C, a second crystallisation from the same solvent mixture provides a product with a melting point of 103°C.

$[\alpha]_D^{20} = +6.0$ (c = 1.0, ethanol).

Elementary analysis: Calculated for $C_{30}H_{41}NO_7$ (molecular weight 527.66) C 68.29 %, H 7.83 %, N 2.65 %, O 21.2 %; found C 68.29 %, H 7.90 %, N 2.72 %, O 21.0 %.

UV/VIS at Σ in nm ($A^{1\%}_{1\text{cm}}$): 191 (1306), 193 (1305), 200 (1143), 220 (456).

IR: 3380, 2978, 2939, 2878, 2692, 2514, 1756, 1702, 1680, 1618, 1496, 1468, 1226, 1040, 1019, 806,


$^1\text{H-NMR}$ (CDCl_3): 1.198, 1.285, 1.287 (CH_3); 2.541 (CHC=O); 3.589 (NCH); 4.585 (CH_2OH); 6.832 ($=\text{CH}$, fumarate); 6.84-7.62 (aryl, = CH).

$^{13}\text{C-NMR}$ (CDCl_3): 17.79, 18.95, 19.16 (CH_3); 31.63 (CHCH_2); 34.09 (CH-C=O); 41.87 (CHCH_2); 45.83 (NCH_2); 54.29 (NCH); 63.78 (OCH_2); 122.23, 126.48, 126.77, 127.56, 140.46, 140.52, 142.35, 147.54 (Aryl CH); 135.54 ($=\text{CH}$, fumarate); 170.48 (C=O , fumarate); 175.62 (i-Pr-C=O).

MS in the direct inlet, m/z (%): 411 (1), 396 (9), 380 (1), 223 (2), 165 (2), 114 (100), 98 (4), 91 (3), 84 (3), 72 (10), 56 (7).

7. Preparation of

R-(+)-2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate



A solution of *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester (8.54 g, 25.0 mmol) in 50 ml dichloromethane is slowly dropped at 0°C into an agitated solution of isobutyrate chloride (2.66 g, 25.0 mmol) in 100 ml dichloromethane. After an hour the cooling is


removed and re-agitation takes place for an additional hour. Following the drawing off of the volatile components in the vacuum on the rotary evaporator a colourless, amorphous-solid foam remains. This residue is dissolved in acetone (17 ml), with 0.45 to 0.50 g water and diethyl ether is added (approx. 20 - 25 ml) until there is a definite onset of turbidity. Following brief treatment with ultrasound crystallisation starts spontaneously and under agitation a further 80 ml of diethyl ether are slowly added. The precipitated colourless crystals are sucked off and dried overnight in the vacuum via phosphorous pentoxide. 10.5 g (93.7 % of theoretical) colourless crystalline *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate with a purity of 97.0% (HPLC) are obtained.

Melting point 97.1 °C.

$[I]_D^{20} = + 4.3$ ($c = 1.03$, ethanol)

^{13}C -NMR (CDCl_3): 16.94, 17.35, 18.24, 18.40, 18.87, 19.05, 31.20, 33.99, 41.64, 45.41, 54.18, 54.42, 63.83, 122.25, 126.50, 126.70, 126.96, 127.34, 128.60, 133.80, 140.55, 142.17, 147.68, 175.79.

8. Phenolic monoester



General work specification for the manufacture of phenolic monoesters

Into a solution of 120.3 mg (0.352 mmol) R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxyphenol (6) in 5 ml dichloromethane, under agitation at 0°C, a solution of acid chloride (0.352 mmol) in 2 ml dichloromethane is dropped. Then triethylamine-dichloromethane (49.1µl/0.353 mmol-2 ml) is added. After 18 hours at room temperature the thin layer chromatography shows that conversion is complete. The deposit is washed successively with 5 ml water, aqueous 0.1N-hydrochloric acid, 5 ml 5% aqueous sodium-hydrogen carbonate solution, 5 ml water, dried via sodium sulphate and following filtration concentrated until dry. Then it is dried in the high-vacuum until constant weight.

The following compounds are, by way of example, manufactured using this method:



R-(+)-3-methylbutyric acid-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl-ester

Colourless oil with 70% yield and >95% purity (NMR).

¹³C-NMR (CDCl₃): 20.45, 20.59, 22.54, 25.70, 36.74, 42.18, 43.27, 43.96, 48.90, 64.67, 122.66, 125.60, 126.20, 126.79, 127.95, 128.37, 136.83, 138.86, 143.83, 147.82, 171.37.

DC (1): 0.76.

R = $\text{CH}_2\text{C}(\text{CH}_3)_3$

R-(+)-3,3-dimethylbutyric acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester, free base

Colourless oil with 69.7% yield and >95% purity (NMR).

^{13}C -NMR (CDCl_3): 20.40, 20.53, 29.73, 30.99, 36.62, 42.17, 44.01, 47.60, 49.01, 64.65, 122.64, 125.60, 126.20, 126.80, 127.96, 128.36, 136.85, 138.90, 143.80, 147.82, 170.55.

DC (1): 0.75.

R = $(\text{CH}_3)_3\text{C}$

R-(+)-3-pivalic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester

hydrochloride.

Colourless crystals, melting point 165-6 °C.

^{13}C -NMR (DMSO-d_6 = 39.7 ppm): 16.52, 16.68, 17.98, 18.11, 26.87, 31.46, 41.71, 45.33, 53.89, 53.98, 62.65, 122.61, 122.97, 125.94, 126.09, 126.57, 126.75, 127.87, 128.58, 131.80, 134.94, 141.02, 142.69, 147.17, 155.32, 163.92, 176.21.

R = $\text{c-C}_3\text{H}_5$

R-(+)-cyclopropane carboxylic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester

hydrochloride.

Colourless, waxy substance.

^{13}C -NMR (DMSO- d_6 =39.7 ppm): 173.02, 172.49, 172.37, 153.10, 147.12, 142.72, 142.03, 140.78, 136.60, 134.79, 134.35, 129.55, 129.13, 128.80, 128.67, 127.87, 126.96, 126.74, 125.94, 125.84, 124.37, 123.71, 122.80, 62.64, 53.92, 45.34, 41.65, 31.44, 18.05, 16.66, 12.84, 9.58, 9.28, 8.49, 7.89.

R = *c*-C₄H₇

R-(+)-cyclobutane carboxylic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester
hydrochloride

Colourless, waxy substance.

^{13}C -NMR (DMSO- d_6 =39.7 ppm): 173.53, 147.12, 142.81, 140.74, 134.77, 128.65, 127.81, 126.74, 125.99, 125.87, 122.75, 62.63, 53.92, 45.34, 41.42, 37.38, 31.54, 25.04, 24.92, 18.03, 16.68, 16.61.

R = *c*-C₅H₉

R-(+)-cyclopentane carboxylic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester
hydrochloride

Colourless, waxy substance.

^{13}C -NMR (DMSO- d_6 =39.7 ppm): 174.80, 147.22, 142.86, 140.76, 134.72, 128.66, 127.80, 126.73, 126.04, 125.88, 122.71, 62.62, 53.94, 45.37, 43.24, 41.39, 31.54, 29.78, 29.59, 25.64, 25.59, 18.07, 16.64.

R = $c-C_6H_{11}$

R-(+)-cyclohexane carboxylic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester
hydrochloride

Colourless, waxy substance.

^{13}C -NMR (DMSO- d_6 = 39.7 ppm):

174.08, 147.15, 142.85, 140.77, 134.78, 128.66, 127.77,
126.74, 126.06, 125.87, 122.69, 62.61, 53.91, 45.36, 42.26,
41.24, 31.53, 28.74, 28.62, 25.48, 25.04, 24.98, 18.05,
16.67, 16.60.

R = 4-($C_2H_5CO_2$)- C_6H_4

R-(+)-4-ethylcarbonyloxy-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester
hydrochloride

Colourless crystals, melting point 195-8 °C.

1H -NMR (DMSO- d_6): 9.87 (s, 1H can be substituted with D_2O , NH), 8.19-8.12 (m, 2H, Phenyl-H), 7.55 (d, $J = 1.0$ Hz, 1H, Phenyl-H3), 7.41-7.13 (m, 9H, Phenyl-H), 5.28 (br s, 1H can be substituted with D_2O , OH), 4.53 (s, 2H, CH_2), 4.23 (t, $J = 7.6$ Hz, 1H, CH), 3.61-3.50 (m, 2H, $2 \times \underline{CH}(CH_3)_2$), 2.97-2.74 (m, 2H, CH_2), 2.67 (q, $J = 7.4$ Hz, 2H, CH_2), 2.56-2.43 (m, 2H, CH_2), 1.23-1.13 (m, 15H, $2 \times \underline{CH}(CH_3)_2$, CH_3).

R = 4-(i-C₃H₇CO₂)-C₆H₄

R-(+)-4-(isopropylcarbonyloxy)-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester hydrochloride

Colourless crystals, melting point 202-4 °C.

¹H-NMR (DMSO-d₆): 9.73 (s, 1H can be substituted with D₂O, NH), 8.19-8.12 (m, 2H, Phenyl-H), 7.55 (d, J = 1.4 Hz, 1H, Phenyl-H3), 7.42-7.14 (m, 9H, Phenyl-H), 5.27 (br s, 1H can be substituted with D₂O, OH), 4.53 (s, 2H, CH₂), 4.23 (t, J = 7.5 Hz, 1H, CH), 3.61-3.50 (m, 2H, 2 × CH(CH₃)₂), 2.99-2.78 (m, 3H, CH₂, CH(CH₃)₂), 2.54-2.47 (m, 2H, CH₂), 1.29-1.13 (m, 18H, 3 × CH(CH₃)₂).

R = 4-(t-C₄H₉CO₂)-C₆H₄

R-(+)-4-(t-butylcarbonyloxy)-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester, free base.

Colourless oil.

¹H-NMR (DMSO-d₆): 8.19-8.12 (m, 2H, phenyl-H), 7.45-7.33 (m, 3H, phenyl-H), 7.25-7.09 (m, 7H, phenyl-H), 5.20 (t, J = 5.6 Hz, 1H, OH), 4.50 (d, J = 5.6 Hz, 2H, CH₂), 4.20 (t, J = 7.5 Hz, 1H, CH), 2.95-2.80 (m, 2H, 2 × CH(CH₃)₂), 2.38-2.25 (m, 2H, CH₂), 2.09-2.03 (m, 2H, CH₂), 1.33 (s, 9H, (CH₃)₃), 0.82-0.76 (m, 12H, 2 × CH(CH₃)₂).

Hydrochloride: colourless crystals, melting point 165-6 °C.

¹H-NMR (CDCl₃): 8.22-8.16 (m, 2H, phenyl-H), 8.02 (d, J = 1.8 Hz, 1H, phenyl-H), 7.27-7.02 (m, 9H, phenyl-H), 4.83-4.60

('m', 2H, CH₂), 4.01-3.94 (m, 1H, CH), 3.66-3.54 (m, 2H), 3.18-2.80 (m, 3H), 2.53-2.44 (m, 1H) (2 × CH₂, 2 × CH(CH₃)₂), 1.43-1.25 (m, 21H, (CH₃)₃, 2 × CH(CH₃)₂).

R = 4-(c-C₃H₅CO₂)-C₆H₄

R-(+)-4-(cyclopropylcarbonyloxy)-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester hydrochloride

Colourless crystals, melting point 208-213 °C.

¹H-NMR (DMSO-d₆): 9.04 (s, 1H can be substituted with D₂O, NH), 8.15-8.09 (m, 2H, phenyl-H), 7.53 ('d', 1H, phenyl-H₃), 7.42-7.13 (m, 9H, phenyl-H), 5.25 (br s, 1H can be substituted with D₂O, OH), 4.52 (s, 2H, CH₂), 4.23 (t, J = 7.5 Hz, 1H, CH), 3.62-3.53 (m, 2H, 2 × CH(CH₃)₂), 3.05-2.70 (m, 2H, CH₂), 2.51-2.37 (m, 2H, CH₂), 2.01-1.89 (m, 1H, cyclopropyl-CH), 1.20-1.05 (m, 16H, 2 × CH(CH₃)₂, 2 × cyclopropyl-CH₂).

¹³C-NMR (DMSO-d₆ = 39.7 ppm): 172.71, 163.93, 154.92, 147.16, 142.69, 141.03, 134.97, 131.76, 128.60, 127.86, 126.76, 126.56, 126.06, 125.94, 122.95, 122.65, 62.65, 54.00, 53.89, 45.33, 41.63, 31.49, 18.10, 17.98, 16.69, 16.51, 12.86, 9.52.

R = 4-(c-C₄H₇CO₂)-C₆H₄

R-(+)-4-(cyclobutylcarbonyloxy)-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester hydrochloride

Colourless crystals, melting point 201-6 °C.

¹H-NMR (DMSO-d₆): 9.50 (s, 1H can be substituted with D₂O, NH), 8.17-8.12 (m, 2H, phenyl-H), 7.54 (d, J = 1.4 Hz, 1H, phenyl-H3), 7.42-7.14 (m, 9H, phenyl-H), 5.25 (br s, 1H can be substituted with D₂O, OH), 4.52 (s, 2H, CH₂), 4.23 (t, J = 7.5 Hz, 1H, CH), 3.62-3.47 (m, 3H, cyclobutyl-CH), 2 × CH(CH₃)₂, 3.00-2.70 (m, 2H, CH₂), 2.51-2.26 (m, 6H, CH₂, 2 × cyclobutyl-CH₂), 2.10-1.85 (m, 2H, cyclobutyl-CH₂), 1.22-1.12 (m, 12H, 2 × CH(CH₃)₂).


R = 4-(c-C₆H₁₁CO₂)-C₆H₄

R-(+)-4-(cyclohexylcarbonyloxy)-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenyl-ester hydrochloride

Colourless crystals, melting point 212-217 °C.

¹H-NMR (DMSO-d₆): 9.34 (s, 1H, can be substituted with D₂O, NH), 8.16-8.12 (m, 2H, phenyl-H), 7.54 (d, J = 1.4 Hz, 1H, phenyl-H3), 7.39-7.14 (m, 9H, Phenyl-H), 5.26 ('t', 1H, can be substituted with D₂O, OH), 4.53 (d, J = 4.2 Hz, 2H, CH₂), 4.22 (t, J = 7.5 Hz, 1H, CH), 3.62-3.48 (m, 2H, 2 × CH(CH₃)₂), 3.00-2.60 (m, 3H, cyclohexyl-CH), CH₂, 2.51-2.40 (m, 2H, CH₂), 2.07-1.98 (m, 2H, cyclohexyl-CH₂), 1.80-1.11 (m, 20H, 4 × cyclohexyl-CH₂), 2 × CH(CH₃)₂)

9. Identical diesters



General work specification for the manufacture of identical diesters

Into a solution of 7.30 g (21.4 mmol) R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxyphenol (6) in 100 ml dichloromethane, under agitation at 0°C, a solution of acid chloride (49.2 mmol) in 50 ml dichloromethane is dropped. Then triethylamine-dichloromethane (6.86 ml/ 49.2 mmol-50 ml) is added. After 1-3 hours at room temperature the thin layer chromatography shows that conversion is complete. The deposit is washed successively with respectively 100 ml water, aqueous 0.1N-hydrochloric acid, 5 ml 5% aqueous sodium-hydrogen carbonate solution, 5 ml water, dried via sodium sulphate and following filtration concentrated until dry. Then it is dried in the high-vacuum until constant weight.

The following compounds are, by way of example, manufactured using this method:

R = Methyl

R-(-)-acetic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-acetoxymethyl-phenyl-ester, free base

Pale yellow oil, purity (HPLC): 95.2%.

¹³C-NMR (CDCl₃): 20.36, 20.69, 20.94, 20.99, 36.41, 42.27, 43.69, 48.79, 65.89, 122.89, 126.28, 127.17, 127.92, 128.36, 133.69, 136.95, 143.61, 148.46, 168.97, 170.76.

LC-MS: 425 (15%, M⁺), 410 (97%), 382 (4%), 308 (3%), 266 (7%), 223 (27%), 195 (13%), 165 (8%), 114 (100%).

[α]_D²⁰ = -33.1 (c = 1, CH₃CN).

DC (1): 0.79.

R = Cyclohexyl

R-(+)-cyclohexane carboxylic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-cyclohexylcarbonyloxymethyl-phenyl-ester

Pale yellow oil, purity (NMR): >95%.

¹³C-NMR (CDCl₃): 20.30, 25.17, 25.58, 25.73, 28.97, 29.12, 41.70, 43.15, 44.03, 48.64, 65.37, 122.67, 125.88, 126.24, 127.06, 127.31, 127.90, 128.37, 134.03, 136.85, 143.55, 148.33, 174.20, 175.72.

DC (1): 0.96.

R = Isopropyl

R-(+)-isobutyrate-2-(3-diisopropylamino-1-phenyl-propyl)-4-isobutyryloxymethyl-phenyl-ester

Free base: pale yellow oil, purity (HPLC): 95.6%.

^{13}C -NMR (CDCl_3): 18.96, 19.08, 20.59, 33.98, 34.20, 36.86, 41.72, 43.72, 48.72, 65.58, 122.65, 126.19, 126.73, 127.91, 128.11, 128.36, 133.91, 136.96, 143.81, 148.41, 175.15, 176.77.

DC (1): 0.74.

Hydrogen fumarate salt: colourless syrup, 94.4% HPLC purity.

^{13}C -NMR (CDCl_3): 17.89, 18.07, 18.94, 18.97, 19.07, 31.22, 33.93, 34.13, 41.78, 45.62, 53.93, 65.33, 122.93, 126.82, 127.45, 127.53, 127.91, 128.75, 134.74, 135.29, 135.42, 142.04, 148.44, 170.24, 175.71, 176.79.


R = 4-(t-C₄H₉CO₂)-C₆H₄

R-4-(t-butylcarbonyloxy)-benzoic acid-2-(3-diisopropylamino-1-phenyl-propyl)-4-(4-t-butylcarbonyloxymethyl-benzoic acid)-phenyl-ester hydrochloride

Colourless crystals, melting point 105-7 °C.

^{13}C -NMR (DMSO-d_6): 16.49, 16.71, 17.97, 18.06, 26.84, 31.36, 38.45, 41.70, 45.24, 53.79, 53.96, 55.09, 66.11, 122.47, 122.62, 123.59, 126.42, 126.83, 127.21, 127.70, 127.88, 128.02, 128.62, 131.17, 131.86, 134.48, 135.64, 142.52, 148.35, 154.86, 155.39, 163.80, 165.09, 176.14, 176.19.


10. Mixed diesters




R' is not equal to R''

General work specification for the manufacture of mixed diesters

Into a solution of 5.30 mmol phenolic monoester of general formula A in 40 ml dichloromethane under agitation at 0°C a solution of acid chloride (5.83 mmol) in 15 ml dichloromethane is dropped. Then triethylamine-dichloromethane (0.589g/ 5.82 mmol-15 ml) is added. After 18 hours at room temperature the thin layer chromatography shows that conversion is complete. The deposit is washed successively with respectively 50 ml water, aqueous 0.1N-hydrochloric acid, 5 ml 5% aqueous sodium-hydrogen carbonate solution, 5 ml water, dried via sodium sulphate and following filtration concentrated until dry. Then it is dried in the high-vacuum until constant weight.



The following example is manufactured using this method:



R-(+)-isobutyrate-2-(3-diisopropylamino-1-phenyl-propyl)-4-acetoxymethyl-phenyl-ester

Colourless oil.

DC (1): 0.56

^{13}C -NMR (CDCl_3): 19.12, 20.65, 21.05, 34.24, 37.02, 41.79, 43.79, 48.72, 65.98, 122.75, 125.98, 126.22, 127.94, 128.39, 128.84, 133.55, 137.04, 143.84, 148.58, 170.84, 175.18.

Hydrochloride: colourless crystals


^{13}C -NMR (CDCl_3): 16.89, 17.04, 18.31, 18.92, 20.95, 31.49, 34.07, 41.64, 46.17, 54.55, 65.49, 122.91, 126.61, 126.93, 127.48, 127.83, 128.74, 134.50, 134.88, 141.61, 148.44, 170.67, 175.63.

$[\alpha]_D^{20} = +14.6$ (c = 1, CHCl_3).

CLAIMS

1. Compounds of general formula I

560
019




Formula I

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

2. Compounds in accordance with claim 1, characterised in that X⁻ in each case is an acid ester of hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid,

hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetyl-glycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.

3. Compounds in accordance with claims 1 and 2, characterised in that they have general formula 2.




Formula 2

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

- 4 Compounds in accordance with claim 3, characterised in that X⁻ in each case is an acid ester of hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-

tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetyl-glycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid.


5. Compounds in accordance with claims 3 and 4, characterised in that they are R-(+)-2-(3-(diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate, R-(+)-2-(3-(diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester-hydrochloride hydrate
6. Compounds in accordance with claims 3 and 4, characterised in that R stands for cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 4-(1-cyclopropylmethanoyloxy)-phenyl, 4-(1-cyclobutylmethanoyloxy)-phenyl, 4-(1-cyclohexylmethanoyloxy)-phenyl or 4-(2,2-dimethyl-propanoyloxy)-phenyl and X⁻ denotes chloride.
7. Compounds in accordance with claims 1 to 6 in the form of a bulk material.
8. Method for manufacturing compounds of general formula I



Formula I


in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid, characterised in that

a) a compound of formula III



Formula III


is split with a hydrogenation agent to form a compound of Formula V



Formula V

whereupon


- b) the compound of formula V so obtained is converted with a reducing agent, in order to give a compound of formula VI



Formula VI

which


- c) is converted with an acylation agent, in order to obtain a compound of formula A



Formula A

in which R has the significance stated above, which

- d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula I




Formula I

X⁻

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, unsubstituted or substituted phenyl and X- is the acid residue of a physiologically compatible inorganic or organic acid.

9. Method in accordance with claim 8, characterised in that for the manufacture of the compounds of general formula I hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetyl-glycine), phloretinic acid (3-(4-hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.

10. Method for manufacturing compounds of general formula 2




Formula 2

X-


in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl and X- is the acid residue of a physiologically compatible inorganic or organic acid, characterised in that

a) a compound of the formula 3



Formula 3


is split with a hydrogenation agent to form a compound of formula 5



Formula 5

whereupon


- b) the compound of formula 5 so obtained is converted with a reducing agent, in order to give a compound of formula 6



Formula 6

which


- c) is converted with an acylation agent, in order to obtain a compound of formula 1



Formula 1

in which R has the significance stated above,
which

- d) is converted with a physiologically compatible inorganic or organic acid to form a compound of formula 2



in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, unsubstituted or substituted phenyl and X⁻ is the acid residue of a physiologically compatible inorganic or organic acid.

11. Method in accordance with claim 10, characterised in that for the manufacture of the compounds of general formula 2 hydrochloric acid, hydrobromic acid, phosphoric acid, sulphuric acid, nitric acid, acetic acid, propionic acid, palmitic acid, stearic acid, maleic acid, fumaric acid, oxalic acid, succinic acid, DL-malic acid, L-(-)-malic acid, D-(+)-malic acid, DL-tartaric acid, L-(+)-tartaric acid, D-(-)-tartaric acid, citric acid, L-aspartic acid, L-(+)-ascorbic acid, D-(+)-glucuronic acid, 2-oxopropionic acid (pyruvic acid), furan-2-carboxylic acid (mucic acid), benzoic acid, 4-hydroxybenzoic acid, salicylic acid, vanillic acid, 4-hydroxycinnamic acid, gallic acid, hippuric acid (N-benzoyl-glycine), aceturic acid (N-acetyl-glycine), phloretinic acid (3-(4-

hydroxyphenyl)-propionic acid), phthalic acid, methanesulfonic acid or orotic acid are used.

12. Method in accordance with claims 8 to 11, characterised in that as the hydrogenation agent, Raney nickel/H₂ in methanol is preferably used as the solvent.

13. Method in accordance with claims 8 to 11, characterised in that for the reducing agent NaBH₄/EtOH, preferably LiAlH₄/THF, is used.

14. Method in accordance with claims 8 to 11, characterised in that for the acylation agent isobutyrylchloride and for the base triethylamine are used.


15. Method in accordance with claims 10 to 14, characterised in that a compound of general formula 6 is converted with an equivalent isobutyryl chloride in the presence of triethylamine using one of the respective solvents ethylacetate, dichloromethane, tetrahydrofurane, acetonitrile or toluene regio- and chemoselectively into R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate.

16. Method in accordance with claims 10 to 15, characterised in that R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester and fumaric acid or

hydrochloric acid are converted with the formation of the respective salt.

17. Method in accordance with claims 10 to 13 for the manufacture of R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxy-methylphenylisobutyrate ester hydrochloride hydrate, characterised in that the phenolic esterification of R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methylphenol (6) is carried out without the addition of an external base, in that solutions of (6) are dropped into solutions of isobutyrate chloride, that contain at least 1 mole equivalent of water, in order to directly obtain a corresponding stable, hydrate-containing hydrochloride.


18. ~~Compound of formula III~~



Formula III


19. Compound of formula V

*A2
cont*




Formula V

20. Compound of formula VI



Formula VI

21. Use of a compound in accordance with claims 18 to 20 as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds.
22. Use of a compound in accordance with claims 18 to 20 as an intermediate product in the manufacture of phenolic monoesters of general formula A




Formula A

in which R denotes C₁-C₆-alkyl, C₃-C₁₀-cycloalkyl, substituted or unsubstituted phenyl.

23. Compound of formula 3


pk
A3



Formula 3


24. Compound of formula 5

A³
cont




Formula 5

25. Compound of formula 6



Formula 6


26. Compound of formula 7



Formula 7

27. Use of a compound in accordance with claims 23 to 26 as a highly pure, crystalline, stable intermediate product in the manufacture of pharmaceutically useful compounds.

28. Use of a compound in accordance with claims 23 to 26 as an intermediate product in the manufacture of phenolic monoesters of general formula 1



Formula 1

29. Use of a compound in accordance with claims ~~23~~ to 26 as an intermediate product in the manufacture of salts of phenolic monoesters of general formula 2, in which R has the same meaning as given in claim 3.

30. Use of a compound in accordance with claims ~~23~~ to 26 as an intermediate product in the manufacture of *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate.

ABSTRACT

The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products.

The method is in particular characterised by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are *R*-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and *R*-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is *R*-(-)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Express Mail N		
DECLARATION FOR UTILITY, DESIGN, DIVISIONAL AND CONTINUATION-IN-PART PATENT APPLICATIONS (37 CFR 1.63)		Attorney Docket Number	41946/32854	
		First Named Inventor	MEESE, Claus	
		COMPLETE IF KNOWN		
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing		Application Number	To be assigned	
<input type="checkbox"/> Supplemental Declaration Submitted	<input type="checkbox"/> Declaration Submitted for Continuation-In-Part Filing	<input type="checkbox"/> Declaration Submitted for Divisional Filing	Filing Date	To be assigned
			Group Art Unit	To be assigned
			Examiner Name	To be assigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-PHENYLPROPYLAMINES

(Title of the invention)

the specification of which

is attached hereto

OR

was filed on (MM/DD/YYYY) 11/15/2000 as United States Application Number or PCT International

Application Number PCT/EP00/11309 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
DE 199 55 190.1	Germany	11/16/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: SCHWARZ PHARMA AG

Application No./Patent No.: _____ Filed/Issue Date: _____

Entitled: STABLE SALTS OF NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES

SCHWARZ PHARMA AG, a CORPORATION
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- 1. the assignee of the entire right, title, and interest; or
- 2. an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

- 1. From _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- 2. From _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
- 3. From _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.


Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

2 May 2002
Date

ppa. K. D. Hommerich i.V. D.W. Schacht
Typed or printed name


Signature

Authorized Officer Assistant Manager
Title

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside the box →

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	
Filing Date	
First Named Inventor	MEESE, Claus
Title	STABLE SALTS OF et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	41946/32854

I hereby appoint:

Practitioners at Customer Number **021888**
OR

Practitioner(s) named below:




Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

The above-mentioned Customer Number
OR

Practitioners at Customer Number **021888**
OR



<input checked="" type="checkbox"/> Firm or Individual Name	Paul A. Lesko	PATENT TRADEMARK OFFICE			
Address	Thompson Coburn LLP				
Address	One US Bank Plaza				
City	St. Louis	State	MO	Zip	63101
Country	USA				
Telephone	314-552-6443	Fax	314-552-7000		

I am the:

Applicant/Inventor.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name	ppa. K.-D. Hommerich i.V. D.W. Schacht
Signature	<i>[Handwritten signatures]</i>
Date	2 May 2002

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

*Total of _____ forms are submitted.

Burden Hour Statement: This form is estimated to take 3 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

10 10 2002 10 10 2002

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: <input checked="" type="checkbox"/>	Customer Number or Bar Code Label <u>021888</u>	OR <input type="checkbox"/>	Correspondence address below
---	---	-----------------------------	------------------------------

Name	Paul A. Lesko, Esq.
-------------	----------------------------

Address	Thompson Coburn LLP One U.S. Bank Plaza, Suite 3500
----------------	--

City	St. Louis	State	MO	ZIP	63101
-------------	-----------	--------------	----	------------	-------

Country	USA	Telephone	314-552- 6443	Fax	314-552-7443
----------------	-----	------------------	---------------	------------	--------------

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR :	<input type="checkbox"/> A petition has been filed for this unsigned inventor
---	---

Given Name (first and middle [if any])	<u>Claus</u>	Family Name or Surname	<u>MEESE</u>				
Inventor's Signature	<i>[Signature]</i>	Date	<u>2 May 2002</u>				
Residence: City	<u>Monheim</u>	State	<u>DEX</u>	Country	Germany	Citizenship	Germany

Mailing Address	<u>Kreuzbergerstrasse 50</u>						
City	<u>40789 Monheim</u>	State		ZIP		Country	GERMANY

NAME OF SECOND INVENTOR :	<input type="checkbox"/> A petition has been filed for this unsigned inventor
----------------------------------	---



Given Name (first and middle [if any])		Family Name or Surname					
Inventor's Signature		Date					
Residence: City		State		Country		Citizenship	

Mailing Address							
City		State		ZIP		Country	

<input type="checkbox"/> Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁵ : C07C 217/62, 215/54, 311/37 C07C 237/30, C07D 295/06, 211/14 C07D 207/06, A61K 31/135</p>	A1	<p>(11) International Publication Number: WO 94/11337 (43) International Publication Date: 26 May 1994 (26.05.94)</p>
<p>(21) International Application Number: PCT/SE93/00927 (22) International Filing Date: 5 November 1993 (05.11.93) (30) Priority data: 9203318-2 6 November 1992 (06.11.92) SE (71) Applicant (for all designated States except US): KABI PHARMACIA AB [SE/SE]; S-751 82 Uppsala (SE). (72) Inventors; and (75) Inventors/Applicants (for US only) : JOHANSSON, Rolf, Arne [SE/SE]; Daggstigen 8 B, S-141 38 Huddinge (SE). MOSES, Pinchas [SE/SE]; Dalvägen 6, S-132 00 Saltsjö-Boo (SE). NILVERBANT, Lisbeth [SE/SE]; Lillsjönsvägen 11, S-161 35 Bromma (SE). SPARF, Bengt, Åke [SE/SE]; Drottningstigen 6, S-142 65 Trångsund (SE).</p>	<p>(74) Agents: WIDEN, Björn et al.; Kabi Pharmacia AB, S-751 82 Uppsala (SE). (81) Designated States: AU, CA, FI, HU, JP, NO, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published With international search report.</p>	
<p>(54) Title: NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION</p>		
<div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center; margin-top: 20px;">  <p>(II)</p> </div>		
<p>(57) Abstract</p> <p>The invention relates to 3,3-diphenylpropylamines of formula (I), wherein R¹ signifies hydrogen or methyl, R² and R³ independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula (II), wherein R⁴ and R⁵ signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R⁴ and R⁵ may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The invention also relates to methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION

The present invention relates to novel therapeutically active compounds, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.

WO 89/06644 discloses 3,3-diphenylpropylamines having anticholinergic activity. In accordance with the present invention novel therapeutically active compounds have now been found, some of which are formed as metabolites in mammals when treated with the 3,3-diphenylpropylamines disclosed in the above-mentioned WO publication. These metabolites have at least as favourable anti-cholinergic properties as the parent compounds and can thus be used for the control of events mediated by acetylcholine, like urination.

The novel compounds of the present invention are represented by the general formula I



wherein R^1 signifies hydrogen or methyl, R^2 and R^3 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula II



wherein R^4 and R^5 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, preferably at least

four carbon atoms, especially at least five carbon atoms, and wherein R⁴ and R⁵ may form a ring together with the amine nitrogen, said ring preferably having no other heteroatom than the amine nitrogen.

5 The compounds of formula I can form salts with physiologically acceptable acids, organic and inorganic, and the invention comprises the free bases as well as the salts thereof. Examples of such acid addition salts include the hydrochloride, hydrobromide, hydrogen
10 fumarate, and the like.

When the novel compounds are in the form of optical isomers, the invention comprises the racemic mixture as well as the individual isomers as such.

In the compounds of formula I, R² is preferably
15 hydrogen, and R³ is preferably hydrogen or hydroxy.



R² is preferably in 3-, 4- or 5-position.


R³ is preferably in 2-position with respect to the propylamine group.

The HOCH₂-group is preferably in 5-position.

20 Preferably, each of R⁴ and R⁵ independently signifies C₁-8-alkyl, especially C₁-6-alkyl, or adamantyl, R⁴ and R⁵ together comprising at least three, preferably at least four carbon atoms. R⁴ and R⁵ may carry one or more hydroxy groups, and they may be joined to form a ring together
25 with the amine nitrogen atom.

Presently preferred tertiary amino groups X in formula I include the following groups a) - h):





5

Preferably, R⁴ and R⁵ are both isopropyl.


A presently preferred specific compound of formula I is N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine.

10

The compounds of formula I may, in accordance with the present invention, be prepared by per se conventional methods, and especially by

a) reducing the group R⁶CO in a 3,3-diphenylpropylamine of formula III

15




20

wherein R¹ to R³ and X are as defined above, R⁶ is hydrogen or R⁷O, where R⁷ is hydrogen, (preferably lower) alkyl, alkenyl, alkynyl or aryl (such as phenyl) and any hydroxy groups may be protected, such as by methylation or benzylation, or

25

b) reacting a reactively esterified 3,3-diphenylpropanol of formula IV


30



35


wherein R¹ to R³ are as defined above and any hydroxy

groups may be protected, and wherein Y is a leaving group, preferably halogen or an alkyl or arylsulphonyloxy group, with an amine of formula V




5 wherein X is as defined above, or

c) reducing a 3,3-diphenylpropionamide of formula VI



15 wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, preferably using a complex metal hydride, or


d) N-methylating a secondary 3,3-diphenylpropylamine of formula VII



25

wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, and wherein Z has the same meaning as R⁴ and R⁵ with the exception of methyl, Z preferably being a hydrocarbonyl group comprising at least
30 three carbon atoms, the N-methylation preferably being carried out using formaldehyde or formic acid, or


e) reducing a 3,3-diphenylpropenamine of formula VIIIa or a 3,3-diphenylpropylamine of formula VIIIb



10 wherein R^1 to R^3 and X are as defined above and any hydroxy groups may be protected, and W signifies a hydroxy group or a halogen atom, preferably by means of catalytic hydrogenation,

f) reacting a 3,3-diphenylpropylamine of formula IX


15



20

wherein R^1 to R^3 and X are as defined above, and Hal is halogen, with formaldehyde or a formaldehyde equivalent (such as s-trioxane), or

25 g) oxidizing the methyl group of a diphenylpropylamine of formula X



wherein R^1 to R^3 and X are as defined above, and

35 i) when necessary splitting off hydroxy protecting groups in the compounds obtained, if desired after mono- or di-halogenation of one or both of the phenyl rings, and/or

ii) if desired converting the obtained bases of formula I into salts thereof with physiologically acceptable acids, or vice versa, and/or

5 iii) if desired separating an obtained mixture of optical isomers into the individual enantiomers, and/or

iv) if desired methylating an ortho-hydroxy group in an obtained compound of formula I, wherein R¹ is hydrogen and/or R³ is hydroxy.

The oxidation in process g) above may be performed 10 chemically, electrochemically or enzymatically. Chemical oxidation is advantageously performed using a metal salt or oxide like ceric ammonium nitrate, manganese oxides, chromium oxides, vanadium oxides, cobalt acetate, aluminium oxide, bismuth molybdate or combinations 15 thereof. Chemical oxidation may also be effected by peracids, with or without a catalyst, or with halides. Electrochemical oxidation may be conducted with or without a catalyst. For enzymatical oxidation, it is preferred to use bacteria or yeast (e.g. Candida Guilliermondi, Candida 20 Tropicalis).

The removal of hydroxy protecting groups according to i) above can e.g. be done by treatment with hydrobromic acid, borontribromide or by catalytic hydrogenation.

25 The separation of mixtures of optical isomers, according to ii) above, into the individual enantiomers can e.g. be achieved by fractional crystallization of salts with chiral acids or by chromatographic separation on chiral columns.

The starting compounds of formula III and IX may be 30 prepared as described in the preparation example described below. The starting materials used in processes b) to e) and g) may be prepared as described in the afore-mentioned WO 89/06644 (the disclosure of which is incorporated by reference herein) with due consideration of the disclosure 35 in the present preparation example.

In accordance with the present invention, the compounds of formula I, in the form of free bases or salts with physiologically acceptable acids, can be brought into

suitable galenic forms, such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures. Such pharmaceutical compositions according to the

5 invention comprise an effective amount of the compounds of formula I in association with compatible pharmaceutically acceptable carrier materials, or diluents, as is well known in the art. The carriers may be any inert material, organic or inorganic, suitable for enteral, percutaneous

10 or parenteral administration, such as: water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such compositions may also contain other

15 pharmaceutically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.

The compositions according to the invention can e.g. be made up in solid or liquid form for oral

20 administration, such as tablets, capsules, powders, syrups, elixirs and the like, in the form of sterile solutions, suspensions or emulsions for parenteral administration, and the like.

The compounds and compositions can, as mentioned

25 above, be used for the same therapeutical indications as the compounds of the above-mentioned WO 89/06644, i.e. for the treatment of acetylcholine-mediated disorders, such as urinary incontinence. The dosage of the specific compound will vary depending on its potency, the mode of

30 administration, the age and weight of the patient and the severity of the condition to be treated. The daily dosage may, for example, range from about 0.01 mg to about 4 mg per kilo of body weight, administered singly or multiply in doses e.g. from about 0,05 mg to about 200 mg each.

35 The invention will be further illustrated by the following non-limiting example and pharmacological tests. Reference will be made to the accompanying drawing where the only figure (Fig. 1) shows bladder pressure inhibition

curves for a compound of the present invention and a prior art compound, respectively.

General

N.M.R data were acquired on a Jeol JNM-EX 270 Fourier
5 transform spectrometer. Spectra were recorded with
tetramethylsilane (TMS) as internal standard at 30°C.
Infrared spectra were recorded on a Perkin Elmer 599B
instrument. Non-corrected melting points were obtained on
a Koeffler apparatus. Gas chromatography was performed on
10 a HP 5940 instrument with a 10 m HP-1 column and the oven
heated in the linear temperature gradient mode.

EXAMPLE 1

(+)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-
phenylpropylamine (+) mandelate, and (-)-N,N-diisopropyl-
15 3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine
(-) mandelate

a) 6-Bromo-4-phenyl-3,4-dihydro-coumarine

A solution of p-bromophenol (138 g, 0.8 mole),
cinnamic acid (148 g, 1.0 mole), acetic acid (200 g) and
20 conc. sulfuric acid was refluxed for 2 h. Volatile
material was distilled at reduced pressure. The residual
syrup was cooled and triturated with cold water, giving a
semi-crystalline mass. This was washed extensively with
water, saturated sodium carbonate and finally with water
25 again. The material was filtered through a sintered glass
funnel, and then mixed with an equal weight of ethanol.
The slurry was stirred at room temperature for 1 h and
then filtered. The resulting product was washed briefly
with ethanol and then diisopropyl ether. After drying, 135
30 g (55.7%) of the title compound was isolated as white
crystals, melting at 117°C.

b) Methyl 3-(2-benzyloxy-5-bromophenyl)-3-phenyl- propanonate

6-Bromo-4-phenyl-3,4-dihydro-coumarine (290 g, 0.96
35 mole) was dissolved in a mixture of methanol (1 L) and
acetone (1 L). To the above solution were added potassium
carbonate (160 g, 1.16 mole), α -chlorotoluene (140 g, 1.1
mole) and sodium iodide (30 g, 0.47 mole), and the mixture

was stirred under reflux for 3 h. The solution was concentrated by distillation, and the residue treated with water and extracted with diethyl ether. The ethereal layer was washed with water, saturated sodium carbonate solution and water, successively. The organic layer was dried over sodium sulfate, filtered and then evaporated to give 420 g ($\approx 100\%$) of the title compound as a light yellow oil.

c) 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanol

Methyl 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanoate (112 g, 0.26 mole) was dissolved in tetrahydrofuran (250 mL) and added dropwise under nitrogen atmosphere to a suspension of lithium aluminiumhydride (5.9 g, 0.16 mole) in tetrahydrofuran (250 mL). The mixture was stirred overnight under nitrogen atmosphere. The excess hydride was decomposed by addition of a small amount of HCl (aq, 2 M). The solution was filtered on a pad of Celatom, and the solids were washed thoroughly with ether. The combined ethereal solution was washed with HCl (2 M), water, sodium hydroxide (2 M) and then with water again. The organic solution was dried over sodium sulfate, filtered and evaporated to give 98.5 g (95%) of the title compound as a colourless oil. A small fraction of the oil was crystallized from diisopropyl ether/petroleum ether giving crystals which melted at 70°C.

d) 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-p-toluenesulfonate

To a solution of 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanol (107 g, 0.24 mole) in dichloromethane (300 mL) and pyridine (75 mL) at 0°C was added p-toluene sulfonylchloride (57 g, 0.3 mole). The solution was stirred at 0°C overnight and then evaporated at reduced pressure and at a bath temperature below 50°C. The remainder was poured onto water and then the mixture was extracted with diethyl ether. The organic layer was washed with water, HCl (2 M) and water successively, and finally dried over sodium sulfate. After filtration the ethereal solution was evaporated at a bath temperature of <50°C

giving 137 g ($\approx 100\%$) of 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-p-toluenesulfonate as a pale yellow oil.

e) N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine

5 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-p-toluenesulfonate (115 g, 0.2 mole) was dissolved in a mixture of acetonitrile (150 g) and diisopropylamine (202 g, 2.0 mole) and the mixture was refluxed for 4 days. The solution was evaporated, and to the resulting syrup was
10 added sodium hydroxide (2 M, 200 mL). The mixture was concentrated, cooled and then extracted with diethyl ether. The ethereal layer was extensively washed with water. The amine was extracted with excess sulfuric acid (1 M). The aqueous layer was washed with diethyl ether and
15 then basified with sodium hydroxide (11 M). The mixture was then extracted with diethyl ether. The organic layer was washed with water, dried over sodium sulfate, filtered and then evaporated to give 78.6 g (78%) of N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-
20 phenylpropylamine as a pale yellow oil. The 1-H N.M.R spectrum was in accordance with the above structure.

f) Resolution

To a solution of N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine (255 g, 0.53 mole) in
25 ethanol (750 g) was added L-(+)-tartaric acid (80 g, 0.53 mole). When all material was dissolved, diethyl ether (90 g) was added and crystallization commenced. After being stored at room temperature overnight, the formed salts were filtered off, washed with fresh ethanol-diethyl ether
30 solution (2:1) and dried to give 98 g of white crystals melting at 156°C . $[\alpha]^{22} = 16.3^{\circ}$ (c = 5.1, ethanol)

The mother liquor from the precipitation with L-(+)-tartaric acid was evaporated. The resulting syrup was treated with sodium hydroxide (2 M) and extracted with
35 diethyl ether. The organic phase was washed with water, dried over sodium sulfate, filtered and then evaporated, giving 170 g of free base. The base (170 g, 0.35 mole) was dissolved in ethanol (500 mL), and D-(-)-tartaric acid (53

g, 0.53 mole) was added. When all had dissolved, diethyl ether (50 mL) was added and crystallization commenced. The crystals were filtered off and washed with fresh ethanol-diethyl ether solution giving 105 g of crystals melting at
5 154-155°C. $[\alpha]^{22} = -16.4^\circ$ (c = 5.0, methanol)

The mother liquor was concentrated, basified and treated as above, yielding 80 g of free base. This base was dissolved in ethanol, and treated with L-(+)-tartaric acid as described above, yielding additional 20 g of the
10 dextrorotatory form of the salt. (M.p. 156°C).

In an analogous manner, 20 g of the levorotatory form could be obtained.

The pooled dextrorotatory form was dissolved in water and basified with sodium hydroxide (2 M). The mixture was
15 then extracted with diethyl ether. The organic phase was washed with water, dried over sodium sulfate, filtered and finally evaporated to give the chiral amine (88 g) as a colourless oil. $[\alpha]^{22} = 16.3^\circ$ (c = 5.1, ethanol)

In an analogous fashion, the levorotatory base was
20 obtained (90 g). $[\alpha]^{22} = -16.1^\circ$ (c = 4.2, ethanol). The optical purity as assessed by chromatography was >99%.

g1) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine hydrochloride

A mixture of magnesium (12.2 g, 0.5 mole), ethyl
25 bromide (2 g), and iodine (a small crystal) in dry diethyl ether (200 mL) was warmed until the reaction started. (+)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine (45.6 g, 0.095 mole) and ethyl bromide (32.7 g, 0.3 mole) dissolved in dry diethyl ether (250 mL)
30 were then added dropwise under nitrogen atmosphere. The mixture was refluxed for 1.5 h and then cooled in an acetone/dry-ice bath, whereupon powdered dry ice (≈ 100 g) was added gently. Tetrahydrofuran was added when needed to prevent the mixture from solidification. The reaction
35 mixture was stirred for 0.5 h when ammonium chloride (200 mL, 20% w/w) was added. The mixture was stirred vigorously until two transparent phases were formed, and then filtered through a pad of Celatom. The aqueous layer was

washed with diethyl ether and then acidified with hydrochloric acid to pH 1. The precipitated semi-crystalline gum was washed with water, and then transferred to a round bottom flask. The product was dried

5 by co-evaporation with acetone, benzene, toluene, diisopropyl ether and methanol, successively. The title compound (35.1 g, 77%) was isolated as friable shiny flakes and used without any further purification.

10 g2) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine hydrochloride

This product was isolated in 81 % yield in a corresponding way as described above from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine.

15 h1) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxy-phenyl)-3-phenylpropylamine

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine (34 g, 0.07 mole) was dissolved in methanol (300 mL) containing sulfuric acid (6 g) and

20 refluxed for 6 h. The solution was then cooled and concentrated. To the mixture were added ice-water and a slight excess of saturated sodium carbonate solution. The mixture was then extracted with diethyl ether. The organic phase was washed with water, dried over sodium sulfate,

25 filtered and evaporated, giving 30 g (93%) of crude ester. Recrystallisation from diisopropyl ether gave white crystals melting at 85-86°C. The 1-H N.M.R. spectrum was in accordance with the above structure.

30 h2) (-)-N,N-diisopropyl-3-(2-benzyloxy-5-carbomethoxy-phenyl)-3-phenylpropylamine

The title compound was obtained from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine in a similar manner as described above for the dextro isomer in a 93 % yield.

35 i1) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethyl-phenyl)-3-phenylpropylamine

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamine (30 g, 0.065 mole)

METHOD

dissolved in diethyl ether (250 mL) was added dropwise under nitrogen to a suspension of lithium aluminiumhydride (1.9 g, 0.05 mole) in dry diethyl ether (150 mL). The mixture was stirred overnight at room temperature, and the
5 excess hydride was decomposed by the addition of water (\approx 5 g). The mixture was stirred for 10 min, when sodium sulfate (s) was added. After stirring for 20 minutes, the mixture was filtered and then evaporated to give 28.4 g of the title compound as a colourless oil.

10 i2) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethyl-phenyl)-3-phenylpropylamine

The title compound was obtained in an analogous fashion as described above for the levo isomer from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-
15 phenylpropylamine.

j1) (+)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethyl-phenyl)-3-phenylpropylammonium (+) mandelate

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethyl-phenyl)-3-phenylpropylamine (28.2 g, 0.065 mole) was
20 dissolved in methanol (300 g). Raney Nickel (one tea-spoon) was added and the mixture was hydrogenated at atmospheric pressure until the theoretical amount of hydrogen was consumed. The progress of the reaction was monitored by gas chromatography. The mixture was then
25 filtered through a pad of Celatom, and the solvent was removed by evaporation at a bath temperature $<50^{\circ}\text{C}$. The resulting oil was dissolved in diethyl ether, and the ethereal solution was washed with water, dried over sodium sulfate and evaporated giving 22.2 g of a colourless oil. *

30 $[\alpha]^{22} = 16.7^{\circ}$ (c = 4.9, ethanol).

To the above oil, dissolved in 2-propanol (50 g) was added S-(+)-mandelic acid (9.6 g, 0.06 mole) in 2-propanol (50 g). Dry diethyl ether (50 g) was added, and the solution was left for several hours. The resulting heavy,
35 white crystals were filtered off and washed with a mixture of 2-propanol and diethyl ether (1:1 v/v) and then dried, yielding 25 g of the title compound which melted at 148°C .
 $[\alpha]^{22} = 38.3^{\circ}$ (c = 5.1, methanol).

The 1-H N.M.R. spectrum was in accordance with the above structure.

Chiral purity as assessed by H.P.L.C. was >99%.

5 Elementary Anal. Theor.: C: 73.0 H: 8.0 N: 2.8 O: 16.2
Found: C: 72.9 H: 8.1 N: 3.0 O: 16.5

j2) (-)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethyl-phenyl)-3-phenylpropylammonium (-) mandelate

10 The title compound was obtained from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine in an analogous manner to that described in j1) above.

Elementary Anal. Theor.: C: 73.0 H: 8.0 N: 2.8 O: 16.2
Found: C: 73.2 H: 8.1 N: 3.0 O: 16.5

15 The free base had an optical rotation of $[\alpha]^{22} = -15.5^\circ$ (c = 5.0, ethanol).

The 1-(-)-mandelic acid salt had a m.p. of 147-148°C and an optical rotation $[\alpha]^{22} = -37.9^\circ$ (c = 4.7, methanol).

The optical purity as assessed by H.P.L.C. was >99 %.

20 Pharmacology

Pharmacological tests performed with one compound of the invention and three prior art compounds disclosed in the above mentioned WO 89/06644 will now be described. The following compounds were used:

- 25 (A) (+)N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, hydrochloride (WO 89/06644);
(B) N,N-diisopropyl-3-bis-(2-hydroxyphenyl)propylamine hydrochloride (WO 89/06644);
(C) (+)N,N-diisopropyl-3-(5-chloro-2-hydroxyphenyl)-3-(2-
30 hydroxyphenyl)propylamine, hydrochloride (WO 89/06644);
(D) N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine (-) mandelic acid salt (Example 1 above).

35 Raised index numerals in the text below refer to literature references listed at the end of the description.

Muscarinic Receptor Binding Studies

The tissue preparations and the general methods used have been described in detail elsewhere for the parotid gland¹, urinary bladder², heart³ and cerebral cortex³,
5 respectively. Male guinea pigs (250-400 g body weight) were killed by a blow on the neck and exsanguinated. The brain was placed on ice for dissection of the cerebral cortex (grey matter only). Urinary bladders, hearts and parotid glands were dissected in a Krebs-Henseleit buffer
10 (pH 7.4) containing 1 mM phenyl methyl sulfonyl fluoride (PMSF, a protease inhibitor). Dissected tissues were homogenized in an ice-cold sodium-potassium phosphate buffer (50 mM, pH 7.4) containing 1 mM PMSF, using a Polytron PT-10 instrument (bladder, heart, parotid) and a
15 Potter-Elvehjem Teflon homogenizer (cortex). All homogenates were finally diluted with the ice-cold phosphate/PMSF buffer to a final protein concentration of ≤ 0.3 mg/ml and immediately used in the receptor binding assays. Protein was determined by the method of Lowry et
20 al. (1951)⁴, using bovine serum albumin as the standard.

The muscarinic receptor affinities of the unlabelled compounds A to D identified above were derived from competition experiments in which the ability to inhibit the receptor specific binding of (-)³H-QNB (1-
25 quinuclidinyl[phenyl-4-³H]benzilate, 32.9 Ci/mmole) was monitored as previously described^{3,5}. Each sample contained 10 μ l of (-)³H-QNB (final concentration 2 nM), 10 μ l solution of test compound and 1.0 ml tissue homogenate. Triplicate samples were incubated under
30 conditions of equilibrium, i.e., at 25°C for 60 minutes (urinary bladder), 80 minutes (heart and cerebral cortex) or 210 minutes (parotid gland), respectively. Non-specific binding was determined in the presence of 10 μ M unlabelled atropine. Incubations were terminated by centrifugation²,
35 and the radioactivity in the pellets was determined by liquid scintillation spectrometry².

IC₅₀-values (concentration of unlabelled compound producing 50% inhibition of the receptor specific (-)³H-

QNB binding) were graphically determined from the experimental concentration-inhibition curves. Affinities, expressed as the dissociation constants K_i , were calculated by correcting the IC_{50} for the radioligand-induced parallel shift and differences in receptor concentration, using the method of Jacobs et al. (1975)⁶.
5 The binding parameters for (-)³H-QNB (K_D and receptor densities) used in these calculations were determined in separate series of experiments¹⁻³. The K_i values obtained
10 for bladder, heart, parotid and cortex, respectively, are presented in Table 1 below.

Functional in vitro studies

Male guinea pigs, weighing about 300 g, were killed by a blow on the neck and exsanguinated. Smooth muscle
15 strips of the urinary bladder were dissected in a Krebs-Henseleit solution (pH 7.4). The strip preparations were vertically mounted between two hooks in thermostatically controlled (37°C) organ baths (5 ml). One of the hooks was adjustable and connected to a force transducer (FT 03,
20 Grass Instruments). The Krebs-Henseleit solution was continuously bubbled with carbogen gas (93.5% O₂/6.5% CO₂) to maintain the pH at 7.4. Isometric tension was recorded by a Grass Polygraph (Model 79D). A resting tension of approximately 5 mN was initially applied on each muscle
25 strip and the preparations were allowed to stabilize for at least 45 min. The resting tension was repeatedly adjusted and the preparations were washed several times during the stabilization period.

Carbachol (carbamylcholine chloride) was used as the
30 standard agonist. In each experiment, the viability of the preparations and the reproducibility of their contractile responses were initially tested by three consecutive additions of a submaximal concentration (3×10^{-6} M) of carbachol. A complete concentration-response curve to
35 carbachol was then generated by cumulative addition of carbachol to the organ-bath (i.e., stepwise increase of the agonist concentration until the maximal contractile response was reached), followed by washing out and a

resting period of at least 15 min. before a fix concentration of the test compound (antagonist) was added to the organ-bath. After 60 min. of incubation with the antagonist, a second cumulative concentration-response curve to carbachol was generated. Responses were expressed as per cent of the maximal response to carbachol. EC₅₀-values for carbachol in the absence (control) and presence of antagonist were graphically derived and dose ratios (r) were calculated. Dissociation constants, K_B, for the antagonists were calculated using equation (1)⁷, where [A] is the concentration of test compound.

$$K_B = [A]/r-1 \quad (1)$$

The K_B values obtained for compounds A, B and D identified above are shown in Table 1 below.

15

Table 1

Test compound	K _B nm bladder	K _i nM bladder	K _i nM heart	K _i nM parotid	K _i nM cortex
(A)	3.0	2.7	1.6	4.8	0.8
(B)		10.2	6.7	2.6	1.5
(C)	2.6	2.5	0.9	2.7	0.4
(D)	4.1	4.5	0.9	4.7	0.7

20

Functional in vivo studiesa) Animal preparation

Adult cats were anaesthetized with mebumal (42 mg/kg) intraperitoneally. When the animal was asleep, an infusion cannula was inserted into the foreleg vein and the cat was given alpha-chloralose. During the experiment the animal was placed on an operation table warmed up with a feedback controlled electric pad. The cat was tracheotomized. For blood pressure registration, a polyethylene catheter was inserted into the femoral artery, with the tip in aorta, and connected via a three-way stopcock to a blood pressure transducer and a Grass polygraph. Heart rate was registered by connecting a tachograph to a driver amplifier which received the signal from the blood pressure transducer. Blood flow in the central mesenteric artery was measured by an ultrasound flow probe around the artery connected to a transonic blood flow meter and then

35

to a Grass polygraph for registration of the flow. For infusion of the test substances, compounds D and A (as identified above), a polyethylene catheter was inserted into the femoral vein three-way stopcock to a syringe placed in an infusion pump (Sage instrument).

Through an incision in the proximal urethra, a catheter was inserted into the urinary bladder. At the beginning of each experiment, this catheter was connected to an open vessel, which was filled with 38°C tempered physiological saline and placed above the animal. During this stabilization period the bladder relaxed, leading to a filling of the bladder with saline, under constant hydrostatic pressure. After the stabilization period, the bladder catheter was connected to a pressure transducer, for registration of intravesical pressure. Blood pressure, heart rate, blood flow and bladder pressure were recorded simultaneously and continuously throughout the experiment. The animals were left for at least 45 minutes to achieve steady state in cardiovascular variables before starting the experiment.

Bladder pressure was measured at 8 minutes after the end of infusion of the test substance. The surgical preparation was tested by intravenous injection of 0.25 µg/kg b.w. of noradrenalin and 0.5 µg/kg b.w. of acetylcholine.

b) Dosing

To study the dose-response relationship of compound D identified above, the substance was administered at the doses 0.000 (physiological saline), 0.003, 0.010, 0.030 and 0.100 mg/kg, respectively, with infusion during 2 minutes and an infusion volume of 1 mL/kg. Every cat got all doses and was left to reestablish at least 45 minutes between the 0.003 and 0.010 mg/kg doses, and 60 minutes between the 0.030 and 0.100 mg/kg doses.

c) Statistical methods and calculation

The results are presented in absolute values and calculated as mean value ± standard deviation

d) Results

(i) Blood pressure

In general, intravenous administration of compound D had little or no effect on the blood pressure except at dose of 0,3 mg/kg. This dose caused an increase with 10% and with 6 % for diastolic blood pressure and systolic blood pressure, respectively.

(ii) Blood flow

Intravenous administration of compound D caused an increase with 8, 17 and 21 % of the blood flow in superior mesenterica artery at 0.003, 0.01, and 0.03 mg/kg, respectively. Again at the highest dose (0.3 mg/kg) a 10% increase in blood flow was observed.

(iii) Heart rate

Intravenous administration of compound D caused a decrease with 9 % at the highest dose (0.3 mg/kg).

(iv) Bladder pressure

As appears from Fig. 1, compound D of the present invention produced a dose-dependent inhibition of the acetylcholine-induced effect on the bladder which was about ten times more efficient than that of prior art compound A.

References

1. Nilvebrant, L.; Sparf, B. Muscarinic receptor binding in the parotid gland. Different affinities of some anticholinergic drugs between the parotid gland and ileum. Scand. J. Gastroenterol. 1982, 17 (suppl. 72), 69-77.
2. Nilvebrant, L.; Sparf, B. Muscarinic receptor binding in the guinea pig urinary bladder. Acta Pharmacol. et Toxicol. 1983 a, 52, 30-38.
3. Nilvebrant, L; Sparf, B. Dicyclomine, benzhexol and oxybutynin distinguish between sub-classes of muscarinic binding-sites. Eur. J. Pharmacol. 1986, 123, 133-143.
4. D Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
5. Nilvebrant, L.; Sparf, B. Differences between binding affinities of some antimuscarinic drugs in the parotid

gland and those in the urinary bladder and ileum. Acta Pharmacol. et Toxicol. 1983 b, 53, 304-313.

6. Jacobs, S.; Chang, K.-J.; Cuatrecasas, P. Estimation of hormone receptor affinity by competitive displacement of labelled ligand. Effects of concentration of receptor and labelled ligand. Biochem. Biophys. Res. Commun. 1975, 66, 687-692.


7. Schild, H. I. pAx and competitive drug antagonism. Br. J. Pharmacol. Chemother. 1949, 4, 277-280.

10

CLAIMS

1. 3,3-Diphenylpropylamines of formula I

5



10

wherein R¹ signifies hydrogen or methyl, R² and R³ independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula II

15



- 20 wherein R⁴ and R⁵ signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R⁴ and R⁵ may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, 25 when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.


2. 3,3-Diphenylpropylamines according to claim 1, wherein each of R⁴ and R⁵ independently signifies a 30 saturated hydrocarbyl group, especially saturated aliphatic hydrocarbyl groups such as C₁₋₈-alkyl, especially C₁₋₆-alkyl, or adamantyl, R⁴ and R⁵ together comprising at least three, preferably at least four carbon atoms.

35


3. 3,3-Diphenylpropylamines according to claim 1 or 2, wherein at least one of R⁴ and R⁵ comprises a branched carbon chain.

4. 3,3-Diphenylpropylamines according to any one of claims 1 to 3, wherein X signifies any of the following groups a) to h):

5




10



15

20



25 5. 3,3-Diphenylpropylamines according to any one of claims 1 to 4, wherein the HOCH₂-group is in 5-position, R² is hydrogen and R³ is hydrogen or hydroxy, preferably in 2-position.

30 6. 3,3-Diphenylpropylamines according to claim 1, selected from N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine, its salts with physiologically acceptable acids, racemates and individual enantiomers thereof.

35


7. 3,3-Diphenylpropylamines according to any one of claims 1 to 6 for use as pharmaceutically active substances, especially as anticholinergic agents.

8. A pharmaceutical composition comprising a 3,3-diphenylpropylamine according to any one of claims 1 to 6 and preferably a compatible pharmaceutical carrier.

5

9. Use of a 3,3-diphenylpropylamine according to any one of claims 1 to 6 for preparing an anticholinergic drug:


10. A method for preparing 3,3-diphenylpropylamines according to any one of claims 1 to 6, comprising:
a) reducing the group R^6CO of a 3,3-diphenylpropylamine of formula III



20

wherein R^1 to R^3 and X are as defined above, R^6 is hydrogen or R^7O , where R^7 is hydrogen, alkyl, alkenyl, alkynyl or aryl, and any hydroxy groups may be protected, such as by methylation or benzylation, or

- 25 b) reacting a reactively esterified 3,3-diphenylpropanol of formula IV




wherein R^1 to R^3 are as defined above, any hydroxy groups may be protected, and wherein Y is a leaving group, with an amine of formula V




wherein X is as defined above, or

c) reducing a 3,3-diphenylpropionamide of formula VI



wherein R¹ to R³ and X are as defined above and any
10 hydroxy groups may be protected, or


d) N-methylating a secondary 3,3-diphenylpropylamine of
formula VII



20 wherein R¹ to R³ and X are as defined above and any
hydroxy groups may be protected, and wherein Z has the
same meaning as R⁴ and R⁵ with the exception of methyl, or

e) reducing a 3,3-diphenylpropenamine of formula VIIIa
or a 3,3-diphenylpropylamine of formula VIIIb


25



wherein R¹ to R³ and X are as defined above and any
hydroxy groups may be protected, and W signifies a hydroxy
group or a halogen atom, or

35 f) reacting a diphenylpropylamine of formula IX


25



5 wherein R¹ to R³ and X are as defined above, and Hal is halogen, with formaldehyde or a formaldehyde equivalent, or

g) oxidizing the methyl group of a diphenylpropylamine of formula X

10



15

wherein R¹ to R³ and X are as defined above, and

- i) when necessary splitting off hydroxy protecting groups in the compounds obtained, if desired after mono- or di-halogenation of one or both of the phenyl rings, and/or
- 20 ii) if desired converting the obtained bases of formula I into salts thereof with physiologically acceptable acids, or vice versa, and/or
- 25 iii) if desired separating an obtained mixture of optical isomers into the individual enantiomers, and/or
- iv) if desired methylating an ortho-hydroxy group in an obtained compound of formula I, wherein R¹ is hydrogen and/or R³ is hydroxy.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 93/00927

A. CLASSIFICATION OF SUBJECT MATTER		
IPC5: C07C 217/62, C07C 215/54, C07C 311/37, C07C 237/30, C07D 295/06, C07D 211/14, C07D 207/06, A61K 31/135 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC5: C07C, C07D, A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 8906644 (KABIVITRUM AB), 27 July 1989 (27.07.89) --	1-10
X	DE, B1, 1216318 (FARBWERKE HOECHST AG VORMALS MEISTER LUCIUS & BRÜNING), 12 May 1966 (12.05.66), column 4, line 1 - line 3; the claims --	1-10
X	GB, A, 1169944 (ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE), 5 November 1969 (05.11.69), page 1, line 10 - line 12; the claims --	1-10
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"B" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search		Date of mailing of the international search report
11 January 1994		07 -02- 1994
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Gerd Strandell Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 93/00927

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB, A, 1169945 (ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE), 5 November 1969 (05.11.69), page 1, line 10 - line 11; the claims -----	1-10

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 93/00927

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1 in part
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The wording "R⁴ and R⁵ may form a ring together with the amine nitrogen" is too broadly formulated to permit a meaningful search. The search on claim 1 has therefore been incomplete (See Art. 6).

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
 Information on patent family members

27/11/93

International application No.
 PCT/SE 93/00927

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 8906644	27/07/89	AU-B- 635493 AU-A- 2932989 DE-U- 6890018 EP-A,B- 0325571 SE-T3- 0325571	25/03/93 11/08/89 12/09/91 26/07/89
DE-B1- 1216318	12/05/66	DK-A- 111894	00/00/00
GB-A- 1169944	05/11/69	NONE	
GB-A- 1169945	05/11/69	US-A- 3446901	27/05/69



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07C 211/06, 215/54, 217/62, 237/30, 255/33, C07D 333/20, A61K 31/135, 31/33</p>	A1	<p>(11) International Publication Number: WO 98/43942</p> <p>(43) International Publication Date: 8 October 1998 (08.10.98)</p>
<p>(21) International Application Number: PCT/SE98/00556</p> <p>(22) International Filing Date: 26 March 1998 (26.03.98)</p> <p>(30) Priority Data: 9701144-9 27 March 1997 (27.03.97) SE</p> <p>(71) Applicant (for all designated States except US): PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): JOHANSSON, Rolf [SE/SE]; Daggstigen 8B, S-141 38 Huddinge (SE). HARALDSSON, Martin [SE/SE]; Runmästarvägen 8, S-183 72 Täby (SE). RINGBERG, Erik [SE/SE]; Gröna Gatan 23F, S-754 26 Uppsala (SE). VÅGBERG, Jan [SE/SE]; Karlslundsvägen 19, S-192 71 Sollentuna (SE). BEIERLEIN, Katarina [SE/SE]; Torbjörnsgatan 14, S-753 35 Uppsala (SE). EMOND, Rikard [SE/SE]; Mörtgatan 5, S-133 43 Saltsjöbaden (SE). SJÖBERG, Birger [SE/SE]; Trädgårdsvägen 98, S-191 46 Sollentuna (SE).</p> <p>(74) Agents: WIDÉN, Björn et al.; Pharmacia & Upjohn AB, Patent Dept., S-751 82 Uppsala (SE).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: NOVEL COMPOUNDS, THEIR USE AND PREPARATION</p>		
<p>(57) Abstract</p> <p>The invention relates to novel compounds of Formula (I) wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and Ar are as defined in claim 1, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The compounds have anticholinergic activity, and the invention also relates to the compounds of Formula (I) for use as therapeutically active substances, pharmaceutical compositions containing compounds of Formula (I), the use of the compounds of Formula (I) for preparing anticholinergic drugs, the use of the compounds of Formula (I) for treating urinary incontinence, and methods for preparing the compounds of Formula (I).</p> <div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL COMPOUNDS, THEIR USE AND PREPARATION

TECHNICAL FIELD

The present invention relates to novel therapeutically active compounds, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.


BACKGROUND OF THE INVENTION

WO 89/06644 and WO 94/11337 disclose tertiary 3,3-diphenylpropylamines having anticholinergic activity, especially for the treatment of urinary incontinence. SE-A-215499 discloses secondary 3,3-diphenylpropylamines having an advantageous effect on the heart and circulation. US-A-3,446,901, GB-A-1,169,944 and GB-A-1,169,945 disclose 3,3-diphenylpropylamines having antidepressant activity. DE-B1-1216318 discloses preparation of diphenylalkylamines having effect on the heart and circulation.

SUMMARY OF THE INVENTION

In accordance with the present invention, novel therapeutically active diarylpropylamines have been found which like the 3,3-diphenylpropylamines known from WO 89/06644 and WO 94/11337 above have favourable anticholinergic properties, and which therefore also can be used for the control of events mediated by acetylcholine, like urination.

In one aspect, the present invention provides novel compounds represented by the general formula I:



30

wherein:

R¹ is hydrogen, hydroxy, alkyl, alkoxy, hydroxyalkyl, trifluoromethyl, amino, alkylcarbonylamino, alkylcarbonyloxy, halogen,

5 R² and R³ independently are hydrogen, hydroxy, alkyl, alkoxy, hydroxyalkyl, halogen, alkoxycarbonylalkyl, carbamoyl, sulphamoyl,

R⁴ is ω-hydroxyalkoxy, ω-aminoalkoxy, ω-aminoalkylamino, alkoxyalkyl, hydroxyalkoxyalkylaminoalkyl, 10 dihydroxyalkyl, formyl, alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonylaminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, carbamoylalkyl, carboxamidoalkyl, carboxyl, amino, nitro, cyano, nitrilo, cyanoalkyl, azido, alkyl of at least two 15 carbon atoms, alkoxy of at least two carbon atoms, hydroxyalkyl of at least two carbon atoms,

R⁵ is hydrogen, halogen, alkyl,

Ar is aryl or heteroaryl which may be mono- or independently disubstituted by alkyl, alkoxy, hydroxy, 20 hydroxyalkyl, halogen, alkoxycarbonylalkyl, carbamoyl, sulphamoyl, and

R⁶ and R⁷ are hydrocarbyl groups which may be the same or different, together containing at least three carbon atoms, and which may carry one or more hydroxy groups, and 25 wherein carbon atoms may be interconnected by oxygen atoms, and wherein R⁶ and R⁷ may form a ring together with the amine nitrogen,

with the provisos that (a) when:

(i) at least two of R², R³ and R⁵ are other than hydrogen, 30 or

(ii) R¹ is other than hydroxy or methoxy, and Ar is other than phenyl that is ortho-substituted by hydroxy or methoxy, or

(iii) Ar is heteroaryl, or

35 (iv) at least one of R⁶ and R⁷ is aromatic hydrocarbyl or cycloalkyl, then

R⁴ may also be hydrogen, methyl, methoxy, hydroxy, hydroxymethyl, halogen, carbamoyl, sulphamoyl;

and (b), when Ar is unsubstituted phenyl, then R¹, R², R³, R⁴ and R⁵ can not all be hydrogen;

their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

In another aspect, the present invention provides the compounds having the general Formula I above for therapeutical use, especially for the treatment of urinary incontinence related disorders.

In still another aspect, the present invention provides a pharmaceutical composition comprising one or more compounds of the general Formula I above as the active ingredient, preferably together with a pharmaceutically acceptable carrier and, if desired, other pharmacologically active agents.

In yet another aspect, the present invention provides a method of treating a patient (animals, including humans) suffering from a disorder related to urinary incontinence, which method comprises the step of administering to the said patient an effective amount of a compound having the general Formula I above.

In another aspect, the present invention provides the compounds according to Formula I for use as a pharmaceutically active substance, especially as an anticholinergic agent.

In yet another aspect, the present invention provides the use of the compounds having the general Formula I above for the manufacture of a medicament for the treatment of urinary incontinence related disorders.

In still another aspect, the present invention provides processes for preparing compounds having the general Formula I above.

DETAILED DESCRIPTION OF THE INVENTION

The present invention comprises novel 3,3-diarylpropylamines and their pharmaceutically acceptable salts which are characterized by Formula I above and which

are useful as anticholinergic agents. The compounds are particularly useful for treatment of urinary incontinence.

One subgroup of compounds of Formula I is defined by the substituent R⁴ being ω-hydroxyalkoxy, ω-aminoalkoxy, ω-aminoalkylamino, alkoxyalkyl, hydroxyalkoxyalkyl-aminoalkyl, dihydroxyalkyl, formyl, alkylcarbonyl, alkoxy carbonyl, alkoxy carbonylalkyl, alkylcarbonyl-aminoalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, carbamoylalkyl, carboxamidoalkyl, carboxyl, amino, nitro, cyano, nitrilo, cyanoalkyl, or azido.

In a limited group of compounds within this subgroup, R¹ is hydrogen or methyl, R², R³ and R⁵ are either all hydrogen or one of R², R³ and R⁵ is methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and the others are hydrogen, and Ar is phenyl or phenyl which is mono- or independently disubstituted by methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen.

Another subgroup of the compounds of Formula I is defined by Ar being heteroaryl.

In a limited group of compounds within this subgroup, R¹ is hydrogen or methyl, and R², R³, R⁴ and R⁵ are either all hydrogen or one of R², R³, R⁴ and R⁵ is methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen, and the others are hydrogen.

Still another subgroup of the compounds of Formula I is defined by R¹ being hydrogen, alkyl, hydroxyalkyl, trifluoromethyl, amino, alkylcarbonylamino, alkylcarbonyloxy, or halogen. Preferably, Ar is then other than phenyl that is ortho-substituted by hydroxy or alkoxy.

In a limited group of compounds within this subgroup, R¹ is hydrogen or methyl, R², R³, R⁴ and R⁵ are either all hydrogen or one of R², R³, R⁴ and R⁵ is methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen, and the others are hydrogen, and Ar is phenyl or phenyl which is mono- or independently disubstituted by methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen.

Yet another subgroup of the compounds of Formula I is defined by at least one of R⁶ and R⁷ being aromatic hydrocarbyl, cycloalkyl or a hydrocarbyl chain wherein carbon atoms are interconnected by an oxygen atom at one or more positions.

In a limited group of compounds within this subgroup, R¹ is hydrogen or methyl, R², R³, R⁴ and R⁵ are either all hydrogen or one of R², R³, R⁴ and R⁵ is methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen, and the others are hydrogen, and Ar is phenyl or phenyl which is mono- or independently disubstituted by methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen.

In the compounds of Formula I, "alkyl", separately and in combinations, is preferably C₁₋₈alkyl, i.e. methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, and isomeric forms thereof, more preferably C₁₋₆alkyl, especially C₁₋₄alkyl.

Similarly, "alkoxy", separately and in combinations, is preferably C₁₋₈alkoxy, i.e. methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, heptoxy, octoxy, and isomeric forms thereof, more preferably C₁₋₆alkoxy, especially C₁₋₄alkoxy.

"Aryl" means phenyl or naphthyl. "Heteroaryl" refers to a 5- or 6-membered heteroaromatic ring having from one to three heteroatoms, and which optionally may be fused to a homoaromatic ring, such as a benzene ring. Exemplary heteroaryl groups are morpholinyl, thienyl, furyl, piperazinyl, piperidinyl, imidazolyl, pyridazolyl, oxazolyl, isoxazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl or pyridazinyl.

"Halogen" includes fluoro, chloro, bromo and iodo.

When aryl is mono-substituted, it is preferably substituted in 2-position. When aryl is di-substituted, it is preferably substituted in positions 2 and 4. Preferred substituents are methyl, methoxy, hydroxy, hydroxymethyl, halogen, alkoxycarbonylalkyl, carbamoyl, sulphamoyl,

especially methyl, hydroxymethyl and halogen. Aryl is preferably phenyl.

Preferred heteroaryl groups are thienyl, pyrrol, thiazolyl, oxazolyl, methylthiazolyl and methylpyrrol.

5 R¹ is preferably hydroxy, halogen, trifluoromethyl, amino, methoxy or hydroxymethyl.

R² and R³ are preferably selected from hydrogen, hydroxy and methoxy.

10 R⁴ is preferably hydrogen, formyl, alkoxycarbonyl, alkylcarbonyl, hydroxyalkyl, alkoxyalkyl, carboxamidoalkyl, carbamoylalkyl, aminoalkyl, amino, azido, cyanoalkyl, carboxy or carboxyalkyl. More preferably, R⁴ is hydrogen, formyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, ethoxymethyl, 15 methoxycarbonyl, amino, aminopropyl, acetyl, 1,2-hydroxyethyl, ethylaminomethyl, or hydroxyethoxyethyl-aminoethyl.

R⁵ is preferably hydrogen.


20 R⁶ and R⁷ independently of each other preferably signify a saturated hydrocarbyl group, especially a saturated aliphatic hydrocarbyl group, such as C₁₋₈-alkyl, especially C₁₋₆-alkyl, or adamantyl, R⁶ and R⁷ together containing at least three, preferably at least four carbon atoms. R⁶ and R⁷ may carry one or more hydroxy groups and 25 they may be joined to form a ring together with the nitrogen atom. It is preferred that at least one of R⁶ and R⁷ comprises a branched carbon chain.

Exemplary groups -NR⁶,R⁷ are diethylamino, diisopropylamino, methyl-tert.-butylamino, methyl-tert.- 30 pentylamino, piperidino, 2,2,6,6-tetramethylpiperidino, methylcyclobutylamino, methylcyclopentylamino, methylcyclohexylamino, methylcycloheptylamino, pyrrolidino, 2,2,5,5-tetramethylpyrrolidino, N-methyl-N-adamantylamino, especially diisopropylamino.

35 Representative compounds of Formula I are:
N,N-diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamine hydrochloride


RECTIFIED SHEET (RULE 91)

- N,N-diisopropyl-3-(5-formyl-2-hydroxy-phenyl)-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-(2-hydroxy-5-methyloxycarbonylphenyl)-3-phenylpropanamine, and its (R)-isomer
- 5 N,N-diisopropyl-3-(5-acetyl-2-hydroxyphenyl)-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-[2-hydroxy-5-(2-hydroxyethyl)phenyl]-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-[2-hydroxy-5-(1-hydroxyethyl)phenyl]-3-phenylpropanamine, and its 3(R)-isomer
- 10 N,N-diisopropyl-3(R)-[5-(1(R*),2-dihydroxyethyl)-2-hydroxy-phenyl]-3-phenylpropanamine, and its 1(S*)-isomer
- N,N-diisopropyl-3-[2-hydroxy-5-(6-hydroxyhexyl)phenyl]-3-phenylpropanamine, and its (R)-isomer
- 15 N,N-diisopropyl-3-(5-ethoxymethyl-2-hydroxyphenyl)-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-[5-(3-aminopropyl)-2-hydroxyphenyl]-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-[5-(3-acetamidopropyl)-2-hydroxyphenyl]-3-phenylpropanamine, and its (R)-isomer
- 20 N,N-diisopropyl-3-[5-(2-cyanoethyl)-2-hydroxyphenyl]-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-(5-amino-2-hydroxyphenyl)-3-phenylpropanamine, and its (R)-isomer
- 25 N,N-diisopropyl-3-(5-azido-2-hydroxyphenyl)-3-phenylpropanamine, and its (R)-isomer
- N,N-diisopropyl-3-[2-hydroxy-5-(3-hydroxypropyl)phenyl]-3-phenylpropanamine, and its (R)-isomer
- N-cyclobutyl-N-methyl-3-(2-hydroxyphenyl)-3-phenylpropanamine
- 30 N,N-diisopropyl-3-(2-hydroxyphenyl)-3-(2-thienyl)propanamine
- N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-(2-thienyl)propanamine, and its (R)-isomer
- 35 The compounds of Formula I may, in accordance with the present invention, be prepared by per se conventional methods, and especially by
- a) reacting a compound of Formula II




wherein R^1 to R^5 and Ar are as defined above for Formula I,
 and Y is a leaving group, with an amine HNR^6, R^7 , wherein R^6
 5 and R^7 are as defined above, or

b) reducing a compound of Formula III




wherein R^1 to R^7 and Ar are as defined above for Formula I
 10 and any hydroxy groups may be protected, or

c) N-alkylating a secondary amine of Formula IV




wherein R^1 to R^5 and Ar are as defined above for Formula I
 15 and any hydroxy groups may be protected, and wherein Z has
 the same meaning as R^6 and R^7 , or

d) reducing a compound of Formula Va or Vb




wherein R^1 to R^7 and Ar are as defined above for Formula I and any hydroxy groups may be protected, and W signifies a hydroxy group or halogen, or

e) in a compound of Formula VI



wherein R^2 to R^7 and Ar are as defined above for Formula I, and R^{1a} is carboxyl or alkoxy, converting R^{1a} to hydroxy, or

f) in a compound of Formula VII




15

wherein R^1 , R^6 , R^7 and Ar are as defined above for Formula I, and one of R^{2b} to R^{5b} is alkylene and the others are as defined above for R^2 to R^5 , reducing alkylene to alkyl, hydroxyalkyl or dihydroxyalkyl, or

g) in a compound of Formula I as defined above, converting one or more of groups R^1 to R^5 to another or other groups R^1 to R^5 , or

5

h) reacting a compound of Formula VIII




wherein R^1 to R^7 are as defined above for Formula I, and X is oxygen or sulphur, with a compound of Formula IX

10




to form a compound of Formula Ia




15 wherein R^1 to R^7 and X are as defined above, or

i) reacting a compound of Formula VIII above, wherein X is oxygen, with a compound of Formula X




to form a compound of Formula Ib



wherein R¹ to R⁷ are as defined above for Formula I, or


5

j) converting a compound of Formula XI




wherein R¹ to R⁷ are as defined above for Formula I, to a

10 compound of Formula XII




wherein R¹ to R⁷ are as defined above for Formula I, or

k) converting a compound of Formula XIII



wherein R¹ to R⁷ are as defined above for Formula I, and X
 5 is oxygen or sulphur, to a compound of Formula XIV



- wherein R¹ to R⁷ and X are as defined above for Formula I,
 and R⁸ and R⁹ independently are hydrogen or alkyl, and
- 10 i) when necessary splitting off hydroxy protecting groups
 in the compounds obtained,
 ii) if desired converting the obtained bases of Formula I
 into salts thereof with physiologically acceptable acids,
 or vice versa, and/or
- 15 iii) if desired separating an obtained mixture of optical
 isomers into the individual enantiomers.

Appropriate reaction conditions in the above reactions
 may readily be selected by the skilled person with
 reference to analogous prior art methods and with due
 20 consideration of the specific Examples below. The necessary
 starting materials are either known or may be prepared in
 analogy with the preparation of known compounds.

The separation of mixtures of optical isomers, according to ii) above, into the individual enantiomers can e.g. be achieved by fractional crystallisation of salts with chiral acids or by chromatographic separation on
5 chiral columns.

In accordance with the present invention, the compounds of Formula I, in the form of free bases or salts with physiologically acceptable acids, can be brought into suitable galenic forms, such as compositions for oral use,
10 for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures. Such pharmaceutical compositions according to the invention comprise an effective amount of the compounds of Formula I in association with compatible pharmaceutically acceptable
15 carrier materials, or diluents, as is well known in the art. The carriers may be any inert material, organic or inorganic, suitable for enteral, percutaneous or parenteral administration, such as: water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch
20 glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such compositions may also contain other pharmaceutically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers,
25 and the like.

The compositions according to the invention can e.g. be made up in solid or liquid form for oral administration, such as tablets, capsules, powders, syrups, elixirs and the like, in the form of sterile solutions, suspensions or
30 emulsions for parenteral administration, and the like.

The compounds and compositions can, as mentioned above, be used for the same therapeutical indications as the compounds of the above-mentioned WO 89/06644 or WO 94/11337, i.e. for the treatment of acetylcholine-mediated
35 disorders, such as urinary incontinence, especially urge incontinence. The dosage of the specific compound will vary depending on its potency, the mode of administration, the age and weight of the patient and the severity of the

condition to be treated. The daily dosage may, for example, range from about 0.01 mg to about 4 mg per kilo of body weight, administered singly or multiply in doses e.g. from about 0,05 mg to about 200 mg each.

5 The invention will be further illustrated by the following non-limiting example and pharmacological tests.

General

N.M.R data were acquired on a Jeol JNM-EX 270 or a Varian Unity 500 spectrometer. Spectra were recorded with
10 tetramethylsilane (TMS) as internal standard at 30°C. Infrared spectra were recorded on a Perkin-Elmer Model Model 841 spectrophotometer. Non-corrected melting points were obtained on a Koeffler apparatus. Gas chromatography was performed on a HP 5940 instrument with a 10 m HP-1
15 column and the oven heated in the linear temperature gradient mode. All lithium aluminum hydride reductions were quenched by the use of the procedure according to V. Micovic and M. Mihailovic (J. Org. Chem. 18, 1190 (1953)).

20

EXAMPLE 1

N-(5-Hydroxy-3-oxapentyl)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine hydrochloride

A solution of N-(5-hydroxy-3-oxapentyl)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamide (2.75 g, 7
25 mmol) in THF (40 mL) was added to lithium aluminum hydride (LAH) (0.50 g, 13 mmol) and the mixture was stirred at ambient temperature for 2 h. The reaction was quenched and the solvent evaporated. The residue was chromatographed on silica (toluene-triethylamine 19:1). The title compound was
30 crystallised by dissolving the free amine in diethyl ether and adding hydrogen chloride in diethyl ether. Yield 0.75 g (27%); mp 70-75°C. ¹H NMR (DMSO-d₆) δ 1.17 (q, 3H), 1.23 (t, 3H), 2.18 (d, 3H), 2.47 (m, 2H), 2.84-3.07 (m, 2H), 3.15 (m, 1H), 3.37 (m, 1H), 3.42 (d, 2H), 3.46 (s, 2H),
35 3.67 (m, 1H), 3.74 (m, 2H), 4.30 (m, 1H), 4.76 (br, 1H), 6.71 (d, 1H), 6.80 (d, 1H), 7.06 (d, 1H), 7.16 (t, 1H), 7.27 (t, 2H), 7.33 (d, 2H), 9.29 (d, 1H) and 10.07 (br, 1H). Anal. (C₂₃H₃₃NO₃·HCl) C, H, N.

The starting compound N-(5-hydroxy-3-oxapentyl)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamide was prepared as follows:

5

1.1 Trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenoic acid

A solution of triethyl phosphonoacetate (22.4 g, 0.10 mol) in THF (150 mL) was added to sodium hydride (80%, 2.7 g, 0.09 mol) under nitrogen during 15 min. The resulting mixture was refluxed for 15 min whereafter a solution of 2-benzyloxy-5-methyl-benzophenone (15.1 g, 0.05 mol) in THF (50 mL) was added. The reaction mixture was refluxed for 19 h. Water and sodium hydroxide (10 g, 0.25 mol) were added and most of the THF was distilled off. Ethanol was added until a clear solution was obtained and the reflux was continued for a few minutes. Water was added to a total volume of 1 L and the mixture was washed with diethyl ether. Hydrochloric acid was added to the water-phase and a crystalline mass was obtained. The pure trans-isomer was obtained by recrystallisation from ethanol. Yield 10.4 g (60%). ¹H NMR (DMSO-d₆) δ 2.24 (s, 3H), 4.92 (s, 2H), 6.41 (s, 1H), 6.87 (d, 1H), 6.98 (d, 1H), 7.03 (m, 2H) 7.12 (m, 1H), 7.22 (m, 3H), 7.29 (m, 1H), 7,30 (m, 1H) and 7.33-7.39 (m, 3H).

1.2 trans-N-(5-Hydroxy-3-oxapentyl)-N-isopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenamide

A solution of DCC (5.2 g, 17 mmol) in THF (20 mL) was added to a solution of trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenoic acid (6.9 g, 20 mmol), 2-(2-isopropylaminoethoxy)-ethanol, triethylamine (2.5 g, 25 mmol) and hydroxysuccinimide (2.8 g, 24 mmol) in THF (50 mL). The reaction mixture was stirred for 20 h. The solvent was evaporated and the residue chromatographed on silica (gradient from toluene to ethyl acetate). Yield 5.9 g (62%).

1.3 trans-N-(5-Hydroxy-3-oxapentyl)-N-isopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamide

A solution of trans-N-(5-hydroxy-3-oxapentyl)-N-isopropyl-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanamide (5.9 g, 12 mmol) in acetic acid (50 mL) was hydrogenated over Pd/C (10 %, 0.5 g) for 16 h. Filtering and evaporation of solvent left a residue that was chromatographed on silica (ethyl acetate). Yield 2.83 g (61 %).

EXAMPLE 2

N-Cycloheptyl-N-methyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine hydrochloride

A solution of N-cycloheptyl-N-methyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamide (0.93 g, 2.5 mmol) in THF (20 mL) was added to LAH (0.22 g, 5.6 mmol) and the mixture was stirred at reflux temperature for 30 min. The reaction was quenched and the solvent evaporated. The residue was chromatographed on silica (chloroform-methanol 9:1). The amine salt was obtained by dissolving the free amine in diethyl ether and adding hydrogen chloride in diethyl ether. Yield 0.45 g (46%); mp. 230-232°C. ¹H NMR (DMSO-d₆) δ 1.27-1.70 (m, 10H), 1.88 (br, 1H), 2.05 (d, 1H), 2.17 (s, 3H), 2.42 (br, 1H), 2.60 (s, 3H), 2.85 (br, 2H), 3.34 (m, 1H), 4.30 (t, 1H), 6.72 (d, 1H), 6.80 (dd, 1H), 7.05 (br, 1H), 7.15 (t, 1H), 7.27 (t, 2H), 7.31 (d, 2H), 9.31 (s, 1H) and 10.53 (br, 1H). Anal. (C₂₄H₃₃NO·HCl) C, H, N.

The starting compound N-cycloheptyl-N-methyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamide was prepared as follows:

2.1 N-Cycloheptyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenamide

A solution of DCC (5.2 g, 25 mmol) in THF (50 mL) was added to a solution of trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenoic acid (Example 1.1), (6.9 g,

20 mmol), cycloheptylamine (2.6 g, 23 mmol), triethylamine (2.0 g, 20 mmol) and hydroxysuccinimide (2.4 g, 21 mmol) in THF (50 mL). The reaction mixture was stirred for 1 h at room temperature. Another portion of cycloheptylamine (1.3 g) was added and the reaction mixture was left stirring for another 1 h. The mixture was filtered and the filtrate evaporated. The residue was dissolved in diethyl ether and washed with hydrochloric acid (1M), water and brine in subsequent order. After evaporation of the solvent, the residue was crystallised from toluene-hexane to give 7.3 g (83%). ^1H NMR (CDCl_3) δ 1.06 (br, 2H), 1.25-1.74 (m, 10H), 2.30 (s, 3H), 3.83 (m, 1H), 4.95 (s, 2H), 5.50 (d, 1H), 6.49 (s, 1H), 6.90-7.08 (m, 4H), and 7.12-7.44 (m, 9H).

2.2 N-Cycloheptyl-N-methyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanamide

A solution of N-cycloheptyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanamide (4.4 g, 10 mmol) and methyl iodide (4 g, 30 mmol) in DMF (10 mL) was added to sodium hydride (80 %, 1.2 g, 40 mmol) at ambient temperature and the mixture was stirred for 60 min. Excess sodium hydride was destroyed by adding methanol, and the reaction mixture was then partitioned between toluene and water. The organic layer was dried (MgSO_4) and the solvent was evaporated. The residue was crystallised from toluene-hexane to yield 4.4 g (97%). ^1H NMR (CDCl_3) (almost 1:1 mixture of rotameres) δ 1.20-1.80 (m, 12H), 2.30 (m, 3H) 2.61 (s, 1.5H), 2.71 (s, 1.5H), 3.93 (m, 0.5H), 4.46 (m, 0.5H), 4.81 (m, 1H), 6.43 (m, 1H), 6.81 (m, 2H) and 7.08-7.35 (m, 10H).

2.3 N-Cycloheptyl-N-methyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamide

A solution of N-cycloheptyl-N-methyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanamide (3.15 g, 7 mmol) in acetic acid (40 mL) was hydrogenated over Pd/C (10%, 0.2 g) for 72 h. The reaction mixture was filtered and the solvent evaporated. The residue was chromatographed

on silica (toluene-ethyl acetate 9:1). Yield 0.95 g (37%).
 $^1\text{H NMR}$ (CDCl_3) δ 1.26-1.98 (m, 12H), 2.02 (s, 3H), 2.12 (s,
3H), 2.28 (m, 1H), 2.52 (m, 1H), 2.71 (m, 1H), 4.36 (dd,
1H), 6.39 (s, 1H), 6.76 (s, 2H), 7.15 (m, 2H) and 7.25 (m,
5 5H).

EXAMPLE 3

N-Cyclohexyl-N-methyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine hydrochloride

10 A solution of N-cyclohexyl-N-methyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenamide (4.0 g, 9 mmol) in THF (90 mL) was added to LAH (0.50 g, 13 mmol) in THF (5 mL) and the mixture was stirred at ambient temperature for 2.5 h. The reaction was quenched and the
15 solvent evaporated. The resulting oil was hydrogenated over Pd/C (10%, 1g) in acetic acid (70 mL) for 20 h. After filtration and evaporation of the solvent, the residue was chromatographed on silica (chloroform:methanol 99:1). The amine salt was obtained by dissolving the free amine in
20 diethyl ether and adding hydrogen chloride in diethyl ether. Yield 1.2 g (36%); mp. 179-183°C. $^1\text{H NMR}$ (DMSO-d_6) δ 1.05 (m, 1H), 1.21-1.38 (m, 4H), 1.51 (d, 1H), 1.74 (br, 2H), 1.86 (br, 1H), 2.00 (d, 1H), 2.17 and 2.19 (s, 3H), 2.39-2.56 (m, 2H), 2.63 (m, 3H), 2.82 (m, 1H), 2.93 (m,
25 1H), 3.17 (m, 1H), 4.32 (q, 1H), 6.73 and 6.75 (d, 1H), 6.79 and 6.81 (t, 1H), 7.02 and 7.10 (d, 1H), 7.14-7.18 (m, 1H), 7.25-7.29 (m, 2H), 7.33 (t, 2H), 9.34 (br, 1H) and 10.78 (s, 1H). Anal. ($\text{C}_{23}\text{H}_{31}\text{NO}\cdot\text{HCl}$) C, H, N.

30 The starting compound N-cyclohexyl-N-methyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenamide was prepared as follows:

3.1 N-Cyclohexyl-N-methyl-trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenamide

35 A solution of DCC (5.2 g, 25 mmol) in THF (50 mL) was added to a solution of trans-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropenoic acid (Example 1.1), (6.9 g,

20 mmol), N-methyl-cyclohexylamine (2.6 g, 23 mmol), triethylamine (2.0 g, 20 mmol) and hydroxysuccinimide (2.4 g, 21 mmol) in THF (50 mL). The reaction mixture was stirred for 2 h. A second portion of DCC (2.5 g, 13 mmol) and N-methyl-cyclohexylamine (1.5 g, 13 mmol) was added and the reaction mixture was left stirring for 16 h. Diethyl ether and hydrochloric acid (1M) were added and the organic phase was washed with brine. The organic layer was evaporated and the residue was chromatographed on silica (toluene-ethyl acetate 9:1). Yield 5.5 g (63%). ¹H NMR (DMSO-d₆) (almost 1:1 mixture of rotameres) δ 0.88-1.06 (m, 2H), 1.16-1.39 (m, 5H), 1.55 (t, 2H), 1.67 (br, 1H), 2.21 (s, 1.5H), 2.23 (s, 1.5H), 2.56 (s, 1.5H), 2.67 (s, 1.5H), 3.67 (m, 0.5H), 4.05 (m, 0.5H), 4.82 (s, 1H), 4.85 (s, 1H), 6.57 (s, 0.5H), 6.59 (s, 0.5H), 6.84 (dd, 1H), 6.87 (d, 0.5H), 6.89 (t, 1H), 6.95 (dd, 1H), 6.98 (d, 0.5H), 7.12 (dd, 1H), 7.17 (m, 3H), 7.27 (m, 2H), and 7.32 (m, 3H).

EXAMPLE 4

20 **N,N-Diisopropyl-3-(2-trifluoromethylphenyl)-3-phenylpropanamine hydrochloride**

Boran·SMe₂-complex in THF (7 mL, 14 mmol) was gently refluxed with a weak stream of nitrogen for 30 minutes. N,N-Diisopropyl-3-(2-trifluoromethylphenyl)-3-phenylpropanamide (1.55 g, 4.2 mmol) was added to the refluxing solution and the reflux was continued for 1 h. The reaction mixture was partitioned between diethyl ether and sodium hydroxide (1M). The solvent of organic layer was evaporated and the residue was chromatographed on silica (toluene-triethylamine 9:1) to yield the free amine. The hydrochloride salt was obtained by dissolving the amine in diethyl ether with the addition of hydrogen chloride in diethyl ether. The resulting oil produced crystals after some time stirring in diethyl ether. Yield 0.39 g (23%); mp. 143-144°C. ¹H NMR (DMSO-d₆) δ 1.19 (q, 6H), 1.25 (dd, 6H), 2.53 (m, 1H), 2.70 (m, 1H), 2.87 (m, 2H), 3.59 (m, 2H), 4.38 (t, 1H), 7.24 (t, 1H), 7.35 (t, 2H), 7.39 (d,

2H), 7.45 (t, 1H), 7.68 (t, 1H), 7.74 (t, 2H) and 10.25 (br, 1H). Anal. (C₂₂H₂₈NF₃·HCl) C, H, N.

The starting compound N,N-diisopropyl-3-(2-trifluoromethylphenyl)-3-phenylpropanamide was prepared as follows:

4.1 Diethyl N,N-diisopropylacetamide phosphonate

A mixture of triethylphosphite (23 g, 0.14 mol) and N,N-diisopropyl 2-bromoacetamide (29 g, 0.13 mol) was heated to 110°C for 3 h to yield 35 g (97%). The product was used without purification.

4.2 N,N-Diisopropyl-3-(2-trifluoromethylphenyl)-3-phenylpropenamide

A solution of diethyl N,N-diisopropylacetamide phosphonate (8.4 g, 30 mmol) in THF (20 mL) was added dropwise to sodium hydride (80 %, 0.85 g, 29 mmol) during 30 min, keeping the temperature below 30°C. A solution of 2-trifluoromethyl-benzophenone (5.0 g, 20 mmol) in THF (20 mL) was added and the reaction mixture was heated to 50°C and kept at that temperature for 16 h. A second portion of the phosphorous ylide (15 mmol), prepared as above, was added. After another 24 h at 50°C the mixture was partitioned between diethyl ether and water. The ethereal layer was evaporated and the residue chromatographed on silica (toluene-ethyl acetate 9:1) yielding 3.0 g (41%) as a mixture of the E- and Z-isomers. Labels a and b refer to the different isomers. ¹H NMR (CDCl₃-d) δ 0.80 (d, 6Ha), 1.08 (d, 3Hb), 1.24 (t, 6Hb), 1.31 (d, 3Hb), 1.44 (d, 6Ha), 3.32 (m, 1Ha), 3.34 (m, 1Hb), 4.19 (m, 1Hb), 4.32 (m, 1Ha), 6.04 (s, 1Ha), 6.65 (s, 1Hb) and 7.18-7.75 (m, 9Ha, 9Hb).

4.3 N,N-Diisopropyl-3-(2-trifluoromethylphenyl)-3-phenylpropanamide

A solution of N,N-diisopropyl-3-(2-trifluoromethylphenyl)-3-phenylpropanamide (2.95 g, 8.1

mmol) in ethanol (50 mL) was hydrogenated over Pd/C (10%, 300 mg) at normal pressure for 24 h. The catalyst was filtered off, the solvent partly evaporated and the product collected after crystallisation. Yield 1.78 g (60%). ¹H NMR (CDCl₃-d) δ 1.16 (m, 6H), 1.30 (m, 6H), 2.86 (dd, 1H), 3.11 (dd, 1H), 3.41 (m, 1H), 4.03 (m, 1H), 5.12 (m, 1H) and 7.10-7.78 (m, 9H).

EXAMPLE 5

10 **N,N-Diisopropyl-3-(2-hydroxyphenyl)-3-(3-pyridyl)-propanamine dihydrochloride**

A solution of N,N-diisopropyl-3-(2-methoxyphenyl)-3-(3-pyridyl)-propanamide (2.8 g, 8 mmol) in THF (25 mL) was added to LAH (1.3 g, 32 mmol). The reaction mixture was
15 refluxed for 4 h whereafter the reaction was quenched and the solvent evaporated. The residue was chromatographed on silica (toluene-triethylamine 99:1) to give 2.2 g. The product (1.3 g, 4 mmol) was dissolved in dichloromethane (20 mL) and the solution was cooled to -78°C and boron
20 tribromide (1 g, 8 mmol) was added dropwise and the reaction mixture was allowed to reach room temperature during 1 h. The reaction mixture was washed with sodium hydroxide (1M) and brine and the organic phase was dried (MgSO₄) and the solvent evaporated. The residue was
25 chromatographed on silica (toluene-triethylamine 9:1) to give 0.35 g. The free amine was dissolved in diethyl ether and hydrogen chloride in diethyl ether was added to produce the dihydrochloride as crystals which soon rearranged to a hard glass. ¹H NMR (DMSO-d₆) δ 1.22 (dd, 6H), 1.28 (dd,
30 6H), 2.60 (m, 1H), 2.70 (m, 1H), 2.93 (m, 2H), 3.60 (m, 2H), 4.60 (t, 1H), 6.85 (t, 1H), 6.89 (d, 1), 7.11 (t, 1H), 7.38 (d, 1H), 7.96 (dd, 1H), 8.46 (d, 1H), 8.75 (d, 1H), 8.85 (s, 1H), 9.90 (br, 1H) and 10.14 (s, 1H).

35 The starting compound N,N-diisopropyl-3-(2-methoxyphenyl)-3-(3-pyridyl)-propanamide was prepared as follows:

5.1 2-Methoxyphenyl-3-pyridyl-ketone

A solution of 2-bromoanisole (21 g, 0.11 mol) in diethyl ether (100 mL) was added to magnesium turnings during 45 minutes with heating. After the addition the reflux was continued for 15 min. The Grignard reagent was cooled to 0°C and a solution of 3-cyanopyridine (10 g, 0.10 mol) in diethyl ether (100 mL) was added dropwise. The mixture was refluxed for a few minutes. Hydrochloric acid (20 mL, 0.24 mol, conc.) and 2-propanol (20 mL) were added and the reflux was continued for 30 min. Water and diethyl ether were added and the phases separated. The water-phase was made alkaline (2M NaOH) and was extracted with diethyl ether. The combined organic phases were dried (MgSO₄) and evaporated to yield 17 g. The crude was chromatographed on silica (toluene-ethyl acetate 19:1) to give 3.75 g (19%).
¹H NMR (CDCl₃-d) δ 3.76 (s, 3H), 7.01 (d, 1H), 7.10 (t, 1H), 7.41 (dd, 1H), 7.46 (dd, 1H), 4.53 (m, 1H), 8.12 (d, 1H), 8.75 (s, 1H) and 8.94 (s,

5.2 N,N-Diisopropyl-3-(2-methoxyphenyl)-3-(3-pyridyl)-propanamide

A solution of of diethyl N,N-diisopropylacetamide phosphonate (Example 4.1), (9.3 g, 33 mmol) in THF (40 mL) was added dropwise to sodium hydride (80 %, 1.0 g, 33 mmol) during 15 min. The mixture was heated to 40°C for 15 minutes and then cooled to 5°C whereafter a solution of 2-methoxyphenyl-3-pyridyl-ketone (4.5 g, 21 mmol) in THF (10 mL) was added dropwise. The reaction mixture was allowed to reach room temperature and was stirred for 16 h. The reaction mixture was partitioned between diethyl ether and water and the organic phase was dried (MgSO₄) and evaporated to yield 7.1 g of solid material. The product was hydrogenated over Pd/C (10%, 0.2 g) in acetic acid (50 mL) for 48 h. The reaction mixture was filtered and the solvent evaporated. The residue was partitioned between diethyl ether and hydrochloric acid (1 M) and the phases were separated. The water-phase was made alkaline (2 M

sodium hydroxide) and extracted with diethyl ether. The combined organic phases were dried (MgSO₄) and filtered. Crystallisation began and the mixture was diluted with hexane. Filtration gave 2.9 g (40%). ¹H NMR (CDCl₃-d) δ

5 1.14 (dd, 6H), 1.28 (d, 6H), 3.04 (dd, 2H), 3.38 (m, 1H), 3.74 (s, 3H), 4.05 (m, 1H), 5.00 (t, 1H), 6.84 (d, 1H), 6.92 (t, 1H), 7.19 (m, 3H), 7.57 (d, 1H), 8.39 (m, 1H) and 8.55 (d, 1H). 1H).

10

EXAMPLE 6**N,N-Diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamine hydrochloride**

A solution of N,N-diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamide (3.1 g, 9.4 mmol) in THF (20 mL) was

15 added to LAH (1.0 g, 25 mmol) and the reaction mixture was stirred at reflux temperature for 2 h. More LAH (0.5 g), was added and the reflux continued for another 2 h. The reaction was quenched and the solvent evaporated. The residue was chromatographed on silica (toluene-ethyl

20 acetate 3:1) to give 0.4 g of the free amine as a syrup. The amine was dissolved in isopropanol/diethyl ether and hydrogen chloride in diethyl ether was added to give the amine salt. Yield 0.32 g (10 %); mp 152-154 °C. ¹H NMR (DMSO-d₆) δ 1.19 (dd, 6H), 1.26 (dd, 6H), 2.57 (m, 2H),

25 2.86 (m, 1H), 2.97 (m, 1H), 3.58 (m, 2H), 4.36 (t, 1H), 6.69 (dd, 1H), 7.14 (m, 1H), 7.22 (m, 2H), 7.29 (m, 1H), 7.32 (d, 2H), 7.33 (s, 2H), 7.54 (m, 1H) and 10.24 (br, 1H). Anal. (C₂₁H₂₈NF·HCl) H, N; C: calcd, 72.1; found, 72.6.

30

The starting compound N,N-diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamide was prepared as follows:

6.1 trans-N,N-Diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamide

35

A solution of diethyl N,N-diisopropylacetamide phosphonate (Example 4.1), (8.4 g, 30 mmol) in THF (20 mL) was added dropwise to sodium hydride (80 %, 0.85 g, 25

mmol) during 30 min, keeping the temperature below 40°C. A solution of 2-trifluoromethyl-benzophenone (4.0 g, 20 mmol) in THF (10 mL) was added and the reaction mixture was stirred at ambient temperature for 30 min. The mixture was partitioned between diethyl ether and brine. The organic layer was dried (MgSO₄) and evaporated to give a crystalline mass. Recrystallisation from hexane yielded 3.9 g (60 %). ¹H NMR (CDCl₃-d) δ 0.85 (d, 6H), 1.39 (d, 6H), 3.29 (m, 1H), 4.27 (m, 1H), 6.29 (s, 1H), 7.10 (m, 3H) and 7.30 (m, 6H).

6.2 N,N-Diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamide

A solution of trans-N,N-diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamide (3.25 g, 10 mmol) was hydrogenated over Pd/C (10%, 300 mg) in acetic acid (30 mL) for 24 h. The catalyst was filtered off and the solvent was evaporated to yield 3.15 g (96%). ¹H NMR (CDCl₃-d) δ 1.12 (q, 6H), 1.28 (q, 6H), 3.05 (d, 2H), 3.38 (m, 1H), 4.03 (m, 1H), 4.93 (t, 1H) and 6.94-7.32 (m, 9H).

20

EXAMPLE 7

(R)-N,N-Diisopropyl-3-(5-formyl-2-hydroxyphenyl)-3-phenylpropanamine hydrochloride

Hydrogen chloride in diethyl ether was added to a solution of (R)-N,N-diisopropyl-3-(5-formyl-2-hydroxyphenyl)-3-phenylpropanamine (0.81 g, 2.4 mmol) in diethyl ether and 2-propanol. Crystals were filtered to yield 0.4 g (45%); mp 178-179°C. [α]_{Hg} = -40° (c 1.1 in methanol). ¹H NMR (DMSO-d₆) δ 1.16 (d, 3H), 1.20 (d, 3H), 1.24 (d, 3H), 1.27 (d, 3H), 2.54 (m, 2H), 2.84 (m, 1H), 2.97 (m, 1H), 3.58 (br, 2H), 4.38 (t, 1H), 7.08 (d, 1H), 7.22 (t, 1H), 7.32 (m, 4H), 7.65 (dd, 1H), 7.83 (d, 1H), 9.80 (s, 1H), 9.86 (br, 1H) 10.99 (s, 1H). Anal. (C₂₂H₂₉NO₂·HCl) H, N; C: calcd, 70.3; found, 70.8.

35

The starting compound (R)-N,N-diisopropyl-3-(5-formyl-2-hydroxy-phenyl)-3-phenylpropanamine was prepared as follows:

5 **7.1 (R)-N,N-Diisopropyl-3-(5-formyl-2-hydroxyphenyl)-3-phenylpropanamine**

DDQ (1.1 eq) was added to a solution of (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine mandelate (prepared as described in WO
10 94/11337, Example 1) (2.46 g, 5 mmol), dichloromethane (20 mL) and phosphate buffer (pH 7) (0.1 mL). Thereafter, sodium hydroxide solution (20 mL, 1 M) and diethyl ether were added and the phases were separated. The water-phase was extracted twice with dichloromethane-diethyl ether
15 (2:1). The organic phase was dried (MgSO₄) and evaporated. The residue was crystallised from ethyl acetate-hexane to yield 1.35 g (80 %).

EXAMPLE 8

20 **(R)-N,N-Diisopropyl-3-[5-(7-hydroxy-2-aza-5-oxaheptyl)-2-hydroxyphenyl]-3-phenylpropanamine di-(S)-mandelate**

Sodiumcyanoborohydride (0.25 g, 3.9 mmol) was added to a solution of (R)-N,N-diisopropyl-3-(5-formyl-2-hydroxy-phenyl)-3-phenylpropanamine (Example 7.1), (1.25 g, 3.7
25 mmol) and 2-ethoxy-(2-amino)-ethanol (19.5 g, 18 mmol) in methanol (10 mL). Hydrochloric acid (conc) was added to adjust pH to about 3. After 3h, the pH was adjusted to about 1 and the solvent was evaporated. The residue was partitioned between diethyl ether and water, whereafter the
30 organic layer was evaporated and the residue chromatographed on silica (chloroform-triethylamine-methanol 88:10:2). The pure amine was dissolved in 2-propanol-diethyl ether with (S)-mandelic acid (2 eq), whereby the product crystallised (the crystals were
35 unstable and an oily mass was soon obtained). Yield 0.2 g (7%); mp dec. ¹H NMR (free amine) (CDCl₃-d) δ 1.05 (d, 6H), 1.09 (d, 6H), 2.10 (m, 1H), 2.35 (m, 2H), 2.67 (m, 3H), 3.19 (m, 2H), 3.47 (m, 2H), 3.49 (t, 2H), 3.56 (d, 2H),

3.63 (t, 2H), 4.45 (dd, 1H), 6.75 (d, 1H), 6.79 (d, 1H),
6.95 (dd, 1H), 7.18 (m, 1H) and 7.26-7.33 (m, 4H).

EXAMPLE 9

5 **(R)-N,N-Diisopropyl-3-(2-hydroxy-5-methyloxycarbonyl-phenyl)-3-phenylpropanamine hydrochloride**

A solution of (R)-N,N-diisopropyl-3-(2-benzyloxy-5-methyloxycarbonyl-phenyl)-3-phenylpropanamine (prepared as described in WO 94/11337, Example 1) (0.92 g, 2 mmol) in
10 ethanol (30 mL) was hydrogenated over Pd/C (10%, 50 mg) at room temperature for 2 h. The catalyst was filtered off and the solution was treated with hydrogen chloride to obtain the amine salt. Yield 0.66 g (81 %); mp 177-178°C; $[\alpha]_D = -23^\circ$ (c 1.0, methanol). ^1H NMR (DMSO-d₆) δ 1.19 (dd, 6H),
15 1.25 (dd, 6H), 2.48 (m, 2H), 2.85 (m, 1H), 2.95 (m, 1H), 3.58 (m, 2H), 3.78 (s, 3H), 4.38 (t, 1H), 6.98 (d, 1H), 7.20 (m, 1H), 7.31 (d, 2H), 7.32 (s, 2H), 7.69 (dd, 1H), 7.81 (d, 1H), 9.85 (br, 1H), 10.74 (s, 1H). Anal. (C₂₃H₃₁NO₃·HCl) H, N, C.

20

EXAMPLE 10

N,N-Diisopropyl-3-(2-hydroxymethyl)phenyl-3-phenylpropanamine hydrochloride

A solution of N,N-diisopropyl-3-(2-carboxyphenyl)-3-phenylpropanamine hydrochloride (1.88 g, 5 mmol) in THF (30
25 mL) was added to LAH (1.5 g, 38 mmol) and the reaction mixture was stirred at ambient temperature for 2 h. The reaction was quenched and the solvent evaporated. The residue was dissolved in hot diethyl ether-2-propanol (100
30 mL, 1:4), whereafter HCl in diethyl ether was added. After cooling the product was filtered and dried at 60°C (vacuum). Yield 1.2 g (68%); mp 223-224°C. ^1H NMR (DMSO-d₆)
 δ 1.18 (t, 6H), 1.25 (q, 6H), 2.91 (m, 2H), 3.26 (disturbed by solvent, 2H), 3.57 (m, 2H), 4.38 (t, 1H), 4.43 (d, 1H),
35 4.74 (d, 1H), 5.22 (s, 1H), 7.20 (q, 2H), 7.25-7.35 (m, 5H), 7.40 (dd, 2H), 9.95 (s, 1H). Anal. (C₂₂H₃₁NO·HCl) H, N, C.

EXAMPLE 11

(S)-N,N-Diisopropyl-3-[2-hydroxy-5-(2-hydroxyethyl)phenyl]-3-phenylpropanamine hydrochloride

5 (S)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-hydroxyethyl)phenyl]-3-phenylpropanamine (0.67 g, 1.5 mmol) was hydrogenated over Pd/C (10%, 67 mg) at atmospheric pressure overnight in ethanol (20 mL). The catalyst was filtered off and the solvent was evaporated. The residue
10 was partitioned between diethyl ether and sodium hydroxide (1 M). The aqueous layer was extracted with diethyl ether. The combined organic layers were washed with water, dried (MgSO₄) and the solvent was evaporated. The amine salt was obtained by dissolving the amine in diethyl ether-
15 isopropanol and treatment with hydrogen chloride in diethyleter. Yield 0.37 g; mp 219-221 °C; [α]_D -11.4° (c=1.0, methanol); ¹H NMR (CD₃OD) δ 1.30 (d, 12H), 2.36-2.60 (m, 2H), 2.68 (t, 2H), 3.05 (t, 2H), 3.60-3.72 (m, 4H), 4.40 (t, 1H), 6.73 (d, 1H), 6.90 (dd, 1H), 7.0 (s,
20 1H), 7.17-7.38 (m, 5H). Anal. (C₂₃H₃₃NO₂·HCl·0.2H₂O) C, H, N.

The starting compound (S)-N,N-diisopropyl-3-[2-benzyloxy-5-(2-hydroxy)ethylphenyl]-3-phenylpropanamine was prepared as follows:
25

11.1 (S)-N,N-Diisopropyl-3-(2-benzyloxy-5-ethenylphenyl)-3-phenylpropanamine

A mixture of (S)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (prepared as described in
30 WO 94/11337, Example 1) (8 g, 12.7 mmol), Pd(OAc)₂ (28 mg, 0.12 mmol), tri-*o*-tolyl-phosphine (74 mg, 0.14 mmol) and tributylamine (5.9 mL, 24.5 mmol) in dimethylacetamide (50 mL) was heated to 60 °C under nitrogen atmosphere. Ethene
35 (g) was then added to 8 bars pressure. After stirring overnight the reaction mixture was allowed to cool to room temperature. Nitrogen was flushed through the reaction vessel, and toluene and water were added. The aqueous layer

was extracted with toluene and the combined organic layers were dried (MgSO₄) and concentrated. The residue was treated with sodium hydroxide (1 M) and extracted with diethyl ether and toluene. The organic layer was dried
5 (MgSO₄) and concentrated in vacuo. The residue was chromatographed on silica (gradient ethyl acetate-methanol 90:10 up to 0.06% NH₃ in ethyl acetate-methanol 90:10)
Yield 1 g (18%); ¹H NMR (CDCl₃) δ 0.94 (d, 12H), 2.20 (br, 2H), 2.37 (br, 2H), 3.0 (br, 2H), 4.38 (t, 1H), 5.0 (s,
10 2H), 5.11 (d, 1H), 5.61 (d, 1H), 6.60-6.70 (m, 1H), 6.80 (d, 1H), 7.12-7.19 (m, 12H).

11.2 (S)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-hydroxyethyl)-phenyl]-3-phenylpropanamine

15 (S)-N,N-Diisopropyl-3-(2-benzyloxy-5-ethenylphenyl)-3-phenylpropanamine (1 g, 2.34 mmol) in THF (25 mL) was added to 9-BBN (0.5 M in THF, 11.7 mL, 5.85 mmol) under nitrogen atmosphere at 0 °C. Additional 9-BBN (2.3 mL, 1.2 mmol) was added after 3 hours of stirring, the temperature was raised
20 to room temperature and the mixture was stirred for 0.5 hour. It was then cooled to 0 °C and 1 M sodium hydroxide (10 mL) was added followed by H₂O₂ (30% in H₂O, 10 mL). After 1 hours stirring, water was added and the mixture was extracted with diethyl ether. The organic layer was washed
25 with water and brine, dried (MgSO₄) and concentrated. The residue was chromatographed on silica (gradient of diethyl ether to 1% NH₃ in diethyl ether). Yield 0.67 g (64%). ¹H NMR (CDCl₃) δ 0.90 (d, 12H), 2.10-2.18 (m, 2H), 2.30-2.37 (m, 2H), 2.80 (t, 2H), 2.90-3.0 (m, 2H), 3.80 (br, 2H),
30 4.40 (t, 1H), 5.0 (s, 2H), 6.80 (d, 1H), 7.0 (m, 1H), 7.10-7.38 (m, 11H).

EXAMPLE 12

35 (R)-N,N-Diisopropyl-3-[2-hydroxy-5-(2-hydroxyethyl)phenyl]-3-phenylpropanamine hydrochloride

The title compound as well as the starting compounds were prepared in an analogous manner to the preparation described in Example 11, with the exception that (S)-N,N-

diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine was changed to (R)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (prepared as described in WO 94/11337, Example 1).

5 Yield 0.35 g (33%); mp 209-215 °C; $[\alpha]_D +9.8^\circ$ (c=1.0, methanol); $^1\text{H NMR}$ (CD_3OD) δ 1.29 (d, 12H), 2.40-2.60 (m, 2H), 2.67 (t, 2H), 3.04 (t, 2H), 3.61-3.72 (m, 4H), 4.40 (t, 1H), 6.70 (d, 1H), 6.90 (dd, 1H), 7.0 (s, 1H), 7.18-7.40 (m, 5H). Anal. ($\text{C}_{23}\text{H}_{33}\text{NO}_2 \cdot \text{HCl} \cdot 0.2\text{H}_2\text{O}$) C, H, N.

10

Preparation of starting compounds:

12.1 (R)-N,N-Diisopropyl-3-(2-benzyloxy-5-ethenylphenyl)-3-phenylpropanamine

15 Yield 5.5 g (53%); $^1\text{H NMR}$ (CDCl_3) δ 0.94 (d, 12H), 2.20 (br, 2H), 2.37 (br, 2H), 3.0 (br, 2H), 4.38 (t, 1H), 5.0 (s, 2H), 5.11 (d, 1H), 5.61 (d, 1H), 6.60-6.70 (m, 1H), 6.80 (d, 1H), 7.12-7.19 (m, 12H).

20 **12.2 (R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-hydroxyethyl)-phenyl]-3-phenylpropanamine**

Yield 1.2 g (75%); $^1\text{H NMR}$ (CDCl_3) δ 0.89 (d, 12H), 2.15 (m, 2H), 2.32 (m, 2H), 2.80 (t, 2H), 2.95 (m, 2H), 3.80 (br, 2H), 4.40 (t, 1H), 4.98 (s, 2H), 6.80 (d, 1H),
25 6.96 (m, 1H), 7.10-7.35 (m, 11H).

EXAMPLE 13

(R)-N,N-Diisopropyl-3-(5-acetyl-2-hydroxyphenyl)-3-phenylpropanamine hydrochloride

30 (R)-N,N-Diisopropyl-3-(5-acetyl-2-benzyloxyphenyl)-3-phenylpropanamine (1 g, 2.25 mmol) was treated as described in Example 11. Yield 0.6 g (68%); mp 105-115 °C; $[\alpha]_D -32.6^\circ$ (c 1.02, methanol); $^1\text{H NMR}$ ($\text{DMSO}-d_6$) δ 1.18-1.28 (m, 12H), 2.5 (m, 3H), 2.50-2.62 (m, 2H), 2.86 (m, 1H), 2.97
35 (m, 1H), 3.58 (m, 2H), 4.38 (t, 1H), 6.99 (d, 1H), 7.2 (m, 1H), 7.29-7.35 (m, 4H), 7.73 (dd, 1H), 7.85 (d, 1H), 9.90

(br, 1H), 10.70 (s, 1H). Anal. ($C_{23}H_{31}NO_2 \cdot HCl \cdot 0.4H_2O$) C, H, N.

The starting compound (R)-N,N-diisopropyl-3-(5-acetyl-2-benzyloxyphenyl)-3-phenylpropanamine was prepared as follows:

13.1 (R)-N,N-Diisopropyl-3-(5-acetyl-2-benzyloxyphenyl)-3-phenylpropanamine

To a stirred solution of (R)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (Example 12) (10.2 g, 21.23 mmol) in DMF (100 mL) under nitrogen atmosphere at room temperature were sequentially added triethylamine (2.58 g, 25.47 mmol), TlOAc (6.15 g, 23.35 mmol), isobutylvinylether (14 mL, 106.14 mmol), DPPP (0.87 g, 2.12 mmol) and $Pd(OAc)_2$ (0.24 g, 1.06 mmol). The reaction temperature was raised to 100 °C and stirred for 3 hours, cooled to room temperature, filtered and treated with HCl (5%, 250 mL) and stirred for another 2 hours. The reaction mixture was repeatedly extracted with dichloromethane and the combined organic layers were dried ($MgSO_4$), filtered and the solvent evaporated. Triethylamine and DMF were distilled off under reduced pressure to yield 9 g (98%); 1H NMR ($CDCl_3$) δ 1.22 (m, 12H), 2.52-2.70 (m, 7H), 3.40 (br, 2H), 4.34 (t, 1H), 5.10 (s, 1H), 6.90 (d, 1H), 7.17-7.40 (m, 10H), 7.82 (m, 1H) and 7.92 (s, 1H).

EXAMPLE 14

N,N-Diisopropyl-3(R)-[2-hydroxy-5-(1-hydroxyethyl)phenyl]-3-phenylpropanamine fumarate

N,N-Diisopropyl-3(R)-[2-benzyloxy-5-(1-hydroxyethyl)-phenyl]-3-phenylpropanamine (2.7 g, 6.05 mmol) was hydrogenated over Pd/C (0.27 g, 10%) in ethanol at atmospheric pressure for 2 hours. The catalyst was filtered off and the solvent was evaporated. The resulting oil was chromatographed on silica (toluene-triethylamine 90:10). Fumarate salt of the amine was afforded by adding fumaric acid (0.13 g, 1.13 mmol) dissolved in warm ethanol to a

solution of the free base in diethyl ether yielding white crystals (0.44 g, 83%); mp 240-244 °C; $[\alpha]_D +9.8^\circ$ (c 1.02, methanol); $^1\text{H NMR}$ (DMSO- d_6) δ 1.05 (d, 6H), 1.26 (dd, 3H), 2.20-2.30 (m, 2H), 2.55-2.67 (m, 2H), 3.30 (m, 2H), 4.32 (t, 1H), 4.59 (q, 1H), 6.53 (s, 2H), 6.72 (dd, 1H), 6.93 (dd, 0.5H), 7.12-7.17 (m, 1H), 7.21-7.31 (m, 5H). Anal. ($\text{C}_{23}\text{H}_{33}\text{NO}_2 \cdot \text{C}_4\text{H}_4\text{O}_4 \cdot 0.3\text{H}_2\text{O}$) C, H, N.

The starting compound N,N-diisopropyl-3(R)-[2-benzyloxy-5-(1-hydroxyethyl)phenyl]-3-phenylpropanamine was prepared as follows:

14.1 N,N-Diisopropyl-3(R)-[2-benzyloxy-5-(1-hydroxyethyl)-phenyl]-3-phenylpropanamine

N,N-Diisopropyl-3(R)-(5-acetyl-2-benzyloxyphenyl)-3-phenylpropanamine, prepared as described in Example 13.1, (3.5 g, 7.90 mmol) dissolved in dry THF was added to LiAlH_4 (0.2 g, 5.41 mmol). After 2 hours of stirring, additional LiAlH_4 (50 mg, 1.32 mmol) was added and the reaction mixture was stirred for 1.5 hours. The reaction was quenched and the solvent evaporated. The residue was chromatographed on silica (toluene- E_3N 90:10) to give 2.74 g (78%) of an oil that crystallised slowly upon storage at room temperature.

25

EXAMPLE 15

(+)-N,N-Diisopropyl-3(R)-[5-(1(R*),2-dihydroxyethyl)-2-hydroxyphenyl]-3-phenylpropanamine fumarate

N,N-Diisopropyl-3(R)-[2-benzyloxy 5-(1(R*),2-dihydroxyethyl)phenyl]-3-phenylpropanamine (0.55 g, 1.2 mmol) was treated in an analogous manner to that described in Example 14 above, which yielded white crystals, 0.32 g (55%); mp 196-200 °C; $[\alpha]_D +13.5^\circ$ (c 1.0, methanol); $^1\text{H NMR}$ (CD_3OD) δ 1.28 (m, 12H), 2.40-2.48 (m, 1H), 2.52-2.60 (m, 1H), 3.03 (t, 2H), 3.55 (d, 2H), 3.66 (m, 2H), 4.42 (t, 1H), 4.57 (t, 1H), 6.7 (s, 2H), 6.79 (d, 1H), 7.05 (dd,

35

1H), 7.16-7.21 (m, 2H), 7.28 (m, 2H), 7.36 (m, 2H). Anal.
(C₂₃H₃₃NO₃·C₄H₄O₄) C, H, N.

The starting compound N,N-diisopropyl-3(R)-[2-
5 benzyloxy-5-(1(R*),2-dihydroxyethyl)phenyl]-3-
phenylpropanamine was prepared as follows:

**15.1 N,N-Diisopropyl-3(R)-[2-benzyloxy-5-(1(R*),2-
dihydroxyethyl)phenyl]-3-phenylpropanamine**

10 To an ice-chilled solution of AD-mix- α (5.7 g) in H₂O
(20 mL) and t-BuOH (10 mL) was added N,N-diisopropyl-3(R)-
(2-benzyloxy-5-ethenylphenyl)-3-phenylpropanamine (Example
12.1), (1.74 g, 4.1 mmol) dissolved in t-BuOH (10 mL).
After 1 hour of stirring, the ice bath was removed and the
15 reaction mixture was stirred for additional 21 hours.
Na₂SO₃ (6 g) was then added and after 1 hours of stirring
the reaction mixture was partitioned between H₂O and ethyl
acetate. The aqueous layer was extracted 3 times with ethyl
acetate, the combined organic layers were dried (MgSO₄) and
20 the solvent evaporated. The residue was chromatographed on
silica (ethyl acetate-triethylamine, 90:10) to afford 0.55
g. ¹H NMR (CDCl₃) δ 0.9 (s, 6H), 0.95 (s, 6H), 2.15-2.20
(m, 2H), 2.30-2.38 (m, 2H), 2.96 (m, 2H), 3.60-3.70 (m,
2H), 4.41 (t, 1H), 4.75 (m, 1H), 5.0 (s, 2H), 6.85 (d, 1H),
25 7.10-7.35 (m, 12H).

EXAMPLE 16

**(-)-N,N-Diisopropyl-3(R)-[5-(1(S*),2-dihydroxyethyl) 2-
hydroxyphenyl]-3-phenylpropanamine fumarate**

30 N,N-Diisopropyl-3(R)-[2-benzyloxy-5-(1(S*),2-
dihydroxyethyl)phenyl]-3-phenylpropanamine (1.1 g, 2.4
mmol) was treated in an analogous manner to that described
in Example 11 which yielded white crystals, 0.25 g (21%);
mp 208-211 °C; [α]_D -8° (c 1.02, methanol); ¹H NMR (CD₃OD)
35 δ 1.28 (m, 12H), 2.39-2.47 (m, 1H), 2.51-2.59 (m, 1H), 3.03
(t, 2H), 3.51-3.53 (m, 2H), 3.67 (m, 2H), 4.42 (t, 1H),
4.54 (dd, 1H), 6.68 (s, 2H), 6.78 (d, 1H), 7.06 (dd, 1H),

7.16-7.20 (m, 2H), 7.26 (m, 2H), 7.34-7.36 (m, 2H). Anal. (C₂₃H₃₃NO₃·C₄H₄O₄) C, H, N.

The starting compound N,N-diisopropyl-3(R)-[2-
5 benzyloxy-5-(1(S*),2-dihydroxyethyl)phenyl]-3-
phenylpropanamine was obtained by treating N,N-diisopropyl-
3(R)-(2-benzyloxy-5-ethenylphenyl)-3-phenylpropanamine
(obtained in Example 12.1) as described in Example 15.1
above, but with AD-mix-β replacing AD-mix-α. Yield 1.2 g
10 (44%).

EXAMPLE 17

**(R)-[N,N-Diisopropyl-3-[2-hydroxy-5-(6-hydroxyhexyl)-
phenyl]-3-phenylpropanamine hydrochloride**

15 N,N-Diisopropyl-3(R)-[2-benzyloxy-5-(6-hydroxyhex-1-
enyl)phenyl]-3-phenylpropanamine (0.35 g, 0.72 mmol) was
treated in an analogous manner to that described in Example
14. Yield 0.10 g (31%); mp 147-156 °C; [α]_D +8.2° (c 1.01,
methanol); ¹H NMR (CD₃OD) δ 1.25-1.32 (m, 16H), 1.45-1.54
20 (m, 4H), 2.40-2.48 (m, 3H), 2.51-2.59 (m, 1H), 3.0-3.10 (m,
2H), 3.51 (t, 2H), 3.68 (m, 2H), 4.40 (t, 1H), 6.72 (d,
1H), 6.86 (dd, 1H), 6.91 (d, 1H), 7.19 (m, 1H), 7.30 (t,
2H), 7.34-7.36 (m, 2H). Anal. (C₂₇H₄₁NO₂·HCl·2H₂O) C, N; H:
calcd, 9.6; found, 8.3.

25

The starting compound (R)-N,N-diisopropyl-3-[2-
benzyloxy-5-(6-hydroxyhex-1-enyl)phenyl]-3-
phenylpropanamine was prepared as follows:

30 **17.1 (R)-N,N-Diisopropyl-3-(2-benzyloxy-5-formylphenyl)-3-
phenylpropanamine**

n-BuLi (2.5 M in hexane, 19 mL, 47.5 mmol) was added
to a solution of (R)-N,N-diisopropyl-3-(2-benzyloxy-5-
bromophenyl)-3-phenylpropanamine (prepared as described in
35 WO 94/11337, Example 1) (8.9 g, 18.52 mmol) in dry diethyl
ether (100 mL) kept at -40 °C under nitrogen atmosphere.
After 1.5 hour of stirring, additional n-BuLi (10 mL, 25

mmol) was added and after 2 hours another n-BuLi (5 mL, 12.5 mmol) was added. The reaction was then stirred for 15 minutes and DMF (6 mL, 77.8 mmol) was added followed by additional DMF (5 mL, 64.8 mmol) after 20 minutes of stirring. The temperature was allowed to rise to room temperature and after 35 minutes of stirring, NH₄Cl (sat.) was added followed by water and diethyl ether. The layers were separated and the aqueous layer was extracted with diethyl ether. The combined organic layers were dried (MgSO₄) and the solvent was evaporated. The residue was chromatographed on silica (toluene-triethylamine 90:10) to afford 8 g (100%) of a yellowish oil; ¹H NMR (CDCl₃) δ 0.90 (m, 12H), 2.12-2.40 (m, 4H), 2.95 (m, 2H), 4.44 (t, 1H), 5.10 (s, 2H), 6.95 (d, 1H), 7.15-7.36 (m, 10H), 7.70 (dd, 1H), 7.91 (s, 1H), 9.88 (s, 1H).

17.2 (R)-N,N-Diisopropyl-3-[2-benzyloxy 5-(5-carboxypent-1-enyl)phenyl]-3-phenylpropanamine

To a slurry of 4-carboxybutyl triphenylphosphonium bromide (4.1 g, 9.31 mmol) in THF (25 mL) at -10 °C under nitrogen atmosphere was added potassium tert-butoxide (2.1 g, 18.62 mmol). The mixture turned orange and after 10 minutes stirring, (R)-N,N-diisopropyl-3-(2-benzyloxy-5-formylphenyl)-3-phenylpropanamine (2 g, 4.65 mmol) in THF (10 mL) was added. After 4 hours of stirring, hydrochloric acid (1M) and diethyl ether were added and the layers were separated. The aqueous layer was extracted with ethyl acetate. The combined organic layers were dried (MgSO₄) and the solvent was evaporated. The residue was chromatographed on silica (ethyl acetate-triethylamine 90:10 followed by methanol) to afford 3 g containing traces of triphenylphosphine. The product was used in the next step without further purification.

17.3 (R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(6-hydroxyhex-1-enyl)phenyl]-3-phenylpropanamine

(R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(5-carboxypent-1-enyl)phenyl]-3-phenylpropanamine was reduced as described
5 in Example 10. Yield 0.35 g (15%).

EXAMPLE 18

(R)-N,N-Diisopropyl-3-[5-(2-diisopropylaminoethyl)-2-hydroxyphenyl]-3-phenylpropanamine hydrochloride

10 (R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-diisopropylaminoethyl)phenyl]-3-phenylpropanamine (0.6 g, 1.13 mmol) was refluxed with concentrated HCl (25 mL) overnight. The reaction mixture was then basified with 10 M sodium hydroxide and extracted with diethyl ether. The
15 organic layer was dried (MgSO₄) and concentrated in vacuo to give 0.5 g oil that was fractionated on a reversed-phase PEP-RPC HR 30/26 column using a gradient of acetonitrile (containing 0.1% TFA) and milliQ-water (containing 0.1% TFA). The pure fractions were pooled and extracted with
20 diethyl ether and 10 M sodium hydroxide. The resulting diethyl ether solution was treated with hydrogen chloride in diethyl ether. Yield 50 mg (9%); [α]_D +1.4° (c 0.94, methanol); ¹H NMR (CD₃OD) δ 1.27-1.34 (m, 12H), 1.36-1.42 (m, 12H), 2.50-2.58 (m, 1H), 2.60-2.67 (m, 1H), 2.95 (t, 2H), 3.05 (m, 2H), 3.15-3.27 (m, 2H), 3.70 (m, 2H), 3.75 (m, 2H), 4.40 (t, 1H), 6.80 (d, 1H), 7.02 (dd, 1H), 7.13 (d, 1H), 7.20 (m, 1H), 7.31 (m, 1H), 7.39-7.41 (m, 1H).
25 Anal. (C₂₉H₄₆N₂O·2HCl·0.4H₂O) C, H, N.

30 The starting compound N,N-diisopropyl-3(R)-[2-benzyloxy-5-(2-diisopropylaminoethyl)phenyl]-3-phenylpropanamine was prepared as follows:

18.1 N,N-Diisopropyl-3(R)-(5-formylmethyl-2-benzyloxy-phenyl)-3-phenylpropanamine

35 DMSO (1.1 mL, 15.5 mmol) dissolved in dichloromethane was added dropwise to oxalyl chloride (0.64 mL, 7.74 mmol) at -78 °C under nitrogen atmosphere. After 10 minutes of

stirring, (R)-N,N-diisopropyl-3-[2-benzyloxy-5-(2-hydroxyethyl)phenyl]-3-phenylpropanamine (Example 12.2) (2.3 g, 5.16 mmol) in dichloromethane was added and the reaction mixture was stirred for additional 1 h.

5 Triethylamine (5.4 mL, 38.7 mmol) was then added and the temperature was allowed to rise to room temperature. The reaction mixture was taken up in water and dichloromethane. The organic layer was dried (MgSO₄) and concentrated in vacuo and the product was used in the next step without

10 further purification.

18.2 (R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-diisopropylaminoethyl)phenyl]-3-phenylpropanamine

Diisopropylamine (4.2 mL, 30 mmol) was dissolved in

15 methanol (12 mL). 5 M HCl in methanol (2 mL) was added followed by N,N-diisopropyl-3(R)-(5-formylmethyl-2-benzyloxyphenyl)-3-phenylpropanamine (5 mmol) in methanol (10 mL) and sodium cyanoborohydride (0.22 g, 3.5 mmol). The reaction mixture was stirred at room temperature overnight.

20 methanol was then evaporated, and diethyl ether and H₂O were added. The organic layer was dried (MgSO₄) and concentrated in vacuo to give 3 g of a crude product that was chromatographed on silica (toluene-triethylamine 95:5). Yield 0.65 g (25%); ¹H NMR (CDCl₃) δ 0.88-0.91 (m, 18H),

25 1.20 (d, 9H), 2.10-2.20 (m, 2H), 2.30-2.38 (m, 2H), 2.87-3.10 (m, 4H), 4.34 (m, 1H), 4.98 (d, 2H), 6.75-6.97 (m, 2H), 7.10-7.30 (m, 11H).

EXAMPLE 19

30 **(R)-N,N-Diisopropyl-3-(5-ethoxymethyl-2-hydroxyphenyl)-3-phenylpropanamine**

(R)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethyl-phenyl)-3-phenylpropanamine (prepared as described in WO 94/11337, Example 1) (3.9 g, 11.5 mmol) and Al₂O₃ (115 g,

35 1.13 mol) refluxed in ethyl acetate (0.5 L) for 60 hours. Al₂O₃ was filtered off and ethyl acetate was evaporated. Chromatography on silica (toluene-triethylamine, 90:10) of the residue yielded 2.5 g (59%). The fumarate salt was

obtained by adding fumaric acid (0.17 g, 1.48 mmol) dissolved in warm ethanol to the free base (0.55 g, 1.48 mmol) in diethyl ether; mp 174-177 °C; $[\alpha]_D +5.5^\circ$ (c 1.02, methanol); $^1\text{H NMR}$ (CD_3OD) δ 1.15 (t, 3H), 1.27-1.30 (m, 12H), 2.41-2.49 (m, 1H), 2.52-2.60 (m, 1H), 3.04 (dd, 2H), 3.49 (q, 2H), 3.67 (m, 2H), 4.35 (s, 2H), 4.43 (t, 1H), 6.69 (s, 2H), 6.80 (d, 1H), 7.04 (dd, 1H), 7.12 (d, 1H), 7.18-7.37 (m, 4H). Anal. ($\text{C}_{24}\text{H}_{35}\text{NO}_2 \cdot \text{C}_4\text{H}_4\text{O}_4$) C, H, N.

10

EXAMPLE 20**N-Isopropyl-3-(5-carboxy-2-hydroxyphenyl)-3-phenylpropanamine hydrochloride**

N-Benzyl-N-isopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropanamine (1.3 g, 2.6 mmol) was dissolved in HOAc. Palladium (10%) on charcoal (0.13 g) was added and the mixture was hydrogenated at atmospheric pressure for 48 hours. The catalyst was then filtered off and the solvent was evaporated. The resulting oil was fractionated on a reversed-phase PEP-RPC HR 30/26 column using a gradient of acetonitrile (containing 0.1% TFA) and milliQ-water (containing 0.1% TFA). This purification was done in 16 portions with about 100 mg material each time. The pure fractions were pooled and freeze-dried to give 0.57 g of trifluoroacetic acid salt. The crystals were dissolved in 1 M HCl and freeze-dried to give 0.4 g (43%) of the hydrochloride salt as white crystals; mp 155-160 °C; $^1\text{H NMR}$ ($\text{DMSO}-d_6$) δ 1.17 (d, 3H), 1.19 (d, 3H), 2.30-2.38 (m, 1H), 2.38-2.46 (m, 1H), 2.72 (br, 1H), 2.80 (br, 1H), 3.25 (m, 1H), 4.40 (t, 1H), 6.94 (d, 1H), 7.18-7.22 (m, 1H), 7.29-7.33 (m, 4H), 7.66 (dd, 1H), 7.76 (d, 1H); Anal. ($\text{C}_{19}\text{H}_{23}\text{NO}_3 \cdot \text{HCl} \cdot 0.5\text{H}_2\text{O}$) C, H, N.

The starting compound N-benzyl-N-isopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropanamine was prepared as follows:

20.1 3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanal

3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanol (16.5 g, 41.5 mmol) (prepared as described in WO 94/11337, Example 1c) was reacted as described in Example 18.1. The combined organic layers were washed with 2 M HCl, 10% NaHCO₃, water and brine, dried (MgSO₄) and evaporated to give 16 g (98%) of yellowish crystals of the product that was used in the next step without further purification; mp 99-100 °C; ¹H NMR (CDCl₃) δ 3.10 (dd, 2H), 5.0 (s, 2H), 4.98-5.10 (m, 1H), 6.76 (d, 1H), 7.16-7.38 (m, 12H), 9.65 (s, 1H).

20.2 N-Benzyl-N-isopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine

To a solution of N-benzylisopropylamine (34 mL, 0.20 mol) in methanol (80 mL) was added 5 M HCl in methanol (16.2 mL, 80.9 mmol) followed by 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanal (16.0 g, 40.5 mmol) in methanol (20 mL) and sodium cyanoborohydride (1.78 g, 28.3 mmol). The resulting solution was stirred for 17 hours. The solvent was evaporated and diethyl ether was added to the resulting syrup. The solution was washed 3 times with water, dried over MgSO₄ and evaporated. The residue was chromatographed on silica (hexane-ethyl acetate, 75:25) giving 15.9 g of a syrup. The hydrochloride salt of the compound was prepared by dissolving the product in diethyl ether and adding HCl dissolved in diethyl ether. The resulting oil was washed with diethyl ether, dissolved in 10 M sodium hydroxide and extracted with diethyl ether 3 times. Purification by chromatography on silica (using a gradient of dichloromethane up to 1% triethylamine in dichloromethane) yielded 7 g (33%) of the product as a colourless oil. ¹H NMR (CDCl₃) δ 0.84 (d, 3H), 0.90 (d, 3H), 2.02-2.12 (m, 2H), 2.38 (t, 2H), 2.90 (m, 1H), 3.50 (d, 2H), 4.50 (t, 1H), 4.95 (s, 2H), 6.70 (s, 1H), 7.10-7.35 (m, 17H).

20.3 N-Benzyl-N-isopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropanamine

A mixture of magnesium turnings (1.18 g, 48.6 mmol) and iodine (one small crystal) was warmed gently. A solution of N-benzyl-N-isopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (6.0 g, 11 mmol) and 1,2-dibromoethane (0.2 mL, 2.3 mmol) in dry THF (25 mL) was added dropwise under nitrogen atmosphere to the refluxing mixture. After 2 hours of refluxing, 1,2-dibromoethane (0.59 mL, 6.8 mmol) was added. The mixture was left overnight under nitrogen atmosphere. The mixture was then added together with 1,2-dibromoethane (0.93 mL, 10.8 mmol) to warmed magnesium turnings (1.18 g, 48.6 mmol) and iodine (one small crystal). After 30 minutes of refluxing, the mixture was cooled to room temperature and CO₂ (g) was bubbled through. After 3 hours, ammonium chloride (aq, 15%, 50 mL) was added followed by diethyl ether (100 mL). The layers were separated and the organic layer was dried (MgSO₄) and concentrated to give 5.8 g of an oil. The crude product was chromatographed on silica (using a gradient of acetone up to 5% ethanol in acetone) to give the pure product (1.3 g, 23%) as an oil. N-benzyl-N-isopropyl-3-(2-benzyloxyphenyl)-3-phenylpropanamine (3.1 g) was obtained as a byproduct from the reaction. ¹H NMR (CDCl₃) δ 0.98 (d, 3H), 1.10 (d, 3H), 2.30-2.40 (m, 2H), 2.46-2.65 (m, 2H), 3.40 (br, 1H), 3.85 (br, 2H), 4.30 (br, 1H), 4.98 (br, 2H), 6.80 (d, 1H), 7.10-7.40 (m, 15H), 7.95 (d, 1H), 7.95 (d, 1H), 8.20 (s, 1H).

30

EXAMPLE 21

N-Benzyl-N-isopropyl-3-(2-hydroxyphenyl)-3-phenylpropanamine hydrochloride

N-Benzyl-N-isopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropanamine, prepared as described in Example 20.3, (3.1 g, 6.90 mmol) was refluxed in concentrated HCl (30 mL) for 20 h. The reaction mixture was allowed to cool to room temperature and the liquid was poured off. The remaining oil was washed with water and diethyl ether and then

dissolved in 2-propanol. The solution was evaporated and treated with 10 M sodium hydroxide to give the free base. Chromatography on silica (hexane:ethyl acetate 75:25) afforded 0.5 g of the compound that was fractionated on a
5 reversed-phase PEP-RPC HR 30/26 column using a gradient of acetonitrile (containing 0.1% TFA) and milliQ-water (containing 0.1% TFA). The pure fractions were pooled and extracted with diethyl ether and 10 M sodium hydroxide. To the resulting diethyl ether solution was added dropwise
10 saturated diethyl ether-HCl (g). The resulting crystals of the hydrochloric salt were collected by filtration; mp 115-122 °C; ¹H NMR (DMSO-d₆) δ 1.28 (m, 6H), 2.27-2.38 (m, 1H), 2.48-2.55 (m, 1H), 2.72-2.97 (m, 2H), 3.55 (m, 1H), 4.23 (m, 2H), 4.35 (m, 1H), 6.68-6.74 (m, 1H), 6.82 (dt, 1H),
15 6.96-7.24 (m, 7H), 7.38-7.42 (m, 3H), 7.64-7.68 (m, 2H), 9.55 (d, 1H), 10.62 (br, 1H). Anal. (C₂₅H₂₉NO·HCl) C, H, N.

EXAMPLE 22

(R)-N,N-Diisopropyl-3-[5-(3-aminopropyl)-2-hydroxyphenyl]-3-phenylpropanamine dihydrochloride
20

(R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-cyanoethenyl)phenyl]-3-phenylpropanamine (3.20 g, 7.07 mmol) was dissolved in 100 % acetic acid and 10% Pd/C (0.52 g) was added. The mixture was hydrogenated (60 psi)
25 overnight at room temperature. The catalyst was filtered off and the solvent was evaporated. The residue was dissolved in water, basified with sodium hydroxide (11 M), extracted with ethyl acetate, the organic phase was dried (MgSO₄), and evaporated. The residue was chromatographed on
30 silica (toluene-ethyl acetate-triethylamine-methanol, 20:5:1.5:1). The amine was redissolved in diethyl ether and a HCl-saturated diethyl ether solution was carefully added. The precipitate was filtered off which gave 0.30 g (10 %);
¹H NMR (CD₃OD) δ 1.29 (m, 12H), 1.88 (m, 2H), 2.51 (m, 2H),
35 2.59 (t, 2H), 2.88 (t, 2H), 3.04 (t, 2H), 3.68 (m, 2H), 4.40 (t, 1H), 4.55 (bs, 1H), 6.76 (d, 1H), 6.93 (d, 1H), 7.03 (s, 1H), 7.19 (t, 1H), 7.30 (t, 2H), 7.37 (d, 2H); mp.

226-228 °C; $[\alpha]_D +11.5^\circ$ (c=1.0, methanol). Anal.
(C₂₄H₃₆N₂O*2HCl) C, H, N.

The starting compound (R)-N,N-diisopropyl-3-[2-benzyloxy-5-(2-cyanoethenyl)phenyl]-3-phenylpropanamine was prepared as follows:

22.1 (R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-cyanoethenyl)phenyl]-3-phenylpropylamine

To a solution of (R)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (13.87 g, 28.87 mmol) (prepared as described in WO 94/11337, Example 1) in DMF (140 mL) was added triethylamin (5.00 mL, 36.10 mmol), Pd(OAc)₂ (0.32 g, 1.44 mmol), tri(o-tolyl)phosphine (1.76 g, 5.77 mmol) and acrylonitrile (2.39 mL, 36.10 mmol). The reaction mixture was stirred overnight at 115 °C in a sealed flask equipped with a reflux condenser under nitrogen atmosphere. The resulting mixture was concentrated, and the residue was dissolved in diethyl ether, washed with aqueous 2 M sodium hydroxide and water. The organic phase was dried (MgSO₄) whereafter petroleum ether was added to the organic phase and a precipitate was formed. Recrystallisation from ethanol yielded 5.50 g (42%). ¹H NMR (CDCl₃) δ 0.90 (s, 6H), 0.95 (s, 6H), 2.15 (q, 2H), 2.35 (q, 2H), 2.95 (m, 2H), 4.40 (t, 1H), 5.05 (s, 2H), 5.70 (d, 1H), 6.85 (d, 1H), 7.10-7.50 (m, 13H).

EXAMPLE 23

(R)-N,N-Diisopropyl-3-[5-3-(acetamidopropyl)-2-hydroxyphenyl]-3-phenylpropanamine hydrochloride

To a solution of (R)-N,N-diisopropyl-3-[5-(3-aminopropyl)-2-hydroxyphenyl]-3-phenylpropanamine, (Example 22), (0.45 g, 1.23 mmol) in methanol (45 mL) was added acetic anhydride (0.23 mL, 2.47 mmol). The mixture was stirred for 3 h at room temperature and then evaporated to dryness. The residue was dissolved in H₂O, basified with aqueous 11 M sodium hydroxide and extracted with toluene. The organic layer was dried with MgSO₄, filtered and

evaporated. The amine was dissolved in diethyl ether and a HCl-saturated diethyl ether solution was carefully added. The precipitate formed was filtered off to give 0.55 g (100 %). ¹H NMR (CD₃OD) δ 1.27 (m, 12H), 1.75 (m, 2H), 2.08 (s, 5 3H), 2.52 (m, 4H), 3.04 (t, 2H), 3.20 (t, 2H), 3.68 (m, 2H), 4.40 (t, 2H), 6.72 (d, 1H), 6.90 (d, 1H), 6.99 (s, 1H), 7.19 (t, 1H), 7.30 (m, 4H); mp. 171-175 °C; [α]_D +3.6° (c=0.5, methanol). (C₂₆H₃₈N₂O₂*HCl) C, H, N.

10

EXAMPLE 24**(R)-N,N-Diisopropyl-3-[5-(2-cyanoethyl)-2-hydroxyphenyl]-3-phenylpropanamine hydrochloride**

(R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-cyanoethenyl)phenyl]-3-phenylpropylamine (Example 22.1), 15 (4.00 g, 8.84 mmol) was treated as described in Example 22, but the hydrogenation was performed at atmospheric pressure. Yield 1.35 g (38 %); ¹H NMR (CD₃OD) δ 1.14 (s, 6H), 1.16 (s, 6H), 2.50 (m, 2H), 2.79 (t, 2H), 3.05 (t, 2H), 3.68 (m, 2H), 4.39 (t, 2H), 6.75 (d, 1H), 6.98 (d, 20 1H), 7.09 (s, 1H), 7.19 (t, 1H), 7.32 (m, 4H); mp. 156-159 °C; [α]_D +4.0° (c=0.5, methanol); Anal. (C₂₄H₃₂N₂O*1.0HCl*0.25H₂O) C, H; N: calcd, 6.9; found, 6.4.

EXAMPLE 25**25 (R)-N,N-Diisopropyl-3-[5-(2-carbamoyl ethyl)-2-hydroxyphenyl]-3-phenylpropanamine hydrochloride.**

A solution of (R)-N,N-diisopropyl-3-[5-(2-cyanoethyl)-2-hydroxyphenyl]-3-phenylpropanamine (Example 24), (2.00 g, 5.48 mmol), in conc. HCl was stirred at 50 °C for 2 h and 30 then evaporated. The residue was dissolved in water, basified with aqueous 11 M sodium hydroxide and extracted with toluene. The organic layer was dried (MgSO₄), filtrated and evaporated. The residue was chromatographed on toluene-ethyl acetate-triethylamine-methanol, 7:2:1:1. 35 The product was obtained from diethyl ether-hydrogen chloride. Yield 0.9 g (39%); ¹H NMR (CD₃OD) δ 1.31 (m, 12H), 2.44 (t, 2H), 2.53 (m, 2H), 2.78 (t, 2H), 3.04 (t, 2H),

3.67 (m, 2H), 4.39 (t, 1H), 6.72 (d, 1H), 6.82 (d, 1H),
7.02 (s, 1H), 7.18 (t, 1H), 7.32 (m, 4H); mp. 200-202 °C;
[α]_D +7.6° (c=0.5, methanol). Anal. (C₂₄H₃₄N₂O₂*1.0HCl
*0.5H₂O) C, H, N.

5

EXAMPLE 26**(R)-N,N-Diisopropyl-3-[5-(2-carboxyethyl)-2-hydroxyphenyl]-3-phenylpropanamine hydrochloride**

To a solution of (R)-N,N-diisopropyl-3-[5-(2-
10 carbamoyl ethyl)-2-hydroxyphenyl]-3-phenylpropanamine
(obtained in Example 25), (0.50 g, 1.31 mmol) in ethanol
(15 mL) and H₂O (10 mL) was added KOH (3.75 g, 66.8 mmol).
The mixture was stirred overnight at 100 °C. The solvent
was evaporated and the residue redissolved in H₂O and
15 washed with diethyl ether. The aqueous layer was acidified
with conc. HCl and the precipitate was collected by
filtration and washed with 2 M HCl. The product was
fractionated on a reversed-phase PEP RPC HR 30/26
(Pharmacia Biotech AB, Sweden) column using a gradient of
20 20-60% acetonitrile with 0.1% TFA. Fractions were pooled
and hydrochloric acid (2 mL, conc.) was added and the
solvent was evaporated. The residue was crystallised from
methanol-diethyl ether to give 0.37 g (0.96 mmol, 74%); ¹H
NMR (CD₃OD) δ 1.28 (m, 12H), 2.48 (m, 4H), 2.76 (t, 2H),
25 3.04 (t, 2H), 3.67 (m, 2H), 4.39 (t, 1H), 6.72 (d, 1H),
6.92 (d, 1H), 7.00 (s, 1H), 7.19 (t, 1H), 7.32 (m, 4H); mp.
205-207 °C; [α]_D +3.7° (c=1.0, methanol). Anal.
(C₂₄H₃₃NO₃*1.0HCl) C, H, N.

30

EXAMPLE 27**(R)-(N,N-Diisopropyl-3-(5-amino-2-hydroxyphenyl)-3-phenylpropanamine dihydrochloride**

(R)-N,N-Diisopropyl-3-(5-azido-2-benzyloxyphenyl)-3-
phenylpropanamine (0.90 g, 2.03 mmol) was dissolved in
35 acetic acid and 10% Pd/C (210 mg, cat.) was added. The
mixture was stirred and exposed to H₂ (1 atm.) at room
temperature overnight. The Pd/C catalyst was filtered off,

and the filtrate evaporated. The residue was dissolved in water and basified with aqueous 11 M sodium hydroxide, extracted with diethyl ether, dried (MgSO₄) filtrated and evaporated. The crude residue was chromatographed on silica
5 (n-hexane-ethanol-triethylamine, 7:3:1). The hydrochloride was obtained from diethyl ether hydrogen chloride. The resulting oil was freeze-dried from water. Yield 0.30 g (37 %); ¹H NMR (DMSO) δ 1.13 - 1.33 (m, 12H), 2.47 (m, 2H), 2.82 (br, 1H), 2.98 (br, 1H), 3.57 (br, 2H), 4.38 (t, 1H),
10 6.96 (d, 1H), 7.08 (d, 1H), 7.19 (s, 1H), 7.22 (m, 1H), 7.32 (m, 4H), 10.05 (br, 2H), 10.13 (s, 1H); mp. 180-183 °C; [α]_D +21.0° (c=0.1, methanol). Anal. (C₂₁H₃₀N₂O*2.0HCl*0.5H₂O) C, H, N.

15 The starting compound (R)-N,N-diisopropyl-3-(5-azido-2-benzyloxyphenyl)-3-phenylpropanamine was prepared as follows:

20 **27.1 (R)-N,N-Diisopropyl-3-(5-azido-2-benzyloxyphenyl)-3-phenylpropanamine**

To a mixture of (R)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (10.00 g, 20.81 mmol) (prepared as described in WO 94/11337, Example 1) and Mg (1.57 g, 64.52 mmol) in THF (50 mL) was added 1,2-
25 dibromoethane (3.59 mL, 41.63 mmol) and the solution was self-refluxing for a while. The mixture was refluxed for 1 h whereafter the solution was cooled and tosyl azide (4.10 g, 20.81 mmol) in diethyl ether (100 mL) was added with constant stirring while keeping the temperature at 0 °C
30 wherafter the temperature was allowed to rise to room temperature for 4 h. A solution of tetra-sodium pyrophosphate decahydrate (4.46 g, 10.00 mmol) in 50 mL water was added. A precipitate was filtered off and the filtrate was evaporated. The residue was extracted with
35 diethyl ether, the organic phase was dried (MgSO₄) and evaporated. The residue was chromatographed on silica (n-hexane-ethanol, 8:2). The product was crystallised from ethanol to give 1.15 g (13 %); IR (KBr) 2116 (N₃) cm⁻¹; ¹H

NMR (CDCl₃) δ 0.92 (d, 12H), 2.10 (m, 2H), 2.33 (m, 2H), 2.95 (m, 2H), 4.40 (t, 1H), 5.00 (s, 2H), 6.81 (d, 2H), 6.97 (s, 1H), 7.10 - 7.40 (m, 10H).

5

EXAMPLE 28**(R)-N,N-Diisopropyl-3-(5-azido-2-hydroxyphenyl)-3-phenylpropanamine hydrochloride**

To a solution of (R)-N,N-diisopropyl-3-(5-amino-2-hydroxyphenyl)-3-phenylpropanamine (0.25 g, 0.76 mmol) in
10 0.78 M HCl (5.35 mL, 4.20 mmol) was added NaNO₂ (0.05 g, 0.76 mmol) dissolved in H₂O (0.4 mL) at -10 °C and the mixture was stirred for 20 minutes. To the mixture was added NaN₃, (57 mg, 0.88 mmol) dissolved in H₂O (0.4 mL), and the mixture was stirred at -10 °C for 30 minutes. The
15 mixture was basified (pH 7-8) with aqueous 11 M sodium hydroxide and extracted with diethyl ether. The diethyl ether phase was dried (MgSO₄) and evaporated to give an oil, which was chromatographed on silica (toluene-ethyl acetate-triethylamine 7:2:1). The product was dissolved in
20 diethyl ether and hydrogen chloride in diethyl ether was added. The precipitate was filtered to give (0.07 g, 0.18 mmol, 24%) of light-brown crystals. IR (KBr) 2111 (N₃) cm⁻¹; ¹H NMR (CD₃OD) δ 1.29 (m, 12H), 2.50 (m, 2H), 3.04 (m, 2H), 3.68 (m, 2H), 4.40 (t, 1H), 6.68 (s, 1H), 6.81 (m,
25 2H), 7.23 (m, 1H), 7.35 (m, 4H); mp. 131-134 °C; [α]_D -5.0° (c=0.1, methanol).

The starting compound (R)-N,N-diisopropyl-3-(5-amino-2-hydroxyphenyl)-3-phenylpropanamine was prepared as
30 follows:

28.1 (R)-N,N-diisopropyl-3-(2-hydroxyphenyl)-3-phenylpropanamine

A solution of (R)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (prepared as described in
35 WO 94/11337, Example 1) (7.30 g, 15.2 mmol) treated as described in Example 1.3 above. Yield 4.47 g (94 %).

28.2 (R)-N,N-Diisopropyl-3-[2-hydroxy-5-(4-methylphenylazo)phenyl]-3-phenylpropanamine

NaNO₂ (0.27 g, 4.30 mmol) was added to a mixture of
5 hydrochloric acid (0.64 mL, 7.70 mmol, conc.) and p-
methylaniline (0.41 g, 3.80 mmol) in ice-water (20 mL). The
mixture was stirred at 0 °C for 10 min. and then added to
an ice-cold solution of (R)-N,N-diisopropyl-3-(2-
hydroxyphenyl)-3-phenylpropanamine (1.00 g, 3.21 mmol) in
10 THF (3mL), H₂O (12 mL) and sodium hydroxide (0.69 g, 17.32
mmol). After stirring the mixture for 20 minutes, it was
extracted with toluene, dried (MgSO₄), and evaporated to
give an oil, which was chromatographed on (toluene-ethyl
acetate-triethylamine 8:1:1) to give 0.83 g, 1.93 mmol,
15 (60%) of the title compound. ¹H NMR (CDCl₃) δ 1.12 (d, 6H),
1.19 (d, 6H), 2.22 (m, 1H), 2.43 (m, 5H), 2.79 (m, 1H),
3.32 (m, 2H), 4.57 (d, 1H), 6.98 (d, 1H), 7.24 (m, 3H),
7.36 (m, 4H), 7.66 (m, 4H).

28.3 (R)-N,N-Diisopropyl-3-(5-amino-2-hydroxyphenyl)-3-phenylpropanamine

A solution of Na₂S₂O₄ (1.23 g, 12.8 mmol) in water (10
mL) was added to a solution of (R)-N,N-diisopropyl-3-[2-
hydroxy-5-(4-methylphenylazo)phenyl]-3-phenylpropanamine
25 (0.55 g, 1.28 mmol) in ethanol (50 mL) at 75 °C during 15
min. More dry Na₂S₂O₄ (1.23 g, 12.8 mmol) was added in 10
portions. Water was added to the solution which was then
extracted with diethyl ether. The organic layer was dried
(MgSO₄) and evaporated to give an oil, which was
30 chromatographed on silica (n-hexane-ethanol-triethylamine
7:3:1) to give an oil. The product was dissolved in ethanol
and hydrogen chloride in diethyl ether was added. The
solvent was evaporated, redissolved in water and vacuum-
dried which yielded 0.25 g (60%).

35

EXAMPLE 29**(R)-N,N-Diisopropyl-3-[2-hydroxy-5-(3-hydroxypropyl)-phenyl]-3-phenylpropanamine hydrochloride**

A solution of (R)-N,N-diisopropyl-3-[5-(2-ethoxycarbonylethyl)-2-hydroxyphenyl]-3-phenylpropanamine (2.0 g, 4.86 mmol) in THF (50 mL) was added dropwise to LAH (0.28 g, 7.29 mmol). After stirring for 2 h, the reaction was quenched and the solvent evaporated. The residue was recrystallized from ethanol-water. The product was dissolved in ethanol and hydrogen chloride in diethyl ether was added. White crystals were filtered off to give 0.82 g (46%); mp. 204-207 °C; $[\alpha]_D +12.8^\circ$ (c=1.0, methanol); ^1H NMR (DMSO) δ 1.18 (t, 6H), 1.24 (t, 6H), 1.63 (m, 2H), 2.47 (m, 4H), 2.87 (br, 2H), 3.38 (q, 2H), 3.57 (br, 2H), 4.32 (t, 1H), 4.42 (t, 1H), 6.74 (d, 1H), 6.83 (d, 1H), 7.03 (s, 1H), 7.17 (t, 1H), 7.30 (m, 4H) Anal. ($\text{C}_{24}\text{H}_{35}\text{NO}_2 \cdot 1.0\text{HCl}$) C, H, N.

The starting compound (R)-N,N-diisopropyl-3-[5-(2-ethoxycarbonylethyl)-2-hydroxyphenyl]-3-phenylpropanamine was prepared as follows:

29.1 (R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-ethoxycarbonylethyl)phenyl]-3-phenylpropanamine

A solution of triethyl phosphonoacetate (6.93 mL, 34.92 mmol) in THF (50 mL) was added dropwise to NaH (0.84 g, 29.10 mmol, 80%). The mixture was cooled to 0 °C and (R)-N,N-diisopropyl-3-(2-benzyloxy-5-formylphenyl)-3-phenylpropanamine, prepared as described in Example 17.1, (5.00 g, 11.64 mmol) in THF (50 mL) was added dropwise. The mixture was stirred for 3 h at 0 °C. The solvent was evaporated and the residue was redissolved in toluene and washed twice with water. The organic layer was dried (MgSO_4) and the solvent evaporated to give 5.0 g (86%).

35

29.2 (R)-N,N-Diisopropyl-3-[5-(2-ethoxycarbonylethyl)-2-hydroxyphenyl]-3-phenylpropanamine

(R)-N,N-Diisopropyl-3-[2-benzyloxy-5-(2-ethoxycarbonylethyl)phenyl]-3-phenylpropanamine (3.0 g, 5.98 mmol) was treated as described in Example 1.3. Yield 2.0 g (81%); ¹H NMR (CDCl₃) δ 1.08 (d, 6H), 1.12 (d, 6H), 1.18 (t, 3H), 2.05 (m, 2H), 2.37 (m, 4H), 2.72 (t, 2H), 3.22 (m, 2H), 4.03 (q, 2H), 4.48 (m, 1H), 6.55 (s, 1H), 6.86 (m, 2H), 7.28 (m, 5H).

10

EXAMPLE 30**N,N-Diisopropyl-3-(5-ethylaminomethyl-2-hydroxyphenyl)-3-phenylpropanamine**

(R)-N,N-Diisopropyl-3-(5-formyl-2-hydroxyphenyl)-3-phenylpropanamine (prepared in Example 7.1) (1.23 g, 3.62 mmol) was dissolved in methanol (20 mL). Ethylamine [3.62 mL, 21.7 mmol (6M hydrochloric acid in methanol)] and sodium cyanoborohydride (0.14 g, 2.17 mmol) were added. The mixture was stirred overnight at room temperature. The solvent was evaporated and the residue was chromatographed on silica (toluene-ethyl acetate-triethylamine 7:3:1). The product was dissolved in diethyl ether and hydrogen chloride in diethyl ether was added. The resulting oil was stirred in diethyl ether over night to give crystals. Yield 0.70 g (44%); mp. 140-142 °C; [α]_D -5.0° (c=0.5, methanol); ¹H NMR (CD₃OD) δ 1.30 (m, 15H), 2.59 (m, 2H), 3.05 (m, 4H), 3.70 (m, 2H), 4.07 (s, 2H), 4.42 (t, 1H), 6.85 (d, 1H), 7.20 (m, 2H), 7.30 (t, 2H), 7.41 (d, 2H), 7.50 (s, 1H). Anal. (C₂₄H₃₆N₂O*2.0HCl*0.5H₂O) C,H,N.

20
25
30**EXAMPLE 31****N-Cyclobutyl-N-methyl-3-(2-hydroxyphenyl)-3-phenylpropanamine hydrochloride**

A solution of N-cyclobutyl-N-methyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (1.60 g, 3.44 mmol) was hydrogenated over Pd/C (160 mg, 10%) in acetic acid at room temperature overnight. The solution was basified with

35

sodium hydroxide (11 M) and the mixture was filtered. The filtrate was extracted with ethyl acetate, dried (MgSO₄) and the solvent evaporated. The residue was chromatographed on silica (toluen-triethylamine 9:1). The free amine was dissolved in diethyl ether and hydrogen chloride in diethyl ether was added to give an oil. The oil was crystallised in 2-propanol to give 0.90 g (79%); mp. 153-155 °C; ¹H NMR (CD₃OD) δ 1.78 (m, 2H), 2.22 (m, 4H), 2.48 (m, 2H), 2.72 (s, 3H), 2.95 (br, 2H), 3.68 (m, 1H), 4.44 (t, 1H), 6.78 (t, 1H), 6.79 (d, 1H), 7.03 (t, 1H), 7.12 (d, 1H), 7.18 (t, 1H), 7.28 (t, 2H), 7.34 (d, 2H); Anal. (C₂₀H₂₅NO*1.0 HCl*0.3 2-propanol) C, H, N.

The starting compound N-cyclobutyl-N-methyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine was prepared as follows:

31.1 N-Cyclobutyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine

5 M HCl-methanol (3.50 mL, 17.71 mmol) was added to a solution of cyclobutylamine (4.50 mL, 53.15 mmol) in methanol (14 mL). The mixture was added to 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanal (Example 20.1), (3.50 g, 8.86 mmol), followed by sodium cyanoborohydride (0.389 g, 6.20 mmol). The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was chromatographed on silica (toluene-ethyl acetate-triethylamine 92:4:4). Yield 2.61 g (65%); ¹H NMR (CDCl₃) δ 1.57 (m, 5H), 2.14 (m, 4H), 2.47 (t, 2H), 3.16 (m, 1H), 4.45 (t, 1H), 5.00 (s, 2H), 6.75 (d, 1H), 7.10-7.47 (m, 12H).

31.2 N-Cyclobutyl-N-methyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine

5 M HCl-methanol (0.46 mL, 2.32 mmol), formaldehyde (0.870 g, 28.97 mmol) and sodium cyanoborohydride (0.255 g, 4.056 mmol) were added to a solution of N-cyclobutyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (2.61 g, 5.79

mmol) in methanol (8 mL). The reaction mixture was stirred at room temperature overnight. The solvent was evaporated and the residue was chromatographed on silica (hexane-triethylamine, 9:1). Yield 1.59 g (59%); ¹H NMR (CDCl₃) δ

5 1.59 (m, 2H), 1.73 (m, 2H), 1.91 (m, 2H), 2.06 (s, 3H), 2.16 (m, 4H), 2.68 (m, 1H), 4.38 (t, 1H), 5.00 (s, 2H), 6.72 (d, 1H), 7.12-7.58 (m, 12H).

EXAMPLE 32

10 N-Cyclopentyl-N-methyl-3-(2-hydroxyphenyl)-3-phenylpropanamine hydrochloride

N-Cyclopentyl-N-methyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (2.46 g, 5.14 mmol) was treated as described in Example 31. The crude was not chromatographed

15 but crystallised from aqueous ethanol. Yield 1.24 g (70%)
¹H NMR (DMSO) δ 1.48 (br, 1H), 1.66 (br, 2H), 1.85 (br, 1H), 2.46 (br, 2H), 2.68 (s, 3H), 2.87 (br, 2H), 3.53 (m, 1H), 4.35 (t, 1H), 6.77 (t, 1H), 6.83 (d, 1H), 7.01 (t, 1H), 7.16 (t, 1H), 7.27 (t, 3H), 7.33 (d, 2H), 9.57 (br,

20 1H), 10.85 (br, 1H); mp 169-172 °C; Anal. (C₂₁H₂₇NO·HCl) C, H, N.

The starting compound N-cyclopentyl-N-methyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine was prepared

25 as follows:

32.1 N-Cyclopentyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine

3-(2-Benzyloxy-5-bromophenyl)-3-phenylpropanal,

30 prepared as described in Example 20.1, (7.00 g, 17.71 mmol) was treated with cyclopentylamine as described in Example 31.1. Yield 4.9 g (59%); ¹H NMR (CDCl₃) δ 1.20 (m, 2H), 1.40-1.80 (m, 6H), 2.18 (m, 2H), 2.55 (t, 2H), 2.98 (m, 1H), 4.45 (t, 1H), 5.00 (s, 2H), 6.75 (d, 1H), 7.10-7.45

35 (m, 12H).

32.2 N-Cyclopentyl-N-methyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine

A solution of N-cyclopentyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanamine (3.50 g, 7.53 mmol) was treated as described in Example 31.2. Yield 2.46 g (68%); ¹H NMR (CDCl₃) δ 1.10-1.80 (m, 8H), 2.19 (m, 5H), 2.36 (m, 2H), 2.58 (m, 1H), 4.37 (t, 1H), 4.98 (s, 2H), 6.72 (d, 1H), 7.10-7.50 (m, 12H).

10

EXAMPLE 33**N,N-Diisopropyl-3-(2-aminophenyl)-3-phenylpropanamine hydrochloride**

LAH (0.94 g, 24.8 mmol) was added to a solution of N,N-diisopropyl-3-(2-aminophenyl)-3-phenylpropenylamide (1.6 g, 4.98 mmol) in THF (90 mL). The mixture was stirred for 72 h at room temperature. The reaction was quenched and the solvent evaporated. The crude residue was fractionated on a reversed-phase PEP RPC HR 30/26 (Pharmacia Biotech AB, Sweden) column using 20 % acetonitrile with 0.1% TFA. Hydrochloric acid was added to the pure fractions and the solvent was evaporated. The residue was redissolved in water and freeze-dried giving 88 mg (5%); mp 138 - 142 °C; ¹H NMR (DMSO) δ 1.25 (m, 12H), 2.47 (m, 1H), 2.65 (m, 1H), 2.87 (m, 1H), 3.13 (m, 1H), 3.59 (br, 2H), 4.58 (t, 1H), 7.20 - 7.37 (m, 5H), 7.42 (m, 2H), 7.54 (d, 2H), 9.94 (br, 2H). Anal. (C₂₁H₃₀N₂*HCl*H₂O) C, N, H: calcd.8.5; found 7.9.

The starting compound N,N-diisopropyl-3-(2-aminophenyl)-3-phenylpropenylamide was prepared as follows:

33.1 2-(3,5-Dimethyl-4-hydroxyphenylazo)benzophenone

A slurry of ice (500 mL), hydrochloric acid (16.8 mL, 202 mmol, conc.), 2-aminobenzophenone (20.00 g, 101 mmol) and NaNO₂ (9.0 g, 131 mmol) were added to a stirred solution of 2,6-dimethylphenol (18.40 g, 151 mmol) and sodium hydroxide (16.20 g, 404 mmol) in ice-cold water (100 mL). After 20 minutes the mixture was extracted with

diethyl ether. The organic phase was washed with hydrochloric acid (6 M), $\text{NaHCO}_3(\text{aq})$, dried (MgSO_4) and the solvent evaporated. The crude residue was chromatographed on silica (toluene) and pure fractions were pooled and
5 evaporated to give a red oil. The oil was crystallised in hexane/toluene to give 7.73 g (23%).

33.2 2-(3,5-Dimethyl-4-tosyloxyphenylazo)benzophenone

A mixture of 2-(3,5-dimethyl-4-hydroxyphenylazo)-
10 benzophenone (7.73 g, 23.41 mmol) and tosyl chloride (9.4 g, 49 mmol) in pyridine (20 mL) was stirred at 90 °C for 9 h. Water was added and the mixture was extracted with diethyl ether. The organic phase was washed with sodium hydroxide (2 M) and hydrochloric acid (2 M), dried (MgSO_4)
15 and the solvent evaporated. The product was crystallised in ethanol to give 7.62 g (67%); $^1\text{H NMR}$ (CDCl_3) δ 2.08 (s, 6H), 2.49 (s, 3H), 7.05 (s, 2H), 7.37 (m, 4H), 7.48 (m, 1H), 7.62 (m, 3H), 7.82 (m, 5H).

20 33.3 N,N-Diisopropyl-3-[2-(3,5-dimethyl-4-tosyloxyphenyl-azo)phenyl]-3-phenylpropenamide

2-(3,5-Dimethyl-4-tosyloxyphenylazo)benzophenone (7.22
g, 14.9 mmol) was treated as described in Example 4.2 but with 3 eq of N,N-diisopropylacetamide diethylphosphonate
25 and sodium hydride. Yield 4.5 g (50%). $^1\text{H NMR}$ (CDCl_3) δ 0.72 (d, 3H), 0.82 (br, 3H), 1.28 (d, 3H), 1.42 (d, 3H), 2.10 (s, 3H), 2.14 (s, 3H), 2.45 (s, 3H), 3.25 (m, 1H), 4.28 (m, 1H), 6.05 and 6.63 (s, 1H), 7.00 - 7.90 (m, 15H).

30 33.4 N,N-Diisopropyl-3-[2-(3,5-dimethyl-4-hydroxyphenyl-azo)phenyl]-3-phenylpropenamide

A solution of potassium hydroxide (10.3 mL, 6 M) and N,N-diisopropyl-3-[2-(3,5-dimethyl-4-tosyloxyphenyl-azo)phenyl]-3-phenylpropenamide (3.5 g, 5.74 mmol) in
35 ethanol (110 mL) was refluxed for 1 h. The mixture was acidified with hydrochloric acid (conc.) and the solvent evaporated. The residue was partitioned between toluene and water. The organic layer was dried (MgSO_4) and the solvent

evaporated. The crude residue was chromatographed on silica (toluene-ethyl acetate 9:2). Yield 1.3 g (50%). ¹H NMR (CDCl₃) δ 0.71 (d, 3H), 0.80 (br, 3H), 1.27 (d, 3H), 1.40 (d, 3H), 2.20 (s, 3H), 2.23 (s, 3H), 3.25 (m, 1H), 4.35 (m, 1H), 5.52 (brd, 1H), 6.05 and 6.60 (s, 1H), 7.00 - 7.80 (m, 11H).

33.5 N,N-Diisopropyl-3-(2-aminophenyl)-3-phenylpropenamide

N,N-Diisopropyl-3-[2-(3,5-dimethyl-4-hydroxyphenyl-azo)phenyl]-3-phenylpropenamide (2.58 g, 5.68 mmol) was treated as described in Example 28.3. The crude residue gave crystals from aqueous ethanol. Yield 1.23g (67%).

EXAMPLE 34

15 N,N-Diisopropyl-3-(benzoxazol-2-yl)-3-phenylpropanamine, hydrochloride

A mixture of N,N-diisopropyl-3-ethoxycarbonyl-3-phenylpropanamine (2.51 g, 8.6 mmol), 75% aqueous ethanol (15 mL) and 2 M NaOH (8.5 mL, 17 mmol) was refluxed over night. After evaporation of the solvent, the residue was made acidic with 2 M HCl and the solvent was evaporated. A mixture of the residual semicrystalline oil was heated with o-aminophenol (1.8 g, 16.5 mmol) and polyphosphoric acid (12 g) at 200°C for 2 hours under N₂. The somewhat cooled hard solid was dissolved in water and washed once with diethyl ether. The aqueous phase was made alkaline (11 M NaOH) and extracted twice with diethyl ether. The combined organic phases were dried (Na₂SO₄) and the solvent evaporated. The crude product was chromatographed on silica (petroleum ether/triethylamine 97:3). The pure amine was precipitated as hydrochloride from diethyl ether affording white crystals, 1.27 g (39%): mp 197-198°C; ¹H NMR (CDCl₃) δ 1.49 (m, 12H), 2.80-3.20 (m, 4H), 3.48 (br, 2H), 4.45 (t, 1H), 7.25-7.48 (m, 8H), 7.70 (m, 1H), 11.48 (br, 1H).

35

The starting compound N,N-diisopropyl-3-ethoxycarbonyl-3-phenylpropanamine was prepared as follows:

34.1 N,N-Diisopropyl-3-cyano-3-phenylpropanamine

Sodium hydride, 80% in mineral oil (2.82 g, 94 mmol), was washed with petroleum ether and dried under a N₂-
5 stream. Dry DMF (100 mL) was added. Benzyl cyanide (12.1 g, 103 mmol) was added to the stirred suspension over a period of 20 min. The temperature rose to approx. 45°C. The mixture was stirred for another 15 min. 2-Chloroethyl-diisopropylamine (15.4 g, 94 mmol) was added. All the amine
10 was consumed within 30 min. Most of the DMF was evaporated under reduced pressure and the residue was dissolved in water/diethyl ether. The aqueous phase was extracted once with diethyl ether and the combined organic phases were extracted twice with 2 M HCl. The combined aqueous phases
15 were made alkaline (11 M NaOH) and extracted twice with diethyl ether. The combined organic phases were then dried (Na₂SO₄) and the solvent was evaporated. The crude product was chromatographed on silica (petroleum ether-triethylamine, 40:1), affording the title compound, 16.8 g
20 (67%), as a colourless liquid. ¹H NMR (CDCl₃) δ 1.01 (m, 12H), 1.97 (m, 2H), 2.62 (m, 2H), 3.00 (m, 2H), 4.02 (dd, 1H), 7.17-7.40 (m, 5H).

34.2 N,N-Diisopropyl-3-carbamoyl-3-phenylpropanamine

25 N,N-Diisopropyl-3-cyano-3-phenylpropanamine (11.6 g, 47.5 mmol) was mixed with H₂SO₄ (90%, 100 mL) and the mixture was stirred at 100°C for 30 min. The reaction mixture was poured on ice, made alkaline (11 M NaOH) and extracted twice with diethyl ether. The combined organic
30 phases were dried (Na₂SO₄) and the solvent evaporated, affording the title compound as a colourless oil, 12.4 g (100%); ¹H NMR (CDCl₃) δ 1.26 (m, 12H), 2.14 (m, 1H), 2.60 (m, 1H), 2.73 (t, 2H), 3.31 (m, 2H), 3.86 (t, 1H), 6.06 (br, 2H), 7.51- 7.61 (m, 5H).

35

34.3 N,N-Diisopropyl-3-ethoxycarbonyl-3-phenylpropanamine

N,N-Diisopropyl-3-carbamyl-3-phenylpropanamine (26.5 g 0.100 mol) was added into aqueous ethanol (90%, 300 mL)

containing conc. HNO₃ (13.3 g, 0.21 mol) and refluxed for five days. Most of the solvent was evaporated under reduced pressure and the residue was mixed with water/diethyl ether. The organic phase was washed once with water. The combined aqueous phases were made alkaline (11 M NaOH) and extracted twice with diethyl ether. The combined organic phases were then dried (Na₂SO₄) and the solvent evaporated. The crude product was chromatographed on silica (petroleum ether-triethylamine, 97/3), to afford the title compound as a colourless liquid, 20.1 g (68.7%): ¹H NMR (CDCl₃) δ 0.96 (m, 12H), 1.21 (t, 3H), 1.81 (m, 1H), 2.22 (m, 1H), 2.40 (t, 2H), 3.66 (dd, 1H), 4.12 (m, 2H), 7.20-7.32 (m, 5H).

EXAMPLE 35

15 **N,N-Diisopropyl-3-(oxazol-5-yl)-3-phenylpropanamine hydrochloride**

Freshly distilled methylisonitrile (1.66 g, 40.4 mmol) was dissolved in dry THF (75 mL) under N₂-atmosphere and the mixture was cooled to -78°C. 1.4 M n-BuLi (29 mL, 40.5 mmol) was slowly added to the solution, followed by N,N-diisopropyl-3-ethoxycarbonyl-3-phenylpropanamine (4.71 g, 16.2 mmol) in THF (10 mL). The reaction temperature was allowed to rise to -20°C, at which the reaction was quenched with HOAc (10 mL). The solvent was evaporated and the residue was mixed with diethyl ether/water. The organic phase was washed once with water and the combined aqueous phases were made alkaline with 11 M NaOH and extracted twice with diethyl ether. The organic phases were put together, dried (Na₂SO₄) and the solvent evaporated. The crude product was chromatographed on silica (chloroform-methanol-conc. ammonia, 490:10:1). The pure amine was precipitated with HCl-saturated diethyl ether, affording the title compound as a glassy oil, 1.4 g (48%). ¹H NMR (CD₃OD) δ 1.21-1.40 (m, 12H), 2.57 (m, 1H), 2.68 (m, 1H), 2.91 (m, 1H), 3.23 (m, 1H), 3.72 (m, 2H), 4.41 (dd, 1H), 7.39 (m, 5H), 7.52 (s, 1H), 9.13 (s, 1H).

EXAMPLE 36**N,N-Diisopropyl-3-(imidazol-4(5)-yl)-3-phenylpropanamine dihydrochloride**

N,N-Diisopropyl-3-oxazol-5-yl-3-phenylpropanamide
5 (0.76 g 2.6 mmol) was mixed with formamide (5 mL). The mixture was heated at 175°C for 6 hours. The solvent was evaporated under vacuum (1 mm Hg) and the residue was partitioned between 1 M HCl and diethyl ether. The aqueous phase was made alkaline (11 M NaOH) and extracted twice
10 with diethyl ether. The combined organic phases were dried (Na₂SO₄) and the solvent evaporated. The light brown oil was dissolved in diethyl ether and added to a suspension of lithium aluminium hydride (LAH) (0.70 g, 5.4 mmol) in diethyl ether. The reaction mixture was stirred at ambient
15 temperature overnight. The reaction was quenched, and the solvent was evaporated. The crude amine was dissolved in EtOAc and precipitated as a hydrochloride salt with HCl-saturated diethyl ether to afford the title compound as hygroscopic crystals, 0.32 g (35%): ¹H NMR (CDCl₃) δ 1.38
20 (m, 12H), 2.80 (m, 2H), 3.00 (m, 1H), 3.16 (m, 1H), 3.64 (br, 2H), 4.41 (m, 1H), 6.89 (s, 1H), 7.27-7.41 (m, 5H), 8.78 (s, 1H), 10.32 (br, 2H).

The starting compound N,N-diisopropyl-3-oxazol-5-yl-3-phenylpropanamide (0.76 g 2.6 mmol) was prepared as
25 follows:

36.1 3-Cyano-3-phenylpropanoic acid

Ethyl cinnamate (85.3 g, 0.484 mol), potassium cyanide
30 (64.2 g, 0.986 mol) and ammonium chloride (38.9 g, 0.726 mol) were mixed with aqueous DMF (90%, 360 mL). The mixture was stirred at 105°C for 7 hours. The somewhat cooled mixture was filtered and most of the DMF was evaporated. The residue was taken up in diethyl ether and 1 M HCl. The
35 aqueous phase was extracted twice with diethyl ether. The combined diethyl ether phases were evaporated and the black oil was suspended in EtOH (200 mL) and 2 M NaOH (250 mL) and stirred at ambient temperature for 2 hours. The mixture

was diluted with brine (200 mL) and water (400 mL) and washed twice with diethyl ether. After acidification (12 M HCl) the aqueous phase was extracted three times with diethyl ether. The pooled organic phases were dried (Na₂SO₄) and the solvent evaporated affording the title compound as a black oil, 74 g (87%): ¹H NMR (CDCl₃) δ 1.05 (d, 3H), 1.17 (d, 3H), 1.22 (d, 6H), 2.68 (dd, 1H); 3.16 (dd, 1H), 3.4 (br, 1H), 3.76 (m, 1H) 4.19 (dd, 1H), 7.31 (m, 5H), 8.9 (br, 1H).

10

36.2 N,N-Diisopropyl-3-cyano-3-phenylpropanamide

3-Cyano-3-phenylpropanoic acid (67.7 g, 0.389 mol) was dissolved in 2-PrOH. To the filtered acid solution was carefully added KOH (18.4 g, 0.33 mol) dissolved in 2-PrOH (200 mL), diethyl ether (100 mL) was added and the precipitate was filtered off. The dried acid salt (51.9 g, 0.24 mol) was suspended in benzene (400 mL) and oxalyl chloride was carefully added. The reaction mixture was stirred at 80°C for 2 hours. The solvent was evaporated and the residue was co-evaporated twice with benzene. The brown oil was dissolved in benzene (200 mL) and cooled in an ice-bath. A solution of diisopropylamine (82 g, 0.81 mol) in benzene (200 mL) was added to the stirred reaction mixture during 45 min. The mixture was left to slowly warm up to room temperature overnight. The solvent was evaporated and the residue was taken up in diethyl ether and 1 M HCl. The organic phase was washed once with water, once with 1 M NaOH, again with water, dried (Na₂SO₄) and the solvent evaporated to afford the title compound as a dark brown oil, 41.7 g (41%): ¹H NMR (CDCl₃) δ 1.07 (d, 3H), 1.17 (d, 3H), 1.36 (m, 6H), 2.77 (m, 1H), 2.97 (m, 1H), 3.51 (br, 1H), 3.81 (m, 1H), 4.50 (dd, 1H), 7.39 (m, 5H).

15
20
25
30

36.3 N,N-Diisopropyl-3-carbamoyl-3-phenylpropanamide

N,N-Diisopropyl-3-cyano-3-phenylpropanamide (21.1 g, 82 mmol) was dissolved in EtOH (130 mL) and 2 M NaOH (100 mL). Hydrogen peroxide (30%, 20.2 mL, 200 mmol) was added and the mixture was stirred at ambient temperature for two

35

hours. The resulting precipitate was filtered, washed with water and dried, yielding the title compound as white crystals, 15.6 g (69%): $^1\text{H NMR}$ (CDCl_3) δ 1.09 (d, 3H), 1.19 (d, 3H), 1.31 (m, 6H), 2.51 (dd, 1H), 3.30 (dd, 1H), 3.41 (m, 1H), 4.02 (m, 1H), 4.18 (dd, 1H), 5.7 (br, 1H), 6.4 (br, 1H), 7.21-7.42 (m, 5H).

36.4 N,N-Diisopropyl-3-ethoxycarbonyl-3-phenylpropanamide

N,N-Diisopropyl-3-carbamoyl-3-phenylpropanamide was treated as described in Example 34:3 (two days of reflux and no chromatography) which gave the title compound as a colourless semicrystalline oil, 15.9 g (93%): $^1\text{H NMR}$ (CDCl_3) δ 1.19 (m, 9H), 1.36 (m, 6H), 2.53 (dd, 1H), 3.18 (dd, 1H), 3.4 (br, 1H), 3.98 (m, 1H), 4.15 (m, 3H), 7.31 (m, 5H).

36.5 N,N-Diisopropyl-3-oxazol-5-yl-3-phenylpropanamide

The method described for Example 35 above was used, starting from N,N-diisopropyl-3-ethoxycarbonyl-3-phenylpropanamide. The crude was chromatographed on silica (petroleum ether-EtOAc, 3:2), affording the title compound as a light yellow oil, 0.77 g (46%): $^1\text{H NMR}$ (CDCl_3) δ 1.00 (d, 3H), 1.14 (d, 3H), 1.29 (m, 6H), 2.98 (m, 2H), 3.4 (br, 1H), 3.93 (m, 1H), 4.79 (t, 1H), 6.82 (s, 1H), 7.28 (m, 5H), 7.76 (s, 1H).

EXAMPLE 37

N,N-Diisopropyl-3-(oxazol-2-yl)-3-phenylpropanamine hydrochloride

A mixture of N,N-diisopropyl-3-carbamoyl-3-phenylpropanamine, prepared in Example 34.2 (4.05 g, 15.4 mmol), 1,2-dichloroethyl ethyl ether (2.32 g, 16.2 mmol), water (0.300 g, 16.6 mmol) and formic acid (50 mL) was stirred at 75°C for 3 hours. The formic acid was evaporated and the residue was dissolved in water/diethyl ether. The aqueous phase was made alkaline (11 M NaOH) and extracted twice with diethyl ether. The combined organic phases were

dried (Na_2SO_4) and the solvent evaporated. The crude product was chromatographed on silica (petroleum ether-triethylamine 97:3). The pure amine was precipitated as hydrochloride salt with HCl-saturated diethyl ether, affording the title compound as white crystals, 0.61 g (12%): mp 157-158°C; ^1H NMR ($\text{DMSO}(d_6)$) δ 1.11 (m, 12H), 2.35 (m, 1H), 2.63 (m, 1H), 3.03 (m, 2H), 3.56 (m, 2H), 4.45 (m, 1H), 7.21-7.40 (m, 6H) 8.06 (d, 1H), 10.20 (br, 1H).

10

EXAMPLE 38**N,N-Diisopropyl-3-phenyl-3-(thiazol-2-yl)propanamine hydrochloride**

The title compound was prepared in an analogous manner to that described in Example 37. N,N-Diisopropyl-3-phenyl-3-thiocarbamoylpropanamine (1.11 g, 4.0 mmol) yielded white crystals of the title compound, 1.12 g (82%): mp 155-156°C; ^1H NMR (CDCl_3) δ 1.37 (m, 12H), 2.75-3.15 (m, 4H), 3.60 (m, 2H), 4.45 (t, 1H), 7.25-7.36 (m, 6H), 7.71 (d, 1H), 11.30 (br, 1H).

20

The starting compound N,N-diisopropyl-3-phenyl-3-thiocarbamoylpropanamine was prepared as follows:

38.1 N,N-Diisopropyl-3-phenyl-3-thiocarbamoylpropanamine

H_2S was bubbled into a solution of N,N-diisopropyl-3-cyano-3-phenylpropanamine, prepared in Example 34.1, (3.45 g, 14.3 mmol) and triethylamine (2.0 g, 20 mmol) in dry pyridine (10 mL) until saturation was achieved. The stirred reaction was held under H_2S -atmosphere at 65°C for 5 days. The pyridine was evaporated and the crude product was chromatographed on silica (chloroform-methanol-conc. ammonia 380:20:1), yielding the title compound as a colourless glassy oil, 3.1 g (78%): ^1H NMR (CDCl_3) δ 0.99 (m, 12H), 2.07 (m, 1H), 2.40 (m, 3H), 3.05 (m, 2H), 4.10 (t, 1H), 7.20-7.45 (m 5H), 7.7-8.1 (b, 1H), 8.0-8.5 (br, 1H).

35

EXAMPLE 39**N,N-Diisopropyl-3-(4-methylthiazol-2-yl)-3-phenylpropanamine hydrochloride**

5 The title compound was prepared in an analogous manner to that described in Example 37. N,N-Diisopropyl-3-phenyl-3-thiocarbamoylpropanamine, prepared in Example 38.1, (1.5 g, 5.4 mmol), and 2-chloroacetone (0.75 g, 8.1 mmol) yielded the title compound as a white amorphous substance,
10 1.1 g (56%): mp 178-181°C; ¹H NMR (CDCl₃) δ 1.44 (m, 12H), 2.50 (s, 3H), 2.98 (m, 3H), 3.18 (m, 1H), 3.60 (m, 2H), 6.94 (d, 1H), 7.30-7.47 (m, 5H), 11.15 (br, 1H).

EXAMPLE 40**15 N,N-Diisopropyl-3-(thiazol-5-yl)-3-phenylpropanamine hydrochloride**

 The title compound was prepared in an analogous manner to that described in Example 35. Reaction with N,N-diisopropylamine-3-ethoxythiocarbonyl-3-phenylpropanamine
20 (1.14 g, 3.7 mmol) gave a crude that was chromatographed on silica (petroleum ether-triethylamine 97:3), affording white crystals of the title compound, 0.19 g (30%): mp 193-194°C; ¹H NMR (CDCl₃) δ 1.1.34 (m, 12H), 2.85 (m, 4H), 5.56 (m, 2H), 4.29 (t, 1H), 7.26-7.39 (m, 5H), 7.73 (s, 1H),
25 8.71 (s, 1H) 11.61 (br, 1H).

 The starting compound N,N-diisopropylamine-3-ethoxythiocarbonyl-3-phenylpropanamine was prepared as follows:
30

40.1 N,N-Diisopropyl-3-ethoxythiocarbonyl-3-phenylpropanamine

 HCl-gas was bubbled through an ice-cold solution of N,N-diisopropyl-3-cyano-3-phenylpropanamine (2.9 g, 12
35 mmol), prepared in Example 34.1, in dried ethanol (50 mL, molecular sieve 3 Å) until saturation. The stirred reaction was held under HCl-atmosphere at room temperature overnight. The solvent was carefully evaporated and the

remaining oil was dissolved in dry pyridine (100 mL). To this solution was added triethylamine (5.7 g, 56 mmol) and to the now thick suspension was bubbled H₂S until saturation was achieved. The dark olive-green reaction mixture was held under a H₂S-atmosphere at 65°C overnight. The solvent was evaporated and the residue was partitioned between 1 M HCl and diethyl ether. The aqueous phase was made alkaline (11 M NaOH) and extracted twice with diethyl ether. The combined organic phases were dried (Na₂SO₄) and the solvent evaporated. The crude product was chromatographed on silica (chloroform-methanol-conc. ammonia, 198:1:1), affording the title compound as a straw-coloured liquid, 1.24 g (33%): ¹H NMR (CDCl₃) δ 0.95 (m, 12H), 1.34 (t, 2H), 1.97 (m, 1H), 2.37 (m, 3H), 2.98 (m, 2H), 4.10 (t, 1H) 4.46 (m, 2H), 7.13-7.39 (m, 5H).

EXAMPLE 41

N,N-Diisopropyl-3-(2-hydroxyphenyl)-3-(2-thienyl)-propanamine fumarate

To a suspension of lithium aluminium hydride (LAH) (0.51 g 13.3 mmol) in THF (30 mL), N,N-diisopropyl-3-(2-hydroxyphenyl)-3-(2-thienyl)propanamide (2.0 g, 5.33 mmol) was added and warmed to 50°C overnight. The reaction mixture was quenched and the solvent was evaporated. The residue was dissolved in diethyl ether and extracted twice with 2 M HCl, and the combined aqueous phases were washed twice with diethyl ether. The aqueous phase was made alkaline (11 M NaOH) and extracted three times with diethyl ether, the combined organic phases were washed once with brine, dried (MgSO₄) and the solvent evaporated. The pure amine was crystallised from methanol as its fumarate, yielding the title compound as white crystals, 1.52 g (58%): mp 203-205°C; ¹H NMR (DMSO) δ 1.00 (d, 12H), 2.02 (q, 2H), 2.33 (m, 2H), 3.18 (m 2H), 4.62 (t, 1H), 6.50 (s, 1H), 6.68-7.18 (m, 6H), 7.28 (t, 1H).

The starting compound N,N-diisopropyl-3-(2-hydroxyphenyl)-3-(2-thienyl)propanamide was prepared as follows:

5 **41.1 N,N-Diisopropyl-3-(2-thienyl)propanamide**

2-Bromothiophene (2.28 g, 14.0 mmol), N,N-diisopropylacrylamide (1.55 g, 10.0 mmol), palladium(II)acetate (34 mg, 0.15 mmol), tri-*o*-tolylphosphine (183 mg, 0.6 mmol), tri-*n*-butyl amine (2.04 g, 11.0 mmol) and dry DMF (5 mL) were mixed under a N₂-atmosphere. The mixture was heated to 130°C for 9 hours. Diethyl ether and H₂O was added to the somewhat cooled mixture. The aqueous phase was extracted twice with diethyl ether. The combined organic phases were washed twice with 2 M HCl, once with water, once with brine, and dried (MgSO₄), and the solvent was then evaporated. The crude product was chromatographed on silica (petroleum ether-ethyl acetate 4:1), affording a yellow oil, 1.58 g (66%): ¹H NMR (CDCl₃) δ 1.35 (br, 12H), 3.9 (br, 1H), 4.1 (br 1H), 6.65 (d, 1H), 7.00-7.30 (m, 3H), 7.72 (d, 1H).

41.2 2-Methoxyphenyllithium

2-Methoxybromobenzene (8.44 g 45.1 mmol) was dissolved in dry diethyl ether (15 mL). The mixture was cooled to -78°C. *n*-BuLi (17.8 mL, 45.0 mmol) was added and the mixture was stirred for one hour at -78°C and then for 20 min. at -10°C. The aryl lithium solution was used immediately.

30 **41.3 N,N-Diisopropyl-3-(2-methoxyphenyl)-3-(2-thienyl)propanamide**

Copper(I)bromide dimethyl sulfide complex (4.63 g 22.5 mmol) was dissolved in dimethyl sulfide (18 mL), and diethyl ether (15 mL). The solution was cooled to 0°C, whereafter 2-methoxyphenyllithium (41.2) (45 mmol) was added. After 10 min., the temperature was lowered to -78°C. Trimethylsilylchloride (4.89 g, 45.0 mmol) was added, followed by N,N-diisopropyl-3-(2-thienyl)propanamide (41.1)

(3.56 g, 15 mmol) in diethyl ether (20 mL). The temperature was allowed to slowly rise to room temperature overnight. The reaction was quenched with saturated NH₄Cl (10 mL) and conc. ammonia (10 mL). Diethyl ether (80 mL) was added and the mixture was filtered through Celite. The aqueous phase was extracted twice with diethyl ether. The combined organic phases were washed once with brine and dried (MgSO₄). The solvent was evaporated and the crude product was chromatographed on silica (petroleum ether-ethyl acetate 3:1), affording a yellow oil, 3.75 g (73%): ¹H NMR (CDCl₃) δ 1.12 (t, 6H), 1.29 (t, 6H), 3.02 (m, 2H), 3.4 (br, 1H), 3.80 (s, 3H), 4.03 (m, 1H), 5.26 (t, 1H), 6.8-7.3 (m, 7H).

41.4 N,N-Diisopropyl-3-(2-hydroxyphenyl)-3-(2-thienyl)propanamide

A solution of N,N-diisopropyl-3-(2-methoxyphenyl)-3-(2-thienyl)propanamide (2.37 g, 6.9 mmol) in dichloromethane (35 mL) was cooled down to -78°C and boron tribromide (5.9 g 23.57 mmol) was added. The reaction mixture was allowed to slowly warm to room temperature. The reaction was quenched by slow addition of water (20 mL). The pH was adjusted to around 6 with NaHCO₃(s) and the mixture was extracted three times with CH₂Cl₂. The combined organic phases were washed once with brine, dried (MgSO₄) and the solvent was evaporated. This crude product (2.46 g, 107%) was used without further purification. ¹H NMR (CDCl₃) δ 1.05 (d, 3H), 1.20 (m, 6H), 1.35 (d, 3H), 3.16 (m, 2H), 3.4 (br, 1H), 4.0 (m, 1H), 5.24 (dd, 1H), 6.7-7.2 (m, 7H).

30

Examples 42-54 and 57 and 58 were prepared with the methodology described for Example 41, starting with the appropriate acrylamides and aryl bromides.

EXAMPLE 42**N,N-Diisopropyl-3-(2,4-dihydroxyphenyl)-3-(2-thienyl)propanamine**

The crude product was crystallised from petroleum
5 ether/ethyl acetate affording the title compound, 0.41 g as
slightly pink crystals: mp 102-109°C; ¹H NMR (CDCl₃) δ 1.11
(m, 12H), 2.01 (m, 1H), 2.41 (m, 2H), 2.72 (m, 1H), 3.26
(m, 2H), 4.66 (dd, 1H), 6.30 (dd, 1H), 6.45 (d, 1H), 6.73
(d, 1H), 6.91-7.00 (m, 2H), 7.17 (dd, 1H).

10

EXAMPLE 43**N,N-Diisopropylamine-3-(2-methoxyphenyl)-3-(2-thienyl)propanamine, fumarate**

White crystals, 0.95 g: mp 153-155°C; ¹H NMR (CD₃OD) δ
15 1.28 (m, 12H), 2.48 (m, 2H), 3.05 (m, 2H), 3.68 (m, 2H),
3.85 (s, 3H), 4.71 (t, 1H), 6.68 (s, 2H), 6.89-7.03 (m,
4H), 7.20-7.30 (m, 3H).

EXAMPLE 44**N,N-Diisopropyl-3-(2,4-dimethoxyphenyl)-3-(2-thienyl)propanamine fumarate**

White crystals, 1.52 g: mp 103-109°C; ¹H NMR (CD₃OD) δ
1.28 (m, 12H), 2.46 (m, 2H), 3.04 (m, 2H), 3.66 (m, 2H),
3.77 (s, 3H), 3.82 (s, 3H), 4.60 (t, 1H), 6.46-6.58 (m,
25 2H), 6.68 (s, 2H), 6.91-6.97 (m, 2H), 7.09- 7.26 (m, 2H).

EXAMPLE 45**N,N-Diisopropyl-3-(3-methoxyphenyl)-3-(2-thienyl)propanamine hydrochloride**

White crystals, 1.16 g: mp 95-97°C; ¹H NMR (CD₃OD) δ
30 1.28 (d, 12H), 2.49 (m, 2H), 2.96 (m, 1H), 3.13 (m, 1H),
3.68 (m, 2H), 3.77 (s, 3H), 4.31 (t, 1H), 6.83 (m, 1H),
6.68-7.02 (m, 4H), 7.27 (m, 2H).

EXAMPLE 46**N,N-Diisopropyl-3-(4-methoxyphenyl)-3-(2-thienyl)-
propanamine hydrochloride**

White amorphous substance, 0.50 g: mp 157-160°C; ¹H
5 NMR (CD₃OD) δ 1.31 (m, 12H), 2.47 (m, 2H), 2.94 (m, 1H),
3.12 (m, 1H); 3.68 (br, 2H), 3.77 (s, 3H), 4.28 (t, 1H),
6.87-7.00 (m, 4H), 7.23-7.32 (m, 3H).

EXAMPLE 47**10 N-Isopropyl-N-methyl-3-(2-methoxyphenyl)-3-(2-
thienyl)propanamine fumarate**

White crystals, 1.32 g: mp 141-143°C; ¹H NMR (CD₃OD) δ
1.24 (m, 6H), 2.50 (m, 2H), 2.73 (s, 3H), 3.04 (m, 2H),
3.58 (m, 1H), 3.84 (s, 3H), 4.73 (t, 1H), 6.68 (s, 2H),
15 6.96 (m, 4H), 7.24 (m, 3H).

EXAMPLE 48**N,N-Diisopropyl-3-phenyl-3-(2-thienyl)propanamine,
hydrochloride**

20 White crystals, 0.74 g: mp 165-166°C; ¹H NMR (CD₃OD) δ
1.28 (d, 12H), 2.52 (m, 2H), 2.96 (m, 1H), 3.13 (m, 1H),
3.70 (br, 2H), 4.34 (t, 2H), 6.92-7.04 (m, 2H), 7.20-7.42
(m, 6H).

25 EXAMPLE 49**N-Cyclohexyl-N-methyl-3-phenyl-3-(2-thienyl)propanamine
hydrochloride**

White crystals, 1.1 g: mp 197-199°C; ¹H NMR (CD₃OD) δ
1.15-1.52 (br, 5H), 1.68 (br, 1H), 1.90 (br, 4H), 2.51 (br,
30 2H), 2.78 (s, 3H), 2.91-3.40 (m, 3H), 4.31 (t, 1H), 6.92-
7.04 (m, 2H), 7.20-7.40 (m, 6H).

EXAMPLE 50**N,N-Diethyl-3-phenyl-3-(2-thienyl)propanamine fumarate**

35 White crystals, 1.7 g (tot. 49 %): mp 135-137°C; ¹H
NMR (CD₃OD) δ 1.22 (t, 3H), 2.50 (m, 2H), 2.90-3.26 (m, 6H),

4.30 (t, 1H), 6.68 (s, 2H), 6.92-7.03 (m, 2H), 7.20-7.40 (m, 6H).

EXAMPLE 51**5 N-Isopropyl-N-methyl-3-phenyl-3-(2-thienyl)propanamine hydrochloride**

White crystals, 1.6 g: mp 139-144°C; ¹H NMR (CD₃OD) δ
1.24 (m, 6H), 2.52 (m, 2H), 2.75 (s, 3H), 3.03 (m, 2H),
3.59 (m, 1H), 4.32 (t, 1H), 6.92-7.04 (m, 2H), 7.20-7.40
10 (m, 6H).

EXAMPLE 52**N-[3-Phenyl-3-(2-thienyl)propyl]pyrrolidine fumarate**

Crystallisation from 2-propanol, 1.1 g: mp 144-145°C;
15 ¹H NMR (CD₃OD) δ 2.02 (m, 4H) 2.31 (m, 2H), 2.97-3.42 (m,
6H), 4.29 (t, 1H), 6.69 (s, 2H), 6.91-7.01 (m, 2H), 7.18-
7.38 (m, 6H).

EXAMPLE 53**20 N-[3-Phenyl-3-(2-thienyl)propyl]piperidine hydrochloride**

The hydrochloride was crystallised from
ethylmethyleketone, 0.84 g: mp 193-194°C; ¹H NMR (CD₃OD) δ
1.40-2.00 (b, 6H), 2.54 (m, 2H), 2.82-3.80 (m, 6H), 4.29
(t, 1H), 6.91-7.03 (m, 2H), 7.20-7.42 (m, 6H).

25

EXAMPLE 54**N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-(2-thienyl)propanamine hydrochloride**

White crystals, 2.1 g: mp 205-210°C; ¹H NMR (CDCl₃) δ
30 1.36 (m, 12H), 2.18 (s, 3H), 2.63 (m, 2H), 2.95 (m, 2H),
3.54 (m, 4H), 4.61 (t, 1H), 6.76-7.01 (m, 5H), 7.16 (d,
1H).

EXAMPLE 55**(R*) N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-(2-thienyl)propanamine**

To the racemic free base of N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-2-thienylpropanamine (20 g, 0.06 mol), prepared in Example 54, in abs. ethanol (50 g) was added L-(+)-tartaric acid (9.5 g 0.063 mol) in ethanol (60 g). The salt formed was filtered off and crystallised twice from ethanol/methanol 10/1, 10 mL per gram of crystals, affording the title compound as white crystals, (6.8 g, 14.1 mmol): mp 214-215°C; $[\alpha]_{\text{Hg}}=+17.3^\circ$ (c=3.82 in methanol).

EXAMPLE 56**(S*) N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-(2-thienyl)propanamine**

From the mother liquid from the first crystallisation to obtain (R*) N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-(2-thienyl)propanamine in Example 55, the free base was recovered. The amine was treated with a 5% excess of D-(-)-tartaric acid in ethanol as above, yielding the title compound as white crystals, 6.1 g (12.7 mmol): mp 214°C; $[\alpha]_{\text{Hg}}=-17.5^\circ$ (c=3.85 in methanol).

EXAMPLE 57**N,N-Diisopropyl-3-phenyl-3-(3-thienyl)propanamine hydrochloride**

White crystals, 0.94 g: mp 141-142 °C; $^1\text{H NMR}$ (CDCl_3) δ 1.42 (m, 12H), 2.87 (m, 4H), 3.56 (br, 2H), 3.98 (t, 1H), 6.94 (dd, 1H), 7.27 (m, 7H), 11.4 (br, 1H).

The starting compound was prepared as follows:

57.1 N,N-Diisopropyl-3-(3-thienyl)propenamide

Sodium hydride, 60% in mineral oil (3.9 g, 98 mmol), was washed several times with petroleum ether and dried under a stream of nitrogen. Sodium-dried THF was added

followed by diethyl N,N-diisopropyl acetamidophosphonate (27.4 g, 98 mmol). When the evolution of gas had ceased, thiophene-3-aldehyde (10.0 g, 89.2 mmol) in THF (50 mL) was added at such a rate that the temperature never exceeded 45°C. After one hour of stirring at ambient temperature, the reaction was quenched with 4 mL of water and stirred for another hour. The solvent was evaporated and the residue was taken up in diethyl ether/2M NaOH. The organic phase was washed once with water and once with brine, dried (Na₂SO₄) and evaporated. The crude was chromatographed on silica (petroleum ether-ethyl acetate 4:1) affording the title compound as a light-brown oil, 14.8 g (70%): ¹H NMR (CDCl₃) δ 1.37 (b, 12H), 3.86 (br, 1H), 4.10 (br, 1H), 6.68 (d, 1H), 7.27-7.41 (m, 3H), 7.59 (d, 1H).

15

EXAMPLE 58**N,N-Diisopropyl-3-(2-furanyl)-3-phenylpropanamine hydrochloride**

White crystals, 60 mg: mp 139-141 °C; ¹H NMR (CDCl₃) δ 1.41 (br, 12H), 2.64 (m, 1H), 2.85 (m, 3H), 3.55 (m, 2H), 3.98 (t, 1H), 6.16 (d, 1H), 6.31 (dd, 1H), 7.30 (m, 6H), 11.4 (br, 1H).

20

The starting compound was prepared as follows:

25

58.1 N,N-Diisopropyl-3-(2-furanyl)propanamide

The title compound was obtained from furfural with the procedure described in Example 57.1, as a colourless oil, 11.2 g (75%): ¹H NMR (CDCl₃) δ 1.32 (d, 12H), 4.0 (br, 2H), 6.41 (m, 2H), 6.76 (d, 1H), 7.38 (m, 2H).

30

EXAMPLE 59**N,N-Diisopropyl-3-(N-methylpyrrol-2-yl)-3-phenylpropanamine fumarate**

A solution of N,N-diisopropyl-3-(N-methyl-pyrr-2-yl)-3-phenyl-propanamide (4.92 g, 15.7 mmol) in THF (75 mL), was dropped into a stirred mixture of LAH (2.38 g, 62.8

35

mmol). Stirring was continued at 50 °C overnight. Standard work-up gave the amine as a yellow oil, which was isolated as the fumarate salt, 2.74 g (42 %): m.p. 134-6°C; ¹H NMR (CD₃OD) δ 1.27 (d, 6H), 1.29 (d, 6H), 2.24 (m, 1H), 2.48 (m, 1H), 2.97 (dt, 1H), 3.26 (dt, 1H), 3.32 (s, 3H), 3.69 (septet, 2H), 4.08 (t, 1H), 6.05 (t, 1H), 6.16 (m, 1H), 6.57 (dd, 1H), 6.71 (s, 2H) and 7.19-7.34 (m, 5H).

The starting compound was prepared as follows:

59.1 N,N-Diisopropyl-3-(N-methylpyrrol-2-yl)-propanamide

The title compound was prepared from N-methyl-2-pyrrolaldehyde and N,N-diisopropyl-dimethylphosphonacetamide analogously to Example 4.2, giving 7.61 g (92%):

¹H NMR (CDCl₃) δ 1.32 (d, 6H), 1.35 (d, 6H), 3.68 (s, 3H), 4.00 (m, 2H), 6.13 (t, 1H), 6.55-6.66 (3H) and 7.57 (d, 1H).

59.2 N,N-Diisopropyl-3-(N-methylpyrrol-2-yl)-3-phenylpropanamide

The title compound was prepared from N,N-diisopropyl-3-(N-methylpyrrol-2-yl)-propanamide by a method analogous to that described in Example 41.3, giving 4.92 g (78 %): ¹H NMR (CDCl₃) δ 0.85-1.32 (4d from rotamers, 12H), 2.91 (d, 2H), 3.31 (s, 3H) 3.45 (m, 1H), 3.88 (m, 1H), 4.65 (t, 1H), 6.07 (2H), 6.50 (dd, 1H) and 7.15-7.22 (5H).

EXAMPLE 60

3-(N-Methylpyrrol-2-yl)-3-phenyl-1-pyrrolidinopropane fumarate

The title compound was prepared analogously to Example 59, using N,N-tetramethylene-dimethylphosphonacetamide, yield 950 mg (36 % tot.): m.p. 194-5°C; ¹H NMR (CD₃OD) δ 1.27 (d, 12H), 2.2-2.6 (m, 2H) 3.05 (m, 2H), 3.66 (sept., 2H), 4.03 (t, 1H), 6.02 (two d, 2H), 6.64 (t, 1H), 6.69 (s, 2H) and 7.28 (m, 5H).

BIOLOGICAL EVALUATION

The pharmacological activity of compounds prepared in the Examples was tested using in vitro methods.

Functional in vitro studies

5 Male guinea pigs, weighing about 300 g, were killed by a blow on the neck and exsanguinated. Smooth muscle strips of the urinary bladder were dissected in a Krebs-Henseleit solution (pH 7.4). The strip preparations were vertically mounted between two hooks in thermostatically controlled
10 (37°C) organ baths (5 ml). One of the hooks was adjustable and connected to a force transducer (FT 03, Grass Instruments). The Krebs-Henseleit solution was continuously bubbled with carbogen gas (93.5% O₂/6.5% CO₂) to maintain the pH at 7.4. Isometric tension was recorded by a Grass
15 Polygraph (Model 79D). A resting tension of approximately 5 mN was initially applied on each muscle strip and the preparations were allowed to stabilise for at least 45 min. The resting tension was repeatedly adjusted and the preparations were washed several times during the
20 stabilisation period.

Carbachol (carbamylcholine chloride) was used as the standard muscarinic receptor agonist. In each experiment, the viability of the preparations and the reproducibility of their contractile responses were initially tested by two
25 consecutive additions of a submaximal concentration (3×10^{-6} M) of carbachol. A concentration-response curve to carbachol was then generated by cumulative addition of carbachol to the organ-bath (i.e., stepwise increase of the agonist concentration until the maximal contractile
30 response was reached), followed by washing out and a resting period of at least 15 min. before a fixed concentration of the test compound (antagonist) was added to the organ-bath. After 60 min. of incubation with the antagonist, a second cumulative concentration-response
35 curve to carbachol was generated. Responses were expressed as per cent of the maximal response to carbachol. EC₅₀-values for carbachol in the absence (control) and presence of antagonist were graphically derived and dose ratios (r)

were calculated. Dissociation constants, K_B , for the antagonists were calculated using equation (1) (Schild, H.I., Br. J. Pharmacol. Chemother. 1949, 4, 277-280), where [A] is the concentration of test compound:

$$5 \quad K_B = [A]/r-1 \quad (1)$$

The K_B values obtained are presented in Table 1 below.


Table 1

Example No.	K_B -value nM	Example No.	K_B -value nM	Example No.	K_B -value nM
1	499	23	1.05	45	51
3	236	24	1.91	46	286
4	132	27	7.1	47	91
5	336	28	8.55	48	31
6	10	29	1.5	49	590
7	13	30	139	50	154
8	26	31	14	51	118
9	3.8	32	36	52	350
10	171	33	56	53	154
11	431	34	803	55	2
12	1.18	35	1773	56	360
13	15	36	2640	59	690
14	4.5	37	520	60	707
15	15	38	207		
16	32	39	235		
17	3.5	40	814		
18	172	41	7.6		
19	2.9	42	286		
20	3315	43	29		
22	2.8	44	2285		

10

CLAIMS

1. A compound of Formula (I):



wherein:

- 5 R^1 is hydrogen, hydroxy, alkyl, alkoxy, hydroxyalkyl, trifluoromethyl, amino, alkylcarbonylamino, alkylcarbonyloxy, halogen,
- R^2 and R^3 independently are hydrogen, hydroxy, alkyl, alkoxy, hydroxyalkyl, halogen, alkoxy-carbonylalkyl, carbamoyl, sulphamoyl,
- 10 R^4 is ω -hydroxyalkoxy, ω -aminoalkoxy, ω -aminoalkylamino, alkoxyalkyl, hydroxyalkoxyalkylaminoalkyl, alkoxy-carbonylalkyl, dihydroxyalkyl, formyl, alkylcarbonyl, alkoxy-carbonyl, alkylcarbonylaminoalkyl, aminoalkyl,
- 15 alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, carbamoylalkyl, carboxamidoalkyl, carboxyl, amino, nitro, cyano, nitrilo, cyanoalkyl, azido, alkyl having at least two carbon atoms, alkoxy having at least two carbon atoms, hydroxyalkyl having at least two carbon atoms,
- 20 R^5 is hydrogen, halogen, alkyl,
- Ar is aryl or heteroaryl which may be mono- or independently disubstituted by alkyl, alkoxy, hydroxy, hydroxyalkyl, halogen, alkoxy-carbonylalkyl, carbamoyl, sulphamoyl, and
- 25 R^6 and R^7 are hydrocarbonyl groups which may be the same or different, together containing at least three carbon atoms, and which may carry one or more hydroxy groups, and wherein carbon atoms may be interconnected by oxygen atoms, and wherein R^6 and R^7 may form a ring
- 30 together with the amine nitrogen;

RECTIFIED SHEET (RULE 91)

with the provisos that (a) when:

(i) at least two of R², R³ and R⁵ are other than hydrogen,
or

(ii) R¹ is other than hydroxy or methoxy, and Ar is other
5 than phenyl that is ortho-substituted by hydroxy or
methoxy, or

(iii) Ar is heteroaryl, or

(iv) at least one of R⁶ and R⁷ is aromatic hydrocarbyl or
cycloalkyl, then

10 R⁴ may also be hydrogen, methyl, methoxy,

hydroxymethyl, hydroxy, halogen, carbamoyl, sulphamoyl;

and (b), when Ar is unsubstituted phenyl, then R¹,
R², R³, R⁴ and R⁵ can not all be hydrogen;

15 their salts with physiologically acceptable acids and,
when the compounds can be in the form of optical isomers,
the racemic mixture and the individual enantiomers.

2. The compound according to claim 1, wherein R⁴ is ω-
hydroxyalkoxy, ω-aminoalkoxy, ω-aminoalkylamino,
20 alkoxyalkyl, hydroxyalkoxyalkylaminoalkyl, dihydroxyalkyl,
formyl, alkylcarbonyl, alkoxy carbonyl, alkoxy carbonylalkyl,
alkylcarbonylaminoalkyl, aminoalkyl, alkylaminoalkyl,
dialkylaminoalkyl, carboxyalkyl, carbamoylalkyl,
carboxamidoalkyl, carboxyl, amino, nitro, cyano, nitrilo,
25 cyanoalkyl, or azido.

3. The compound according to claim 2, wherein R¹ is
hydrogen or methyl, R², R³ and R⁵ are either all hydrogen
or one of R², R³ and R⁵ is methyl, methoxy, hydroxy,
30 carbamoyl, sulphamoyl or halogen, and the others are
hydrogen, and Ar is phenyl or phenyl which is mono- or
independently disubstituted by methyl, methoxy, hydroxy,
hydroxymethyl, carbamoyl, sulphamoyl or halogen.

35 4. The compound according to claim 1, wherein Ar is
heteroaryl.

5. The compound according to claim 4, wherein R¹ is hydrogen or methyl, and R², R³, R⁴ and R⁵ are either all hydrogen or one of R², R³, R⁴ and R⁵ is methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen, and the others are hydrogen.

6. The compound according to claim 1, wherein R¹ is hydrogen, alkyl, hydroxyalkyl, trifluoromethyl, amino, alkylcarbonylamino, alkylcarbonyloxy, or halogen, and Ar is other than phenyl that is ortho-substituted by hydroxy or alkoxy.

7. The compound according to claim 6, wherein R¹ is hydrogen or methyl, R², R³, R⁴ and R⁵ are either all hydrogen or one of R², R³, R⁴ and R⁵ is methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and the others are hydrogen, and Ar is phenyl or phenyl which is mono- or independently disubstituted by methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen.

8. The compound according to claim 1, wherein at least one of R⁶ and R⁷ is aromatic hydrocarbyl, cycloalkyl or a hydrocarbyl chain wherein carbon atoms are interconnected by an oxygen atom in at least one position.

9. The compound according to claim 8, wherein R¹ is hydrogen or methyl, R², R³, R⁴ and R⁵ are either all hydrogen or one of R², R³, R⁴ and R⁵ is methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and the others are hydrogen, and Ar is phenyl or phenyl which is mono- or independently disubstituted by methyl, methoxy, hydroxy, hydroxymethyl, carbamoyl, sulphamoyl or halogen.

10. The compound according to any one of claims 1 to 9, wherein R¹ is hydroxy, halogen, trifluoromethyl, amino, methoxy or hydroxymethyl.

11. The compound according to any one of claims 1 to 10, wherein R² and R³ independently are hydrogen, hydroxy or hydroxymethyl.
- 5 12. The compound according to any one of claims 1 to 10, wherein R⁴ is hydrogen, formyl, alkoxycarbonyl, alkylcarbonyl, hydroxyalkyl, alkoxyalkyl, carboxamidoalkyl, carbamoylalkyl, aminoalkyl, amino, azido, cyanoalkyl, carboxy or carboxyalkyl.
- 10 13. The compound according to claim 12, wherein R⁴ is hydrogen, formyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, ethoxymethyl, methoxycarbonyl, amino, aminopropyl, acetyl, 15 1,2-hydroxyethyl, ethylaminomethyl, or hydroxyethoxyethyl-aminoethyl.
14. The compound according to any one of claims 1 to 13, wherein R⁵ is hydrogen.
- 20 15. The compound according to any one of claims 1 to 14, wherein each of R⁶ and R⁷ independently signify a saturated hydrocarbyl group, especially a saturated aliphatic hydrocarbyl group such as C₁₋₈alkyl, especially C₁₋₆alkyl, 25 or adamantyl, R⁶ and R⁷ together containing at least three, preferably at least four carbon atoms.
16. The compound according to any one of claims 1 to 14, wherein R⁶ and R⁷ taken together form a ring with the amine 30 nitrogen.
17. The compound according to any one of claims 1 to 16, wherein at least one of R⁶ and R⁷ comprises a branched carbon chain.
- 35 18. The compound according to any one of claims 1 to 17, wherein Ar is thienyl, pyrrolyl, thiazolyl, oxazolyl, methylthiazolyl or methylpyrrolyl.

19. The compound according to claim 1, which is:
N,N-diisopropyl-3-(2-fluorophenyl)-3-phenylpropanamine hydrochloride,
- 5 N,N-diisopropyl-3-(5-formyl-2-hydroxy-phenyl)-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-(2-hydroxy-5-methyloxycarbonyl-phenyl)-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-(5-acetyl-2-hydroxyphenyl)-3-phenylpropanamine, or its (R)-isomer,
- 10 N,N-diisopropyl-3-[2-hydroxy-5-(2-hydroxyethyl)-phenyl]-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-[2-hydroxy-5-(1-hydroxyethyl)-phenyl]-3-phenylpropanamine, or its 3(R)-isomer,
- 15 N,N-diisopropyl-3(R)-[5-(1(R*),2-dihydroxyethyl)-2-hydroxyphenyl]-3-phenylpropanamine, or its 1(S*)-isomer,
N,N-diisopropyl-3-[2-hydroxy-5-(6-hydroxyhexyl)-phenyl]-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-(5-ethoxymethyl-2-hydroxyphenyl)-3-phenylpropanamine, or its (R)-isomer,
- 20 N,N-diisopropyl-3-[5-(3-aminopropyl)-2-hydroxyphenyl]-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-[5-(3-acetamidopropyl)-2-hydroxyphenyl]-3-phenylpropanamine, or its (R)-isomer,
- 25 N,N-diisopropyl-3-[5-(2-cyanoethyl)-2-hydroxyphenyl]-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-(5-amino-2-hydroxyphenyl)-3-phenylpropanamine, or its (R)-isomer,
N,N-diisopropyl-3-(5-azido-2-hydroxyphenyl)-3-phenylpropanamine, or its (R)-isomer,
- 30 N,N-diisopropyl-3-[2-hydroxy-5-(3-hydroxypropyl)-phenyl]-3-phenylpropanamine, or its (R)-isomer,
N-cyclobutyl-N-methyl-3-(2-hydroxyphenyl)-3-phenylpropanamine,
- 35 N,N-diisopropyl-3-(2-hydroxyphenyl)-3-(2-thienyl)propanamine, or
N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-(2-thienyl)propanamine, or its (R)-isomer.

20. The compound according to any one of claims 1 to 19 for use as a pharmaceutically active substance, especially as an anticholinergic agent.

5


21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19, and preferably a compatible pharmaceutical carrier.

10 22. Use of a compound according to any one of claims 1 to 19 for preparing an anticholinergic drug.

23. A method of treating a living body suffering from a disorder related to urinary incontinence, which method
15 comprises the step of administering to said living body an effective amount of a compound according to any one of claims 1 to 19.


24. A method of preparing a compound according to any one
20 of claims 1 to 19, which comprises:

a) reacting a compound of Formula II




25 wherein R¹ to R⁵ and Ar are as defined in claim 1, and Y is a leaving group, with an amine HNR⁶,R⁷, wherein R⁶ and R⁷ are as defined above, or

b) reducing a compound of Formula III



wherein R^1 to R^7 and Ar are as defined in claim 1 and any hydroxy groups may be protected, or


- 5 c) N-alkylating a secondary amine of Formula IV




wherein R^1 to R^5 and Ar are as defined in claim 1 and any hydroxy groups may be protected, and wherein Z has the same meaning as R^6 and R^7 , or

10

- d) reducing a compound of Formula Va or Vb






wherein R¹ to R⁷ and Ar are as defined in claim 1 and any hydroxy groups may be protected, and W signifies a hydroxy group or halogen, or

5


e) in a compound of Formula VI



wherein R² to R⁷ and Ar are as defined in claim 1, and R^{1a} is carboxyl or alkoxy, converting R^{1a} to hydroxy, or

10

f) in a compound of Formula VII




wherein R¹, R⁶, R⁷ and Ar are as defined in claim 1, and one of R^{2b} to R^{5b} is alkylene and the others are as defined in claim 1 for R² to R⁵, reducing alkylene to alkyl, hydroxyalkyl or dihydroxyalkyl, or

15

g) in a compound of Formula I as defined in claim 1, converting one or more of groups R¹ to R⁵ to another or other groups R¹ to R⁵, or

5 h) reacting a compound of Formula VIII




wherein R¹ to R⁷ are as defined in claim 1, and X is oxygen or sulphur, with a compound of Formula IX

10




to form a compound of Formula Ia




wherein R¹ to R⁷ and X are as defined above, or

15

i) reacting a compound of Formula VIII above, wherein X is oxygen, with a compound of Formula X




to form a compound of Formula Ib




5 wherein R¹ to R⁷ are as defined in claim 1, or

j) converting a compound of Formula XI




10 wherein R¹ to R⁷ are as defined in claim 1, to a compound of Formula XII




wherein R¹ to R⁷ are as defined in claim 1, or

k) converting a compound of Formula XIII



wherein R¹ to R⁷ are as defined in claim 1, and X is oxygen or sulphur, to a compound of Formula XIV

5



wherein R¹ to R⁷ and X are as defined above, and R⁸ and R⁹ independently are hydrogen or alkyl, and

- 10 i) when necessary splitting off hydroxy protecting groups in the compounds obtained,
- ii) if desired converting the obtained bases of Formula I into salts thereof with physiologically acceptable acids, or vice versa, and/or
- 15 iii) if desired separating an obtained mixture of optical isomers into the individual enantiomers.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/00556

A. CLASSIFICATION OF SUBJECT MATTER		
IPC6: C07C 211/06, C07C 215/54, C07C 217/62, C07C 237/30, C07C 255/33, C07D 333/20, A61K 31/135, A61K 31/33 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC6: C07C, C07D, A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
CA, WPI		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9411337 A1 (KABI PHARMACIA AB), 26 May 1994 (26.05.94) --	1-22,24
X	WO 8906644 A1 (KABIVITRUM AB), 27 July 1989 (27.07.89) --	1-22,24
X	DE 1216318 B1 (FARBWERKE HOECHST AKTIENGESELLSCHAFT VORMALS MEISTER LUCIUS & BRÜNING), 12 May 1966 (12.05.66), column 4, line 1 - line 4, the claims --	1-21,24
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search		Date of mailing of the international search report
15 June 1998		29 -06- 1998
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Gerd Strandell Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/00556

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1169944 A (ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE), 5 November 1969 (05.11.69), page 1, line 10 - line 12, the claims --	1-21,24
X	GB 1169945 A (ED GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE), 5 November 1969 (05.11.69), page 1, line 10 - line 11, the claims -- -----	1-21,24

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/00556

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 23
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

09/06/98

International application No.
PCT/SE 98/00556

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9411337 A1	26/05/94	AT 164828 T	15/04/98
		AU 672458 B	03/10/96
		AU 5438094 A	08/06/94
		CA 2148827 A	26/05/94
		DE 69317898 D	00/00/00
		EP 0667852 A,B	23/08/95
		FI 952179 A	05/05/95
		HU 72742 A	28/05/96
		HU 9501329 D	00/00/00
		JP 8503208 T	09/04/96
		NO 951775 A	05/05/95
		SE 9203318 D	00/00/00
		US 5559269 A	24/09/96
		US 5686464 A	11/11/97
WO 8906644 A1	27/07/89	AU 635493 B	25/03/93
		AU 2932989 A	11/08/89
		DE 6890018 U	12/09/91
		DK 163403 B,C	02/03/92
		DK 172103 B	27/10/97
		DK 172590 A	19/07/90
		DK 538289 A	27/10/89
		EP 0325571 A,B	26/07/89
		SE 0325571 T3	
		EP 0354234 A	14/02/90
		FI 894902 D	00/00/00
		FI 903688 D	00/00/00
		HK 64494 A	15/07/94
		HU 210603 B	29/05/95
		HU 212729 B	28/10/96
		HU 9400053 A	30/01/95
		JP 2664503 B	15/10/97
		JP 3503163 T	18/07/91
		NO 173496 C	22/12/93
		SE 8800207 D	00/00/00
US 5382600 A	17/01/95		
DE 1216318 B1	12/05/66	DK 111894 A	00/00/00
GB 1169944 A	05/11/69	NONE	
GB 1169945 A	05/11/69	US 3446901 A	27/05/69

BA



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 667 852 B1

(12) EUROPEAN PATENT SPECIFICATION

- (45) Date of publication and mention of the grant of the patent:
08.04.1998 Bulletin 1998/15
- (21) Application number: 93924876.1
- (22) Date of filing: 05.11.1993
- (51) Int Cl.⁶: C07C 217/62, C07C 215/54, C07C 311/37, C07C 237/30, C07D 295/06, C07D 211/14, C07D 207/06, A61K 31/135
- (86) International application number:
PCT/SE93/00927
- (87) International publication number:
WO 94/11337 (26.05.1994 Gazette 1994/12)

(54) **NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION**
 3,3-DIPHENYLPROPYLAMINE, IHRE VERWENDUNG UND HERSTELLUNG
 NOUVELLES 3,3-DIPHENYLPROPYLAMINES, LEUR UTILISATION ET LEUR PREPARATION

<p>(84) Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE</p> <p>(30) Priority: 06.11.1992 SE 9203318</p> <p>(43) Date of publication of application: 23.08.1995 Bulletin 1995/34</p> <p>(73) Proprietor: Pharmacia & Upjohn Aktiebolag 112 87 Stockholm (SE)</p> <p>(72) Inventors: • JOHANSSON, Rolf, Arne S-141 38 Huddinge (SE)</p>	<ul style="list-style-type: none"> • MOSES, Pinchas S-132 00 Saltsjö-Boo (SE) • NILVERBANT, Lisbeth S-161 35 Bromma (SE) • SPARF, Bengt, Ake S-142 65 Trangsund (SE) <p>(74) Representative: Widén, Björn et al Pharmacia & Upjohn AB, Patent Department 751 82 Uppsala (SE)</p> <p>(56) References cited: WO-A-89/06644 DE-B- 1 216 318 GB-A- 1 169 944 GB-A- 1 169 945</p>
---	---

EP 0 667 852 B1


Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

The present invention relates to novel therapeutically active compounds, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs.

WO 89/06644 discloses 3,3-diphenylpropylamines having anticholinergic activity. In accordance with the present invention novel therapeutically active compounds have now been found, some of which are formed as metabolites in mammals when treated with the 3,3-diphenylpropylamines disclosed in the above-mentioned WO publication. These metabolites have at least as favourable anti-cholinergic properties as the parent compounds and can thus be used for the control of events mediated by acetylcholine, like urination.

The novel compounds of the present invention are represented by the general formula I



wherein R¹ signifies hydrogen or methyl, R² and R³ independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula II



wherein R⁴ and R⁵ signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, preferably at least four carbon atoms, especially at least five carbon atoms, and wherein R⁴ and R⁵ may form a ring together with the amine nitrogen, said ring having no other heteroatom than the amine nitrogen.

The compounds of formula I can form salts with physiologically acceptable acids, organic and inorganic, and the invention comprises the free bases as well as the salts thereof. Examples of such acid addition salts include the hydrochloride, hydrobromide, hydrogen fumarate, and the like.

When the novel compounds are in the form of optical isomers, the invention comprises the racemic mixture as well as the individual isomers as such.

In the compounds of formula I, R² is preferably hydrogen, and R³ is preferably hydrogen or hydroxy.


R² is preferably in 3-, 4- or 5-position.


R³ is preferably in 2-position with respect to the propylamine group.

The HOCH₂-group is preferably in 5-position.

Preferably, each of R⁴ and R⁵ independently signifies C₁₋₈-alkyl, especially C₁₋₆-alkyl, or adamantyl, R⁴ and R⁵ together comprising at least three, preferably at least four carbon atoms. R⁴ and R⁵ may carry one or more hydroxy groups, and they may be joined to form a ring together with the amine nitrogen atom.

Presently preferred tertiary amino groups X in formula I include the following groups a) - h):






Preferably, R⁴ and R⁵ are both isopropyl.

20 A presently preferred specific compound of formula I is N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine.


The compounds of formula I may, in accordance with the present invention, be prepared by per se conventional methods, and especially by

25 a) reducing the group R⁶CO in a 3,3-diphenylpropylamine of formula III



wherein R¹ to R³ and X are as defined above, R⁶ is hydrogen or R⁷O, where R⁷ is hydrogen, (preferably lower) alkyl, alkenyl, alkynyl or aryl (such as phenyl) and any hydroxy groups may be protected, such as by methylation or benzylation, or

40 b) reacting a reactively esterified 3,3-diphenylpropanol of formula IV




wherein R¹ to R³ are as defined above and any hydroxy groups may be protected, and wherein Y is a leaving group, preferably halogen or an alkyl or arylsulphonyloxy group, with an amine of formula V



V


wherein X is as defined above, or

c) reducing a 3,3-diphenylpropionamide of formula VI



wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, preferably using a complex metal hydride, or


d) N-methylating a secondary 3,3-diphenylpropylamine of formula VII



25

wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, and wherein Z has the same meaning as R⁴ and R⁶ with the exception of methyl, Z preferably being a hydrocarbyl group comprising at least three carbon atoms, the N-methylation preferably being carried out using formaldehyde or formic acid, or


e) reducing a 3,3-diphenylpropenamine of formula VIIIa or a 3,3-diphenylpropylamine of formula VIIIb



40

wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, and W signifies a hydroxy group or a halogen atom, preferably by means of catalytic hydrogenation,


f) reacting a 3,3-diphenylpropylamine of formula IX



55

wherein R¹ to R³ and X are as defined above, and Hal is halogen, with formaldehyde or a formaldehyde equivalent (such as s-trioxane), or

g) oxidizing the methyl group of a diphenylpropylamine of formula X



wherein R¹ to R³ and X are as defined above, and

- 15
- i) when necessary splitting off hydroxy protecting groups in the compounds obtained, if desired after mono- or di-halogenation of one or both of the phenyl rings, and/or
 - ii) if desired converting the obtained bases of formula I into salts thereof with physiologically acceptable acids, or vice versa, and/or
 - iii) if desired separating an obtained mixture of optical isomers into the individual enantiomers, and/or
 - iv) if desired methylating an ortho-hydroxy group in an obtained compound of formula I, wherein R¹ is hydrogen and/or R³ is hydroxy.
- 20

The oxidation in process g) above may be performed chemically, electrochemically or enzymatically. Chemical oxidation is advantageously performed using a metal salt or oxide like ceric ammonium nitrate, manganese oxides, chromium oxides, vanadium oxides, cobalt acetate, aluminium oxide, bismuth molybdate or combinations thereof. Chemical oxidation may also be effected by peracids, with or without a catalyst, or with halides. Electrochemical oxidation may be conducted with or without a catalyst. For enzymatical oxidation, it is preferred to use bacteria or yeast (e.g. *Candida Guilliermondi*, *Candida Tropicalis*).

25

The removal of hydroxy protecting groups according to i) above can e.g. be done by treatment with hydrobromic acid, borontribromide or by catalytic hydrogenation.

The separation of mixtures of optical isomers, according to ii) above, into the individual enantiomers can e.g. be achieved by fractional crystallization of salts with chiral acids or by chromatographic separation on chiral columns.

30

The starting compounds of formula III and IX may be prepared as described in the preparation example described below. The starting materials used in processes b) to e) and g) may be prepared as described in the afore-mentioned WO 89/06644 (the disclosure of which is incorporated by reference herein) with due consideration of the disclosure in the present preparation example.

35

In accordance with the present invention, the compounds of formula I, in the form of free bases or salts with physiologically acceptable acids, can be brought into suitable galenic forms, such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures. Such pharmaceutical compositions according to the invention comprise an effective amount of the compounds of formula I in association with compatible pharmaceutically acceptable carrier materials, or diluents, as is well known in the art.

40

The carriers may be any inert material, organic or inorganic, suitable for enteral, percutaneous or parenteral administration, such as: water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such compositions may also contain other pharmaceutically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.

45

The compositions according to the invention can e.g. be made up in solid or liquid form for oral administration, such as tablets, capsules, powders, syrups, elixirs and the like, in the form of sterile solutions, suspensions or emulsions for parenteral administration, and the like.

The compounds and compositions can, as mentioned above, be used for the same therapeutical indications as the compounds of the above-mentioned WO 89/06644, i.e. for the treatment of acetylcholine-mediated disorders, such as urinary incontinence. The dosage of the specific compound will vary depending on its potency, the mode of administration, the age and weight of the patient and the severity of the condition to be treated. The daily dosage may, for example, range from about 0.01 mg to about 4 mg per kilo of body weight, administered singly or multiply in doses e.g. from about 0,05 mg to about 200 mg each.

50

The invention will be further illustrated by the following non-limiting example and pharmacological tests. Reference will be made to the accompanying drawing where the only figure (Fig. 1) shows bladder pressure inhibition curves for a compound of the present invention and a prior art compound, respectively.

55

General

N.M.R data were acquired on a Jeol JNM-EX 270 Fourier transform spectrometer. Spectra were recorded with tetramethylsilane (TMS) as internal standard at 30°C. Infrared spectra were recorded on a Perkin Elmer 599B instrument. Non-corrected melting points were obtained on a Koeffler apparatus. Gas chromatography was performed on a HP 5940 instrument with a 10 m HP-1 column and the oven heated in the linear temperature gradient mode.

EXAMPLE 1

(+)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine (+) mandelate, and (-)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine (-) mandelate

a) 6-Bromo-4-phenyl-3,4-dihydro-coumarine

A solution of p-bromophenol (138 g, 0.8 mole), cinnamic acid (148 g, 1.0 mole), acetic acid (200 g) and conc. sulfuric acid was refluxed for 2 h. Volatile material was distilled at reduced pressure. The residual syrup was cooled and triturated with cold water, giving a semi-crystalline mass. This was washed extensively with water, saturated sodium carbonate and finally with water again. The material was filtered through a sintered glass funnel, and then mixed with an equal weight of ethanol. The slurry was stirred at room temperature for 1 h and then filtered. The resulting product was washed briefly with ethanol and then diisopropyl ether. After drying, 135 g (55.7%) of the title compound was isolated as white crystals, melting at 117°C.

b) Methyl 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanoate

6-Bromo-4-phenyl-3,4-dihydro-coumarine (290 g, 0.96 mole) was dissolved in a mixture of methanol (1 L) and acetone (1 L). To the above solution were added potassium carbonate (160 g, 1.16 mole), α -chlorotoluene (140 g, 1.1 mole) and sodium iodide (30 g, 0.47 mole), and the mixture was stirred under reflux for 3 h. The solution was concentrated by distillation, and the residue treated with water and extracted with diethyl ether. The ethereal layer was washed with water, saturated sodium carbonate solution and water, successively. The organic layer was dried over sodium sulfate, filtered and then evaporated to give 420 g (\approx 100%) of the title compound as a light yellow oil.

c) 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanol

Methyl 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanoate (112 g, 0.26 mole) was dissolved in tetrahydrofuran (250 mL) and added dropwise under nitrogen atmosphere to a suspension of lithium aluminiumhydride (5.9 g, 0.16 mole) in tetrahydrofuran (250 mL). The mixture was stirred overnight under nitrogen atmosphere. The excess hydride was decomposed by addition of a small amount of HCl (aq, 2 M). The solution was filtered on a pad of Celatom, and the solids were washed thoroughly with ether. The combined ethereal solution was washed with HCl (2 M), water, sodium hydroxide (2 M) and then with water again. The organic solution was dried over sodium sulfate, filtered and evaporated to give 98.5 g (95%) of the title compound as a colourless oil. A small fraction of the oil was crystallized from diisopropyl ether/petroleum ether giving crystals which melted at 70°C.

d) 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-p-toluenesulfonate

To a solution of 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropanol (107 g, 0.24 mole) in dichloromethane (300 mL) and pyridine (75 mL) at 0°C was added p-toluene sulfonylchloride (57 g, 0.3 mole). The solution was stirred at 0°C overnight and then evaporated at reduced pressure and at a bath temperature below 50°C. The remainder was poured onto water and then the mixture was extracted with diethyl ether. The organic layer was washed with water, HCl (2 M) and water successively, and finally dried over sodium sulfate. After filtration the ethereal solution was evaporated at a bath temperature of <50°C giving 137 g (\approx 100%) of 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-p-toluenesulfonate as a pale yellow oil.

e) N,N-Diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine

3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-p-toluenesulfonate (115 g, 0.2 mole) was dissolved in a mixture of acetonitrile (150 g) and diisopropylamine (202 g, 2.0 mole) and the mixture was refluxed for 4 days. The solution was evaporated, and to the resulting syrup was added sodium hydroxide (2 M, 200 mL). The mixture was concentrated, cooled and then extracted with diethyl ether. The ethereal layer was extensively washed with water. The amine was extracted with excess sulfuric acid (1 M). The aqueous layer was washed with diethyl ether and then basified with sodium hydroxide (11 M). The mixture was then extracted with diethyl ether. The organic layer was washed with water, dried over sodium sulfate, filtered and then evaporated to give 78.6 g (78%) of N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine as a pale yellow oil. The 1-H N.M.R spectrum was in accordance with the above structure.

f) Resolution

To a solution of N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine (255 g, 0.53 mole) in ethanol (750 g) was added L-(+)-tartaric acid (80 g, 0.53 mole). When all material was dissolved, diethyl ether (90

g) was added and crystallization commenced. After being stored at room temperature overnight, the formed salts were filtered off, washed with fresh ethanol-diethyl ether solution (2:1) and dried to give 98 g of white crystals melting at 156°C. $[\alpha]_D^{25} = 16.3^\circ$ (c = 5.1, ethanol)

The mother liquor from the precipitation with L-(+)-tartaric acid was evaporated. The resulting syrup was treated with sodium hydroxide (2 M) and extracted with diethyl ether. The organic phase was washed with water, dried over sodium sulfate, filtered and then evaporated, giving 170 g of free base. The base (170 g, 0.35 mole) was dissolved in ethanol (500 mL), and D-(-)-tartaric acid (53 g, 0.53 mole) was added. When all had dissolved, diethyl ether (50 mL) was added and crystallization commenced. The crystals were filtered off and washed with fresh ethanol-diethyl ether solution giving 105 g of crystals melting at 154-155°C. $[\alpha]_D^{25} = -16.4^\circ$ (c = 5.0, methanol)

The mother liquor was concentrated, basified and treated as above, yielding 80 g of free base. This base was dissolved in ethanol, and treated with L-(+)-tartaric acid as described above, yielding additional 20 g of the dextrorotatory form of the salt. (M.p. 156°C).

In an analogous manner, 20 g of the levorotatory form could be obtained.

The pooled dextrorotatory form was dissolved in water and basified with sodium hydroxide (2 M). The mixture was then extracted with diethyl ether. The organic phase was washed with water, dried over sodium sulfate, filtered and finally evaporated to give the chiral amine (88 g) as a colourless oil. $[\alpha]_D^{25} = 16.3^\circ$ (c = 5.1, ethanol)

In an analogous fashion, the levorotatory base was obtained (90 g). $[\alpha]_D^{25} = -16.1^\circ$ (c = 4.2, ethanol). The optical purity as assessed by chromatography was >99%.

g1) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine hydrochloride

A mixture of magnesium (12.2 g, 0.5 mole), ethyl bromide (2 g), and iodine (a small crystal) in dry diethyl ether (200 mL) was warmed until the reaction started. (+)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine (45.6 g, 0.095 mole) and ethyl bromide (32.7 g, 0.3 mole) dissolved in dry diethyl ether (250 mL) were then added dropwise under nitrogen atmosphere. The mixture was refluxed for 1.5 h and then cooled in an acetone/dry-ice bath, whereupon powdered dry ice (≈100 g) was added gently. Tetrahydrofuran was added when needed to prevent the mixture from solidification. The reaction mixture was stirred for 0.5 h when ammonium chloride (200 mL, 20% w/w) was added. The mixture was stirred vigorously until two transparent phases were formed, and then filtered through a pad of Celatom. The aqueous layer was washed with diethyl ether and then acidified with hydrochloric acid to pH 1. The precipitated semi-crystalline gum was washed with water, and then transferred to a round bottom flask. The product was dried by co-evaporation with acetone, benzene, toluene, diisopropyl ether and methanol, successively. The title compound (35.1 g, 77%) was isolated as friable shiny flakes and used without any further purification.

g2) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine hydrochloride

This product was isolated in 81 % yield in a corresponding way as described above from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-bromophenyl)-3-phenylpropylamine.

h1) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamine

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine (34 g, 0.07 mole) was dissolved in methanol (300 mL) containing sulfuric acid (6 g) and refluxed for 6 h. The solution was then cooled and concentrated. To the mixture were added ice-water and a slight excess of saturated sodium carbonate solution. The mixture was then extracted with diethyl ether. The organic phase was washed with water, dried over sodium sulfate, filtered and evaporated, giving 30 g (93%) of crude ester. Recrystallisation from diisopropyl ether gave white crystals melting at 85-86°C. The ¹H N.M.R. spectrum was in accordance with the above structure.

h2) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamine

The title compound was obtained from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamine in a similar manner as described above for the dextro isomer in a 93 % yield.

i1) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamine (30 g, 0.065 mole) dissolved in diethyl ether (250 mL) was added dropwise under nitrogen to a suspension of lithium aluminiumhydride (1.9 g, 0.05 mole) in dry diethyl ether (150 mL). The mixture was stirred overnight at room temperature, and the excess hydride was decomposed by the addition of water (≈5 g). The mixture was stirred for 10 min, when sodium sulfate (s) was added. After stirring for 20 minutes, the mixture was filtered and then evaporated to give 28.4 g of the title compound as a colourless oil.

i2) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine

The title compound was obtained in an analogous fashion as described above for the levo isomer from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamine.

j1) (+)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylammonium (+) mandelate

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine (28.2 g, 0.065 mole) was dissolved in methanol (300 g). Raney Nickel (one teaspoon) was added and the mixture was hydrogenated at atmospheric pressure until the theoretical amount of hydrogen was consumed. The progress of the reaction was

monitored by gas chromatography. The mixture was then filtered through a pad of Celatom, and the solvent was removed by evaporation at a bath temperature 50°C. The resulting oil was dissolved in diethyl ether, and the ethereal solution was washed with water, dried over sodium sulfate and evaporated giving 22.2 g of a colourless oil. $[\alpha]^{22} = 16.7^{\circ}$ ($c = 4.9$, ethanol).

To the above oil, dissolved in 2-propanol (50 g) was added S-(+)-mandelic acid (9.6 g, 0.06 mole) in 2-propanol (50 g). Dry diethyl ether (50 g) was added, and the solution was left for several hours. The resulting heavy, white crystals were filtered off and washed with a mixture of 2-propanol and diethyl ether (1:1 v/v) and then dried, yielding 25 g of the title compound which melted at 148°C . $[\alpha]^{22} = 38.3^{\circ}$ ($c = 5.1$, methanol).

The 1-H N.M.R. spectrum was in accordance with the above structure.

Chiral purity as assessed by H.P.L.C. was >99%.

Elementary Anal.	Theor.	C: 73.0	H: 8.0	N: 2.8	O: 16.2
	Found	C: 72.9	H: 8.1	N: 3.0	O: 16.5

j2) (-)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylammonium (-) mandelate

The title compound was obtained from (-)-N,N-diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine in an analogous manner to that described in j1) above.

Elementary Anal.	Theor.	C: 73.0	H: 8.0	N: 2.8	O: 16.2
	Found	C: 73.2	H: 8.1	N: 3.0	O: 16.5

The free base had an optical rotation of $[\alpha]^{22} = -15.5^{\circ}$ ($c = 5.0$, ethanol).

The 1-(-)-mandelic acid salt had a m.p. of $147-148^{\circ}\text{C}$ and an optical rotation $[\alpha]^{22} = -37.9^{\circ}$ ($c = 4.7$, methanol).

The optical purity as assessed by H.P.L.C. was >99%.

Pharmacology

Pharmacological tests performed with one compound of the invention and three prior art compounds disclosed in the above mentioned WO 89/06644 will now be described. The following compounds were used:

- (A) (+)N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamine, hydrochloride (WO 89/06644);
- (B) N,N-diisopropyl-3-bis-(2-hydroxyphenyl)propylamine hydrochloride (WO 89/06644);
- (C) (+)N,N-diisopropyl-3-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyphenyl)propylamine, hydrochloride (WO 89/06644);
- (D) N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine (-) mandelic acid salt (Example 1 above).

Raised index numerals in the text below refer to literature references listed at the end of the description.

Muscarinic Receptor Binding Studies

The tissue preparations and the general methods used have been described in detail elsewhere for the parotid gland¹, urinary bladder², heart³ and cerebral cortex³, respectively. Male guinea pigs (250-400 g body weight) were killed by a blow on the neck and exsanguinated. The brain was placed on ice for dissection of the cerebral cortex (grey matter only). Urinary bladders, hearts and parotid glands were dissected in a Krebs-Henseleit buffer (pH 7.4) containing 1 mM phenyl methyl sulfonyl fluoride (PMSF, a protease inhibitor). Dissected tissues were homogenized in an ice-cold sodium-potassium phosphate buffer (50 mM, pH 7.4) containing 1 mM PMSF, using a Polytron PT-10 instrument (bladder, heart, parotid) and a Potter-Elvehjem Teflon homogenizer (cortex). All homogenates were finally diluted with the ice-cold phosphate/PMSF buffer to a final protein concentration of ≤ 0.3 mg/ml and immediately used in the receptor binding assays. Protein was determined by the method of Lowry et al. (1951)⁴, using bovine serum albumin as the standard.

The muscarinic receptor affinities of the unlabelled compounds A to D identified above were derived from competition experiments in which the ability to inhibit the receptor specific binding of (-)-³H-QNB (1-quinuclidinyl[phenyl-4-3H]benzilate, 32.9 Ci/mole) was monitored as previously described^{3,5}. Each sample contained 10 μl of (-)-³H-QNB (final concentration 2 nM), 10 μl solution of test compound and 1.0 ml tissue homogenate. Triplicate samples were incubated under conditions of equilibrium, i.e., at 25°C for 60 minutes (urinary bladder), 80 minutes (heart and cerebral cortex)

or 210 minutes (parotid gland), respectively. Non-specific binding was determined in the presence of 10 μ M unlabelled atropine. Incubations were terminated by centrifugation², and the radioactivity in the pellets was determined by liquid scintillation spectrometry².

IC_{50} -values (concentration of unlabelled compound producing 50% inhibition of the receptor specific (-)-³H-QNB binding) were graphically determined from the experimental concentration-inhibition curves. Affinities, expressed as the dissociation constants K_i , were calculated by correcting the IC_{50} for the radioligand-induced parallel shift and differences in receptor concentration, using the method of Jacobs et al. (1975)⁶. The binding parameters for (-)-³H-QNB (K_D and receptor densities) used in these calculations were determined in separate series of experiments¹⁻³. The K_i values obtained for bladder, heart, parotid and cortex, respectively, are presented in Table 1 below.

Functional in vitro studies

Male guinea pigs, weighing about 300 g, were killed by a blow on the neck and exsanguinated. Smooth muscle strips of the urinary bladder were dissected in a Krebs-Henseleit solution (pH 7.4). The strip preparations were vertically mounted between two hooks in thermostatically controlled (37°C) organ baths (5 ml). One of the hooks was adjustable and connected to a force transducer (FT 03, Grass Instruments). The Krebs-Henseleit solution was continuously bubbled with carbogen gas (93.5% O₂/6.5% CO₂) to maintain the pH at 7.4. Isometric tension was recorded by a Grass Polygraph (Model 79D). A resting tension of approximately 5 mN was initially applied on each muscle strip and the preparations were allowed to stabilize for at least 45 min. The resting tension was repeatedly adjusted and the preparations were washed several times during the stabilization period.

Carbachol (carbamylcholine chloride) was used as the standard agonist. In each experiment, the viability of the preparations and the reproducibility of their contractile responses were initially tested by three consecutive additions of a submaximal concentration (3×10^{-6} M) of carbachol. A complete concentration-response curve to carbachol was then generated by cumulative addition of carbachol to the organ-bath (i.e., stepwise increase of the agonist concentration until the maximal contractile response was reached), followed by washing out and a resting period of at least 15 min. before a fix concentration of the test compound (antagonist) was added to the organ-bath. After 60 min. of incubation with the antagonist, a second cumulative concentration-response curve to carbachol was generated. Responses were expressed as per cent of the maximal response to carbachol. EC_{50} -values for carbachol in the absence (control) and presence of antagonist were graphically derived and dose ratios (r) were calculated. Dissociation constants, K_B , for the antagonists were calculated using equation (1)⁷, where $[A]$ is the concentration of test compound.

$$K_B = [A]/r-1 \quad (1)$$

The K_B values obtained for compounds A, B and D identified above are shown in Table 1 below.

Table 1

Test compound	K_B nM bladder	K_i nM bladder	K_i nM heart	K_i nM parotid	K_i nM cortex
(A)	3.0	2.7	1.6	4.8	0.8
(B)		10.2	6.7	2.6	1.5
(C)	2.6	2.5	0.9	2.7	0.4
(D)	4.1	4.5	0.9	4.7	0.7

Functional in vivo studies

a) Animal preparation

Adult cats were anaesthetized with mebumal (42 mg/kg) intraperitoneally. When the animal was asleep, an infusion cannula was inserted into the foreleg vein and the cat was given alpha-chloralose. During the experiment the animal was placed on an operation table warmed up with a feedback controlled electric pad. The cat was tracheotomized. For blood pressure registration, a polyethylene catheter was inserted into the femoral artery, with the tip in aorta, and connected via a three-way stopcock to a blood pressure transducer and a Grass polygraph. Heart rate was registered by connecting a tachograph to a driver amplifier which received the signal from the blood pressure transducer. Blood flow in the central mesenteric artery was measured by an ultrasound flow probe around the artery connected to a transonic blood flow meter and then to a Grass polygraph for registration of the flow. For infusion of the test substances, compounds D and A (as identified above), a polyethylene catheter was inserted into the femoral vein three-way stopcock to a syringe placed in an infusion pump (Sage instrument).

Through an incision in the proximal urethra, a catheter was inserted into the urinary bladder. At the beginning of each experiment, this catheter was connected to an open vessel, which was filled with 38°C tempered physiological saline and placed above the animal. During this stabilization period the bladder relaxed, leading to a filling of the bladder with saline, under constant hydrostatic pressure. After the stabilization period, the bladder catheter was connected to a pressure transducer, for registration of intravesical pressure. Blood pressure, heart rate, blood flow and bladder pressure were recorded simultaneously and continuously throughout the experiment. The animals were left for at least 45 minutes to achieve steady state in cardiovascular variables before starting the experiment.

Bladder pressure was measured at 8 minutes after the end of infusion of the test substance. The surgical preparation was tested by intravenous injection of 0.25 µg/kg b.w. of noradrenalin and 0.5 µg/kg b.w. of acetylcholine.

b) Dosing

To study the dose-response relationship of compound D identified above, the substance was administered at the doses 0.000 (physiological saline), 0.003, 0.010, 0.030 and 0.100 mg/kg, respectively, with infusion during 2 minutes and an infusion volume of 1 mL/kg. Every cat got all doses and was left to reestablish at least 45 minutes between the 0.003 and 0.010 mg/kg doses, and 60 minutes between the 0.030 and 0.100 mg/kg doses.

c) Statistical methods and calculation

The results are presented in absolute values and calculated as mean value ± standard deviation

d) Results

(i) Blood pressure

In general, intravenous administration of compound D had little or no effect on the blood pressure except at dose of 0,3 mg/kg. This dose caused an increase with 10% and with 6 % for diastolic blood pressure and systolic blood pressure, respectively.

(ii) Blood flow

Intravenous administration of compound D caused an increase with 8, 17 and 21 % of the blood flow in superior mesenterica artery at 0.003, 0.01, and 0.03 mg/kg, respectively. Again at the highest dose (0.3 mg/kg) a 10% increase in blood flow was observed.

(iii) Heart rate

Intravenous administration of compound D caused a decrease with 9 % at the highest dose (0.3 mg/kg).

(iv) Bladder pressure

As appears from Fig. 1, compound D of the present invention produced a dose-dependent inhibition of the acetylcholine-induced effect on the bladder which was about ten times more efficient than that of prior art compound A.


References

1. Nilvebrant, L.; Sparf, B. Muscarinic receptor binding in the parotid gland. Different affinities of some anticholinergic drugs between the parotid gland and ileum. *Scand. J. Gastroenterol.* 1982, 17 (suppl. 72), 69-77.
2. Nilvebrant, L.; Sparf, B. Muscarinic receptor binding in the guinea pig urinary bladder. *Acta Pharmacol. et Toxicol.* 1983 a, 52, 30-38.
3. Nilvebrant, L.; Sparf, B. Dicyclomine, benzhexol and oxybutynin distinguish between sub-classes of muscarinic binding-sites. *Eur. J. Pharmacol.* 1986, 123, 133-143.
4. D Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 1951, 193, 265-275.
5. Nilvebrant, L.; Sparf, B. Differences between binding affinities of some antimuscarinic drugs in the parotid gland and those in the urinary bladder and ileum. *Acta Pharmacol. et Toxicol.* 1983 b, 53, 304-313.
6. Jacobs, S.; Chang, K.-J.; Cuatrecasas, P. Estimation of hormone receptor affinity by competitive displacement of labelled ligand. Effects of concentration of receptor and labelled ligand. *Biochem. Biophys. Res. Commun.* 1975, 66, 687-692.
7. Schild, H. I. pAx and competitive drug antagonism. *Br. J. Pharmacol. Chemother.* 1949, 4, 277-280.

Claims

1. 3,3-Diphenylpropylamines of formula I

5



10

wherein R¹ signifies hydrogen or methyl, R² and R³ independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula II

15



20

wherein each of R⁴ and R⁵ independently signify non-aromatic hydrocarbyl groups, which may carry one or more hydroxy groups and which together contain at least three carbon atoms, and wherein R⁴ and R⁵ may be joined to form a ring having no other heteroatom than the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

25

2. 3,3-Diphenylpropylamines according to claim 1, wherein each of R⁴ and R⁵ independently signifies a saturated hydrocarbyl group, especially saturated aliphatic hydrocarbyl groups such as C₁₋₈-alkyl, especially C₁₋₆-alkyl, or adamantyl, R⁴ and R⁵ together comprising at least three, preferably at least four carbon atoms.


30

3. 3,3-Diphenylpropylamines according to claim 1 or 2, wherein at least one of R⁴ and R⁵ comprises a branched carbon chain.


35

4. 3,3-Diphenylpropylamines according to any one of claims 1 to 3, wherein X signifies any of the following groups a) to h):

40




45



50


55



EP 0 667 852 B1


5. 3,3-Diphenylpropylamines according to any one of claims 1 to 4, wherein the HOCH₂-group is in 5-position, R² is hydrogen and R³ is hydrogen or hydroxy, preferably in 2-position.
6. 3,3-Diphenylpropylamines according to claim 1, selected from N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamine, its salts with physiologically acceptable acids, racemates and individual enantiomers thereof.
7. 3,3-Diphenylpropylamines according to any one of claims 1 to 6 for use as pharmaceutically active substances, especially as anticholinergic agents.
8. A pharmaceutical composition comprising a 3,3-diphenylpropylamine according to any one of claims 1 to 6 and preferably a compatible pharmaceutical carrier.
9. Use of a 3,3-diphenylpropylamine according to any one of claims 1 to 6 for preparing an anticholinergic drug.
10. A method for preparing 3,3-diphenylpropylamines according to any one of claims 1 to 6, comprising:

a) reducing the group R⁶CO of a 3,3-diphenylpropylamine of formula III



wherein R¹ to R³ and X are as defined above, R⁶ is hydrogen or R⁷O, where R⁷ is hydrogen, alkyl, alkenyl, alkynyl or aryl, and any hydroxy groups may be protected, such as by methylation or benzylation, or

b) reacting a reactively esterified 3,3-diphenylpropanol of formula IV



wherein R¹ to R³ are as defined above, any hydroxy groups may be protected, and wherein Y is a leaving group, with an amine of formula V




V

wherein X is as defined above, or

c) reducing a 3,3-diphenylpropionamide of formula VI


5



10

wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, or
d) N-methylating a secondary 3,3-diphenylpropylamine of formula VII

15





20

wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, and wherein Z has the same meaning as R⁴ and R⁵ with the exception of methyl, or

25

e) reducing a 3,3-diphenylpropenamine of formula VIIIa or a 3,3-diphenylpropylamine of formula VIIIb

30




35

wherein R¹ to R³ and X are as defined above and any hydroxy groups may be protected, and W signifies a hydroxy group or a halogen atom, or

40

f) reacting a diphenylpropylamine of formula IX

45




50

wherein R¹ to R³ and X are as defined above, and Hal is halogen, with formaldehyde or a formaldehyde equivalent, or

55

g) oxidizing the methyl group of a diphenylpropylamine of formula X




10 wherein R¹ to R³ and X are as defined above, and

- 15 i) when necessary splitting off hydroxy protecting groups in the compounds obtained, if desired after mono- or di-halogenation of one or both of the phenyl rings, and/or
 ii) if desired converting the obtained bases of formula I into salts thereof with physiologically acceptable acids, or vice versa, and/or
 iii) if desired separating an obtained mixture of optical isomers into the individual enantiomers, and/or
 iv) if desired methylating an ortho-hydroxy group in an obtained compound of formula I, wherein R¹ is hydrogen and/or R³ is hydroxy.

20 **Patentansprüche**

1. 3,3-Diphenylpropylamine der Formel I











30 worin R¹ für Wasserstoff oder Methyl steht, R² und R³ unabhängig voneinander für Wasserstoff, Methyl, Methoxy, Hydroxy, Carbamoyl, Sulfamoyl oder Halogen stehen und X für eine tertiäre Aminogruppe der Formel II




45 steht, in der jedes R⁴ und R⁵ unabhängig voneinander für nichtaromatische Kohlenwasserstoffgruppen steht, die eine oder mehrere Hydroxygruppen tragen können und die zusammen wenigstens drei Kohlenstoffatome enthalten und in der R⁴ und R⁵ miteinander verbunden sein können, um einen Ring zu bilden, der kein anderes Heteroatom besitzt als den Aminstickstoff, ihre Salze mit physiologisch annehmbaren Säuren und, wenn die Verbindungen in Form optischer Isomere vorliegen können, die racemischen Gemische und die individuellen Enantiomere.

- 50 2. 3,3-Diphenylpropylamine nach Anspruch 1, dadurch **gekennzeichnet**, daß jedes R⁴ und R⁵ unabhängig voneinander eine gesättigte Kohlenwasserstoffgruppe, insbesondere eine gesättigte aliphatische Kohlenwasserstoffgruppe, wie C₁₋₈-Alkyl, insbesondere C₁₋₆-Alkyl, oder Adamantyl bedeutet und R⁴ und R⁵ zusammen wenigstens drei, vorzugsweise wenigstens vier Kohlenstoffatome umfassen.
3. 3,3-Diphenylpropylamine nach Anspruch 1 oder 2, dadurch **gekennzeichnet**, daß wenigstens ein Rest aus der Gruppe R⁴ und R⁵ eine verzweigte Kohlenstoffkette umfaßt.
- 55 4. 3,3-Diphenylpropylamine nach einem der Ansprüche 1 bis 3, dadurch **gekennzeichnet**, daß X für eine der folgenden Gruppen a) bis h) steht:



5. 3,3-Diphenylpropylamine nach einem der Ansprüche 1 bis 4, dadurch **gekennzeichnet**, daß die HOCH₂-Gruppe in der 5-Position ist, R² Wasserstoff und R³ Wasserstoff oder Hydroxy, vorzugsweise in der 2-Position, ist.
6. 3,3-Diphenylpropylamine nach Anspruch 1, ausgewählt aus N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamin, seinen Salzen mit physiologisch annehmbaren Säuren, Racemate und individuellen Enantiomere davon.
7. 3,3-Diphenylpropylamine nach einem der Ansprüche 1 bis 6 zur Verwendung als pharmazeutisch aktive Substanzen, insbesondere als anticholinerge Mittel.
8. Pharmazeutisches Mittel, umfassend ein 3,3-Diphenylpropylamin nach einem der Ansprüche 1 bis 6 und vorzugsweise einen kompatiblen pharmazeutischen Träger.
9. Verwendung eines 3,3-Diphenylpropylamins nach einem der Ansprüche 1 bis 6 zur Herstellung eines anticholinergen Medikaments.
10. Verfahren zur Herstellung von 3,3-Diphenylpropylaminen nach einem der Ansprüche 1 bis 6, umfassend die folgenden Stufen:

a) Reduktion der R⁶CO-Gruppe eines 3,3-Diphenylpropylamins der Formel III




in der R¹ bis R³ und X die oben definierten Bedeutungen haben, R¹ Wasserstoff oder R⁷O ist, wobei R¹ Wasserstoff, Alkyl, Alkenyl, Alkynyl oder Aryl ist, und jegliche Hydroxygruppen z.B. durch Methylierung oder

Benzylierung geschützt sein können oder

b) Umsetzung eines reaktiv veresterten 3,3-Diphenylpropanols der Formel IV

5



10

in der R¹ bis R³ die oben definierten Bedeutungen haben, jegliche Hydroxygruppen geschützt sein können und in der Y eine Austrittsgruppe ist, mit einem Amin der Formel V

15




V,

20

in der X die oben definierte Bedeutung hat oder

c) Reduktion eines 3,3-Diphenylpropionamids der Formel VI

25




30

in der R¹ bis R³ und X die oben definierten Bedeutungen haben und jegliche Hydroxygruppen geschützt sein können, oder

d) N-Methylierung eines sekundären 3,3-Diphenylpropylamins der Formel VII

35




40

in der R¹ bis R³ und X die oben definierten Bedeutungen haben, und jegliche Hydroxygruppen geschützt sein können und in der Z die gleiche Bedeutung wie R⁴ und R⁵ mit Ausnahme von Methyl hat oder


e) Umsetzung eines 3,3-Diphenylpropenamids der Formel VIIIa oder eines 3,3-Diphenylpropylamins der Formel VIIIb

50

55




VIIIa




VIIIb

15
 worin R¹ bis R³ und X die oben definierten Bedeutungen haben und jegliche Hydroxygruppen geschützt sein können und W für eine Hydroxygruppe oder ein Halogenatom steht oder
 f) Umsetzung eines Diphenylpropylamins der Formel IX



30
 in der R¹ bis R³ und X die oben definierten Bedeutungen haben und Hal für Halogen steht, mit Formaldehyd oder einem Formaldehyd-Äquivalent oder
 g) Oxidation der Methylgruppe eines Diphenylpropylamins der Formel X




in der R¹ bis R³ und X die oben definierten Bedeutungen haben und

- 45
- i) falls nötig, Abspaltung der Hydroxyschutzgruppen in den erhaltenen Verbindungen, falls erwünscht nach Mono- oder Dihalogenierung eines oder beider Phenylringe und/oder
 - ii) falls gewünscht, Umwandlung der erhaltenen Basen der Formel I in die Salze davon mit physiologisch annehmbaren Säuren oder umgekehrt, und/oder
 - iii) falls gewünscht, Trennung eines erhaltenen Gemisches optischer Isomere in die individuellen Enantiomeren, und/oder
 - 50 iv) falls gewünscht, Methylierung einer ortho-Hydroxygruppe in einer erhaltenen Verbindung der Formel I, in der R¹ für Wasserstoff und/oder R³ für Hydroxy steht.

55 **Revendications**

1. 3,3-diphénylpropylamines de formule I



10 dans laquelle R¹ représente l'hydrogène ou un groupe méthyle, R² et R³ représentent indépendamment l'hydrogène, un groupe méthyle, méthoxy, hydroxy, carbamoyle, sulfamoyle ou halogéno, et X représente un groupe amino tertiaire de formule II



20 dans laquelle chacun des groupes R⁴ et R⁵ représente indépendamment un groupe hydrocarbyle non aromatique, qui peut porter un ou plusieurs groupes hydroxy, les groupes R⁴ et R⁵, conjointement, contenant au moins trois atomes de carbone, et dans laquelle R⁴ et R⁵ peuvent être joints en formant un noyau n'ayant aucun autre hétéroatome que l'atome d'azote d'amine, leurs sels formés avec des acides physiologiquement acceptables et, lorsque les composés peuvent être sous forme d'isomères optiques, le mélange racémique et les énantiomères distincts.


- 25
2. 3,3-diphénylpropylamines suivant la revendication 1, dans lesquelles chacun des groupes R⁴ et R⁵ représente indépendamment un groupe hydrocarbyle saturé, notamment un groupe hydrocarbyle aliphatique saturé tel qu'un groupe alkyle en C₁ à C₈, notamment alkyle en C₁ à C₆ ou un groupe adamantyle, les groupes R⁴ et R⁵, conjointement, comprenant au moins trois, de préférence au moins quatre atomes de carbone.


30

 3. 3,3-diphénylpropylamines suivant la revendication 1 ou 2, dans lesquelles au moins un des groupes R⁴ et R⁵ comprend une chaîne carbonée ramifiée.

35


 4. 3,3-diphénylpropylamines suivant l'une quelconque des revendications 1 à 3, dans lesquelles X représente l'un quelconque des groupes a) à h) suivants :






5. 3,3-diphénylpropylamines suivant l'une quelconque des revendications 1 à 4, dans lesquelles le groupe HOCH₂ est en position 5, R² représente l'hydrogène et R³ représente l'hydrogène ou un groupe hydroxy, de préférence en position 2.
6. 3,3-diphénylpropylamines suivant la revendication 1, choisies entre la N,N-diisopropyl-3-(2-hydroxy-5-hydroxy-méthylphényl)-3-phénylpropylamine, ses sels formés avec des acides physiologiquement acceptables, ses racémates et les énantiomères distincts correspondants.
7. 3,3-diphénylpropylamines suivant l'une quelconque des revendications 1 à 6, destinées à être utilisées comme substances pharmaceutiquement actives, notamment comme agents anticholinergiques.
8. Composition pharmaceutique comprenant une 3,3-diphénylpropylamine suivant l'une quelconque des revendications 1 à 6 et, de préférence, un support pharmaceutiquement compatible.
9. Utilisation d'une 3,3-diphénylpropylamine suivant l'une quelconque des revendications 1 à 6 pour la préparation d'un médicament anticholinergique.
10. Procédé pour la préparation de 3,3-diphénylpropylamines suivant l'une quelconque des revendications 1 à 6, comprenant :

a) la réduction du groupe R⁶CO d'une 3,3-diphénylpropylamine de formule III



dans laquelle R¹ à R³ et X répondent aux définitions précitées, R⁶ représente l'hydrogène ou un groupe R⁷O, dans lequel R⁷ représente l'hydrogène, un groupe alkyle, alcényle, alcynyle ou aryle, et n'importe quels groupes hydroxy peuvent être protégés, par exemple par méthylation ou benzylation, ou

b) la réaction d'un 3,3-diphénylpropanol, estérifié réactivement, de formule IV




dans laquelle R¹ à R³ répondent aux définitions précitées, n'importe quels groupes hydroxy pouvant être protégés, et dans laquelle Y représente un groupe partant, avec une amine de formule V

H - X

V

dans laquelle X répond à la définition précitée, ou
 c) la réduction d'un 3,3-diphénylpropionamide de formule VI

5




10

dans laquelle R¹ à R³ et X répondent aux définitions précitées et n'importe quels groupes hydroxy peuvent être protégés, ou

15

d) la N-méthylation d'une 3,3-diphénylpropylamine secondaire de formule VII

20




25


dans laquelle R¹ à R³ et X répondent aux définitions précitées et n'importe quels groupes hydroxy peuvent être protégés, et dans laquelle Z répond à la même définition que R⁴ et R⁵ à l'exception du groupe méthyle, ou
 e) la réduction d'une 3,3-diphénylpropène-amine de formule VIIIa ou d'une 3,3-diphénylpropylamine de formule VIIIb

30

35




40



dans laquelle R¹ à R³ et X répondent aux définitions précitées et n'importe quels groupes hydroxy peuvent être protégés, et W représente un groupe hydroxy ou un atome d'halogène, ou
 f) la réaction d'une diphenylpropylamine de formule IX


45



50

55

dans laquelle R¹ à R³ et X répondent aux définitions précitées, et Hal représente un halogène, avec le formaldéhyde ou un équivalent de formaldéhyde, ou
 g) l'oxydation du groupe méthyle d'une diphenylpropylamine de formule X



10 dans laquelle R¹ à R³ et X répondent aux définitions précitées, et

- 15
- 15 i) lorsque cela est nécessaire, la scission des groupes protecteurs de la fonction hydroxy dans les composés obtenus, si besoin après mono- ou dihalogénéation d'un des ou des deux noyaux phényle, et/ou
- ii) si cela est désiré, la transformation des bases obtenues de formule I en leurs sels formés avec des acides physiologiquement acceptables, ou vice versa, et/ou
- 20
- 25
- 30
- 35
- 40
- 45
- 50
- 55
- iii) si cela est désiré, la séparation d'un mélange obtenu d'isomères optiques en les énantiomères distincts, et/ou
- iv) si cela est désiré, la méthylation d'un groupe ortho-hydroxy dans un composé obtenu de formule I, dans laquelle R¹ représente l'hydrogène et/ou R³ représente un groupe hydroxy.




FIG. 1

19 BUNDESREPUBLIK
DEUTSCHLAND



DEUTSCHES
PATENTAMT

11 Übersetzung der
europäischen Patentschrift

67 EP 0 667 852 B 1

10 DE 693 17 898 T 2

51 Int. Cl.⁶ BB
C 07 C 217/62

C 07 C 215/54
C 07 C 311/37
C 07 C 237/30
C 07 D 295/06
C 07 D 211/1A
C 07 D 207/06
A 61 K 31/135

- 21 Deutsches Aktenzeichen: 693 17 898.1
66 PCT-Aktenzeichen: PCT/SE93/00927
68 Europäisches Aktenzeichen: 93 924 876.1
67 PCT-Veröffentlichungs-Nr.: WO 94/11337
68 PCT-Anmeldetag: 5. 11. 93
67 Veröffentlichungstag
der PCT-Anmeldung: 26. 5. 94
67 Erstveröffentlichung durch das EPA: 23. 8. 95
67 Veröffentlichungstag
der Patenterteilung beim EPA: 8. 4. 98
67 Veröffentlichungstag im Patentblatt: 15. 10. 98

DE 693 17 898 T 2

- 30 Unionspriorität:
9203318 06. 11. 92 SE
- 73 Patentinhaber:
Pharmacia & Upjohn AB, Stockholm, SE
- 74 Vertreter:
W. Kraus und Kollegen, 80539 München
- 84 Benannte Vertragsstaaten:
AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC,
NL, PT, SE

- 72 Erfinder:
JOHANSSON, Rolf, Arne, S-141 38 Huddinge, SE;
MOSES, Pinchas, S-132 00 Saltsjö-Boo, SE;
NILVERBANT, Lisbeth, S-161 35 Bromma, SE;
SPARF, Bengt, Ake, S-142 65 Trångsund, SE

54 3,3-DIPHENYLPROPYLAMINE, IHRE VERWENDUNG UND HERSTELLUNG

Anmerkung: Innerhalb von neun Monaten nach der Bekanntmachung des Hinweises auf die Erteilung des europäischen Patents kann jedermann beim Europäischen Patentamt gegen das erteilte europäische Patent Einspruch einlegen. Der Einspruch ist schriftlich einzureichen und zu begründen. Er gilt erst als eingelegt, wenn die Einspruchsgebühr entrichtet worden ist (Art. 99 (1) Europäisches Patentübereinkommen).

Die Übersetzung ist gemäß Artikel II § 3 Abs. 1 IntPatÜG 1991 vom Patentinhaber eingereicht worden. Sie wurde vom Deutschen Patentamt inhaltlich nicht geprüft.

DE 693 17 898 T 2

02 08 90


93 924 876.1

EPO 1895 MA/rie

Die Erfindung betrifft neue therapeutisch aktive Verbindungen, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen, die die neuen Verbindungen enthalten und die Verwendung der Verbindungen zur Herstellung von Arzneimitteln.

WO 89/06644 beschreibt 3,3-Diphenylpropylamine, die anticholinerge Aktivität besitzen. Erfindungsgemäß wurden nun neue therapeutisch aktive Verbindungen gefunden, von denen einige als Metaboliten in Säugetieren gebildet werden, wenn diese mit den 3,3-Diphenylpropylaminen, die in der oben erwähnten WO-Publikation beschrieben wurden, behandelt werden. Diese Metaboliten haben wenigstens genauso günstige anticholinerge Eigenschaften wie die Ausgangsverbindungen und können somit zur Kontrolle von Ereignissen verwendet werden, die durch Acetylcholin vermittelt werden, wie z.B. das Urinieren.

Die neuen erfindungsgemäßen Verbindungen werden durch die allgemeine Formel I dargestellt



worin R¹ Wasserstoff oder Methyl bedeutet, R² und R³ unabhängig Wasserstoff, Methyl, Methoxy, Hydroxy, Carbamoyl, Sulfamoyl oder Halogen bedeuten und X eine tertiäre Aminogruppe der Formel II darstellt,



in der R⁴ und R⁵ nichtaromatische Kohlenwasserstoffgruppen bedeuten, die gleich oder verschieden sein können, und die zusammen wenigstens drei Kohlenstoffatome enthalten, vorzugsweise wenigstens vier Kohlenstoffatome, insbesondere wenigstens fünf Kohlenstoffatome, und in der R⁴ und R⁵ zusammen mit dem Aminstickstoff einen Ring bilden können, wobei der Ring kein anderes Heteroatom besitzt als den Aminstickstoff.

Die Verbindungen der Formel I können Salze mit physiologisch annehmbaren organischen und anorganischen Säuren bilden, und die Erfindung umfaßt die freien Basen ebenso wie die Salze davon. Beispiele für derartige Säureadditionssalze schließen die Salze der Salzsäure, der Bromwasserstoffsäure, der Fumarsäure und dgl. ein.

Liegen die neuen Verbindungen in Form optischer Isomere vor, umfaßt die Erfindung das racemische Gemisch ebenso wie die individuellen Isomere als solche.

In den Verbindungen der Formel I ist R² vorzugsweise Wasserstoff und R³ ist vorzugsweise Wasserstoff oder Hydroxy.


R² ist vorzugsweise in der 3-, 4- oder 5-Position.

R³ ist vorzugsweise in der 2-Position in Bezug auf die Propylamingruppe.

Die HOCH₂-Gruppe befindet sich vorzugsweise in der 5-Position.

Vorzugsweise bedeutet jedes R⁴ und R⁵ unabhängig voneinander C₁₋₈-Alkyl, insbesondere C₁₋₆-Alkyl, oder Adamantyl, R⁴ und R⁵ umfassen zusammen wenigstens drei, vorzugsweise wenigstens 4 Kohlenstoffatome. R⁴ und R⁵ können eine oder mehrere Hydroxygruppen tragen, und sie können miteinander verbunden werden, um zusammen mit dem Aminstickstoffatom einen Ring zu bilden.

Derzeit bevorzugte tertiäre Aminogruppen X in der Formel I schließen die folgenden Gruppen a) - h) ein:




Vorzugsweise sind sowohl R⁴ als auch R⁵ Isopropyl.

Eine derzeit bevorzugte spezifische Verbindung der Formel I ist N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamin.


Die Verbindungen der Formel I können erfindungsgemäß durch an sich konventionelle Verfahren hergestellt werden und insbesondere durch

a) Reduktion der R⁶CO-Gruppe in einem 3,3-Diphenylpropylamin der Formel III



in der R^1 bis R^3 und X die wie oben definierte Bedeutung haben, R^6 Wasserstoff oder R^7O ist, wobei R^7 Wasserstoff, (vorzugsweise niedrig-)Alkyl, Alkenyl, Alkynyl (oder Aryl) (wie z.B. Phenyl) ist und jegliche Hydroxygruppen z.B. durch Methylierung oder Benzylierung geschützt sein können, oder

b) Umsetzung eines reaktiv veresterten 3,3-Diphenylpropanol der Formel IV




in der R^1 bis R^3 die oben definierte Bedeutung haben und jegliche Hydroxygruppen geschützt sein können, und in der Y eine Abgangsgruppe, vorzugsweise Halogen oder eine Alkyl- oder Arylsulfonyloxygruppe ist, mit einem Amin der Formel V




in der X die wie oben definierte Bedeutung hat, oder

c) Reduktion eines 3,3-Diphenylpropionamids der Formel VI





in der R^1 bis R^3 und X die oben definierte Bedeutung haben und jegliche Hydroxygruppen geschützt sein können, vorzugsweise unter Verwendung eines Komplexmetallhydrids, oder

d) N-Methylierung eines sekundären 3,3-Diphenylpropylamins der Formel VII




in der R^1 bis R^3 und X die wie oben definierte Bedeutung haben und jegliche Hydroxygruppen geschützt sein können, und in der Z mit Ausnahme von Methyl die gleiche Bedeutung wie R^4 und R^5 hat, wobei Z vorzugsweise eine Kohlenwasserstoffgruppe ist, die wenigstens drei Kohlenstoffatome umfaßt, und wobei die N-Methylierung vorzugsweise unter Verwendung von Formaldehyd oder Ameisensäure durchgeführt wird, oder

e) Reduktion eines 3,3-Diphenylpropenamids der Formel VIIIa oder eines 3,3-Diphenylpropylamins der Formel VIIIb




wobei R¹ bis R³ und X die wie oben definierte Bedeutung haben, und jegliche Hydroxygruppen geschützt sein können, und W für eine Hydroxygruppe oder ein Halogenatom steht, vorzugsweise mittels katalytischer Hydrierung,

f) Umsetzung eines 3,3-Diphenylpropylamins der Formel IX



in der R¹ bis R³ und X die wie oben definierte Bedeutung haben, und Hal für Halogen steht, mit Formaldehyd oder einem Formaldehydäquivalent (z.B. s-Trioxan), oder

g) Oxidation der Methylgruppe eines Diphenylpropylamins der Formel X



in der R¹ bis R³ und X die wie oben definierte Bedeutung haben, und

i) falls nötig, Abtrennen der Hydroxyschutzgruppen in den erhaltenen Verbindungen, falls gewünscht, nach der Mono- oder Dihalogenierung eines oder beider Phenylringe(s) und/oder

ii) falls gewünscht, Umwandlung der erhaltenen Basen der Formel I in die Salze davon mit physiologisch annehmbaren Säuren oder umgekehrt, und/oder

iii) falls gewünscht, Auftrennung eines erhaltenen Gemisches optischer Isomere in die individuellen Enantiomere, und/oder

iv) falls gewünscht, Methylierung einer Orthohydroxygruppe in einer erhaltenen Verbindung der Formel I, in der R¹ Wasserstoff und/oder R³ Hydroxy ist.

Die Oxidation im oben beschriebenen Verfahren g) kann chemisch, elektrochemisch oder enzymatisch durchgeführt werden. Die chemische Oxidation wird vorteilhafterweise unter Verwendung eines Metallsalzes oder -oxides, wie Cerammoniumnitrat, Manganoxiden, Chromoxi-

den, Vanadiumoxiden, Kobaltacetat, Aluminiumoxid, Wismuthmolybdat, oder Kombinationen davon durchgeführt. Die chemische Oxidation kann auch durch Persäuren mit oder ohne Katalysator oder mit Halogeniden bewerkstelligt werden. Die elektrochemische Oxidation kann mit oder ohne Katalysator durchgeführt werden. Bei enzymatischer Oxidation wird die Verwendung von Bakterien oder Hefen (z.B. *Candida guilliermondi*, *Candida tropicalis*) vorgezogen.

Die Entfernung der Hydroxyschutzgruppen nach i) oben kann z.B. durch Behandlung mit Bromwasserstoffsäure, Bortribromid oder durch katalytische Hydrierung erfolgen.

Die Trennung von Gemischen optischer Isomere nach ii) oben in die individuellen Enantiomere kann z.B. durch fraktionelle Kristallisierung der Salze mit chiralen Säuren oder durch chromatographische Trennung auf chiralen Säulen erzielt werden.

Die Ausgangsverbindungen der Formel III und IX können wie in dem unten beschriebenen Herstellungsbeispiel beschrieben, hergestellt werden. Die Ausgangssubstanzen, die in den Verfahren b) bis e) und g) verwendet werden, können wie in der zuvor erwähnten WO 89/06644 (deren Offenbarung durch Bezugnahme hierin aufgenommen wird) beschrieben, hergestellt werden, wobei die Beschreibung im vorliegenden Herstellungsbeispiel sorgfältig in Betracht gezogen werden muß.

Erfindungsgemäß können die Verbindungen der Formel I, in Form der freien Basen oder in Form von Salzen mit physiologisch annehmbaren Säuren, gemäß gebräuchlicher pharmazeutischer Verfahren in geeignete galenische Formen gebracht werden, wie z.B. Mittel zur oralen Verwendung, zur Injektion, zur Verabreichung als Nasenspray oder dergleichen. Derartige erfindungsgemäße pharmazeutische Mittel umfassen eine wirksame Menge der Verbindungen der Formel I in Verbindung mit pharmazeutisch annehmbaren kompatiblen Trägermaterialien oder Verdünnungsmitteln, wie sie dem Fachmann bekannt sind. Die Träger können jegliche inerte, organische oder anorganische Substanzen sein, die für enterale, perkutane oder parenterale Verabreichung geeignet sind, wie z.B. Wasser, Gelatine, Gummi arabicum, Lactose, mikrokristalline Cellulose, Stärke, Natriumstärkeglykolat, Calciumhydrogenphosphat, Magnesiumstearat, Talkum, kolloidales Siliciumdioxid, und dergleichen. Derartige Mittel können auch andere pharmazeutisch aktive Bestandteile und konventionelle Zusätze, wie z.B. Stabilisatoren, Benetzungsmittel, Emulgatoren, Geschmacksstoffe, Puffer und dgl. enthalten.

Die erfindungsgemäßen Mittel können z.B. für orale Verabreichung in fester oder flüssiger Form, wie z.B. in Form von Tabletten, Kapseln, Pulvern, Sirup, Elixieren und dgl. und für parenterale Verabreichung in Form steriler Lösungen, Suspensionen oder Emulsionen oder dgl. hergestellt werden.

Die Verbindungen und Mittel können, wie oben erwähnt, für die gleichen therapeutischen Indikationsgebiete verwendet werden, wie die Verbindungen der oben erwähnten WO 89/06644, d.h. zur Behandlung von Acetylcholin-vermittelten Leiden, wie z.B. Harninkontinenz. Die Dosis der spezifischen Verbindung wird in Abhängigkeit ihrer Wirksamkeit, der Verabreichungsweise,

des Alters und Gewichts des Patienten und des Schweregrades des zu behandelnden Leidens variieren. Die tägliche Dosis kann z.B. im Bereich von 0,01 mg bis etwa 4 mg je Kilogramm Körpergewicht liegen, und in Form einer Einzeldosis oder in Form multipler Gaben, z.B. von etwa 0,05 mg bis etwa 200 mg je Gabe verabreicht werden.

Die Erfindung wird weiter durch das folgende, nichtbeschränkende Beispiel und durch pharmakologische Tests dargestellt werden. Es wird auf die begleitende Zeichnung Bezug genommen werden, wobei die einzige Figur (Figur 1) die Hemmungskurven des Blasendrucks für eine erfindungsgemäße Verbindung bzw. eine im Stand der Technik bekannte Verbindung zeigt.

Allgemeines

NMR-Daten wurden mit einem Jeol JNM-EX 270 Fourier-Transformationspektrometer erhalten. Die Spektren wurden mit Tetramethylsilan (TMS) als internen Standard bei 30°C aufgenommen. Infrarotspektren wurden mit einem Perkin Elmer 599B-Instrument aufgenommen. Nichtkorrigierte Schmelzpunkte wurden mit einem Koeffler-Gerät erhalten. Die Gaschromatographie wurde mit einem HP 5940-Gerät mit einer 10 m HP-1-Säule und dem im linearen Temperaturgradientenbetrieb geheizten Ofen durchgeführt.

BEISPIEL 1

(+)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamin-
(+)-mandelat und (-)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropyl-
amin(-)-mandelat

a) 6-Brom-4-phenyl-3,4-dihydrocumarin

Eine Lösung von p-Bromphenol (138 g, 0,8 mol), Zimtsäure (148 g, 1,0 mol), Essigsäure (200 g) und konzentrierter Schwefelsäure wurde während 2 Stunden unter Rückfluß gekühlt. Flüchsiges Material wurde bei reduziertem Druck destilliert. Der im Rückstand befindliche Sirup wurde abgekühlt und mit kaltem Wasser fein gemahlen. Dies führte zu einer halbkristallinen Masse. Diese wurde in extensiver Weise mit Wasser, gesättigtem Natriumcarbonat und zum Schluß erneut mit Wasser gewaschen. Das Material wurde durch einen gesinterten Glastrichter filtriert, und dann mit einem gleichen Gewicht an Ethanol gemischt. Die Aufschlämmung wurde während einer Stunde bei Raumtemperatur gerührt und dann filtriert. Das erhaltene Produkt wurde kurz mit Ethanol und dann mit Diisopropylether gewaschen. Nach dem Trocknen wurden 135 g (55,7%) der Titelverbindung als weiße Kristalle, die bei 117°C schmelzen, isoliert.

b) Methyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropanonat

6-Brom-4-phenyl-3,4-dihydrocumarin (290 g, 0,96 mol) wurden in einem Gemisch an Methanol (1 l) und Aceton (1 l) aufgelöst. Zu der obigen Lösung wurden Kaliumcarbonat (160 g, 1,16 mol), α -Chlortoluol (140 g, 1,1 mol) und Natriumiodid (30 g, 0,47 mol) zugegeben, und das Gemisch wurde unter Rückflußkühlung während 3 Stunden gerührt. Die Lösung wurde durch Destillation konzentriert, und der Rückstand wurde mit Wasser behandelt und mit Diethylether extrahiert. Die Etherschicht wurde aufeinanderfolgend mit Wasser, mit gesättigter Natriumcarbonatlösung und Wasser gewaschen. Die organische Schicht wurde über Natriumsulfat



getrocknet, filtriert, und dann eingedampft, um dann 420 g (etwa 100%) der Titelverbindung als hellgelbes Öl zu ergeben.

c) 3-(2-Benzoyloxy-5-bromphenyl)-3-phenylpropanol

Methyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropanonat (112 g, 0,26 mol) wurde in Tetrahydrofuran (250 ml) gelöst und tropfenweise in einer Stickstoffatmosphäre zu einer Suspension von Lithiumaluminiumhydrid (5,9 g, 0,16 mol) in Tetrahydrofuran (250 ml) gegeben. Das Gemisch wurde über Nacht in Stickstoffatmosphäre gerührt. Das überschüssige Hydrid wurde durch Zugabe einer kleinen Menge an HCl (wässrig, 2 M) gespalten. Die Lösung wurde auf ein Celatomkissen filtriert, und die Feststoffe wurden gründlich mit Ether gewaschen. Die kombinierte Etherlösung wurde mit HCl (2 M), Wasser, Natriumhydroxid (2 M) und dann erneut mit Wasser gewaschen. Die organische Lösung wurde über Natriumsulfat getrocknet, filtriert und eingedampft, um 98,5 g (95%) der Titelverbindung als farbloses Öl zu ergeben. Eine kleine Fraktion des Öls wurde aus Diisopropylether/Petrolether kristallisiert und ergab Kristalle, die bei 70°C schmolzen.

d) 3-(2-Benzoyloxy-5-bromphenyl)-3-phenylpropyl-p-toluolsulfonat

Zu einer Lösung von 3-(2-Benzoyloxy-5-bromphenyl)-3-phenylpropanol (107 g, 0,24 mol) in Dichlormethan (300 ml) und Pyridin (75 ml) bei 0°C wurde p-Toluolsulfonylchlorid (57 g, 0,3 mol) zugegeben. Die Lösung wurde über Nacht bei 0°C gerührt, und dann bei reduziertem Druck und einer Badtemperatur unterhalb von 50°C eingedampft. Der Rückstand wurde in Wasser gegossen, und dann wurde das Gemisch mit Diethylether extrahiert. Die organische Phase wurde aufeinanderfolgend mit Wasser, HCl (2 M) und Wasser gewaschen und zuletzt über Natriumsulfat getrocknet. Nach der Filtration wurde die Etherlösung bei einer Badtemperatur von <50°C eingedampft, um 137 g (etwa 100%) 3-(2-Benzoyloxy-5-bromphenyl)-3-phenylpropyl-p-toluolsulfonat als blaßgelbes Öl zu ergeben.

e) N,N-Diisopropyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropylamin

3-(2-Benzoyloxy-5-bromphenyl)-3-phenylpropyl-p-toluolsulfonat (115 g, 0,2 mol) wurde in einem Gemisch von Acetonitril (150 g) und Diisopropylamin (202 g, 2,0 mol) aufgelöst, und das Gemisch wurde während 4 Tagen unter Rückfluß gekühlt. Die Lösung wurde eingedampft, und zu dem entstehenden Sirup wurde Natriumhydroxid (2 M, 200 ml) zugegeben. Das Gemisch wurde konzentriert, abgekühlt und dann mit Diethylether extrahiert. Die Etherphase wurde extensiv mit Wasser gewaschen. Das Amin wurde mit einem Überschuß an Schwefelsäure (1 M) extrahiert. Die wässrige Phase wurde mit Diethylether gewaschen und dann mit Natriumhydroxid (11 M) basisch gemacht. Das Gemisch wurde dann mit Diethylether extrahiert. Die organische Phase wurde mit Wasser gewaschen, über Natriumsulfat getrocknet, filtriert und dann eingedampft, um 78,6 g (78%) N,N-Diisopropyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropylamin als blaßgelbes Öl zu ergeben. Das ¹H-NMR-Spektrum stimmte mit der obigen Struktur überein.

f) Auflösung



Zu einer Lösung von N,N-Diisopropyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropylamin (255 g, 0,53 mol) in Ethanol (750 g) wurde L-(+)-Weinsäure (80 g, 0,53 mol) gegeben. Nachdem das ganze Material aufgelöst war, wurde Diethylether (90 g) zugegeben, und die Kristallisierung begann. Nachdem sie über Nacht bei Raumtemperatur gelagert worden waren, wurden die gebildeten Salze abfiltriert, mit frischer Ethanoldiethyletherlösung (2:1) gewaschen und getrocknet, um 98 g weißer Kristalle, die bei 156°C schmelzen, zu ergeben. $[\alpha]^{22} = 16,3^\circ$ (c = 5,1, Ethanol)

Die Mutterlauge aus der Fällung mit L-(+)-Weinsäure wurde eingedampft. Der resultierende Sirup wurde mit Natriumhydroxid (2 M) behandelt und mit Diethylether extrahiert. Die organische Phase wurde mit Wasser gewaschen, über Natriumsulfat getrocknet, filtriert, und dann eingedampft, wodurch 170 g freie Base entstanden. Die Base (170 g, 0,35 mol) wurde in Ethanol (500 ml) gelöst, und es wurde D-(-)-Weinsäure (53 g, 0,53 mol) zugegeben. Nachdem sich alles gelöst hatte, wurde Diethylether (50 ml) zugegeben, und die Kristallisation begann. Die Kristalle wurden abfiltriert und mit frischer Ethanoldiethyletherlösung gewaschen. Es entstanden 105 g Kristalle, die bei 154-155°C schmelzen. $[\alpha]^{22} = -16,4^\circ$ (c = 5,0, Methanol).


Die Mutterlauge wurde konzentriert, basisch gemacht und wie oben behandelt, was zu 80 g freier Base führte. Diese Base wurde in Ethanol gelöst und mit L-(+)-Weinsäure, wie oben beschrieben, behandelt, wodurch weitere 20 g der rechtsdrehenden Form des Salzes entstanden. (Schmelzpunkt 156°C). Auf analoge Weise konnten 20 g der linksdrehenden Form erhalten werden.

Die gesammelte rechtsdrehende Form wurde in Wasser gelöst und mit Natriumhydroxid (2 M) basisch gemacht. Das Gemisch wurde dann mit Diethylether extrahiert. Die organische Phase wurde mit Wasser gewaschen, über Natriumsulfat getrocknet, filtriert, und zuletzt eingedampft, um das chirale Amin (88 g) als farbloses Öl zu ergeben. $[\alpha]^{22} = 16,3^\circ$ (c = 5,1, Ethanol).

Auf analoge Weise wurde die linksdrehende Base erhalten (90 g). $[\alpha]^{22} = -16,1^\circ$ (c = 4,2, Ethanol). Die durch Chromatographie ermittelte optische Reinheit betrug >99%.

g1) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylaminhydrochlorid

Ein Gemisch von Magnesium (12,2 g, 0,5 mol), Ethylbromid (2 g), und Iod (ein kleiner Kristall) in trockenem Diethylether (200 ml) wurde erwärmt bis die Reaktion begann. (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropylamin (45,6 g, 0,095 mol) und Ethylbromid (32,7 g, 0,3 mol), die in trockenem Diethylether (250 ml) aufgelöst worden waren, wurden dann unter Stickstoffatmosphäre tropfenweise zugegeben. Das Gemisch wurde während 1,5 Stunden unter Rückfluß gekühlt, dann in einem Aceton/Trockeneisbad, in das pulverisiertes Trockeneis (etwa 100 g) vorsichtig zugegeben wurde, gekühlt. Tetrahydrofuran wurde dann zugegeben, wenn es notwendig war zu verhindern, daß das Gemisch fest wurde. Das Reaktions-



gemisch wurde während 0,5 Stunden gerührt, nachdem Ammoniumchlorid (200 ml, 20% Gew./Gew.) zugegeben worden waren. Das Gemisch wurde heftig gerührt bis 2 transparente Phasen entstanden und dann wurde das Gemisch durch ein Celatomkissen filtriert. Die wässrige Schicht wurde mit Diethylether gewaschen und dann mit Salzsäure bis zu einem pH-Wert von 1 angesäuert. Die gefällte halbkristalline gummiartige Masse wurde mit Wasser gewaschen und dann in eine Rundbodenflasche überführt. Das Produkt wurde aufeinanderfolgend mit Aceton, Benzol, Toluol, Diisopropylether und Methanol getrocknet. Die Titelverbindung (35,1 g, 77 %) wurde als bröckelnde glänzende Flocken isoliert und ohne weitere Reinigung verwendet.

g2) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylaminhydrochlorid

Dieses Produkt wurde in einer Ausbeute von 81% auf entsprechende Weise, wie oben für (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-bromphenyl)-3-phenylpropylamin beschrieben, isoliert.

h1) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamin

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamin (34 g, 0,07 mol) wurde in Schwefelsäure (6 g) enthaltendem Methanol (300 ml) gelöst und während 6 Stunden unter Rückfluß gekühlt. Die Lösung wurde dann abgekühlt und konzentriert. Zu dem Gemisch wurden Eiswasser und ein leichter Überschuß einer gesättigten Natriumcarbonatlösung zugegeben. Das Gemisch wurde dann mit Diethylether extrahiert. Die organische Phase wurde mit Wasser gewaschen, über Natriumsulfat getrocknet, filtriert und eingedampft, wodurch 30 g (93%) des Rohesters entstanden. Die Rekristallisierung von Diisopropylether ergab weiße Kristalle, die bei 85-86°C schmelzen. Das ¹H-NMR-Spektrum war in Übereinstimmung mit der obigen Struktur.

h2) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamin

Die Titelverbindung wurde von (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carboxyphenyl)-3-phenylpropylamin auf ähnliche Weise wie oben für das rechtsdrehende Isomer beschrieben in einer 93%igen Ausbeute erhalten.

i1) (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamin

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamin (30 g, 0,065 mol), aufgelöst in Diethylether (250 ml) wurde unter Stickstoff tropfenweise zu einer Suspension von Lithiumaluminiumhydrid (1,9 g, 0,05 mol) in trockenem Diethylether (150 ml) gegeben. Das Gemisch wurde über Nacht bei Raumtemperatur gerührt, und das überschüssige Hydrid wurde durch Zugabe von Wasser (ungefähr 5 g) zersetzt. Das Gemisch wurde während 10 Stunden gerührt, als Natriumsulfat(e) zugesetzt wurde(n). Nach Rühren während 20 Minuten wurde das Gemisch filtriert und dann eingedampft, um 28,4 g der Titelverbindung als farbloses Öl zu ergeben.

i2) (+)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamin

Die Titelverbindung wurde auf analoge Weise, wie oben für die linksdrehende Isomerform des (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-carbomethoxyphenyl)-3-phenylpropylamin beschrieben, erhalten.

j1) (+)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylammonium-(+)mandelat

(+)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamin (28,2 g, 0,065 mol) wurden in Methanol (300 g) gelöst. Raney Nickel (ein Teelöffel) wurde zugegeben, und das Gemisch wurde bei Atmosphärendruck hydriert, bis die theoretische Menge an Wasserstoff verbraucht wurde. Das Voranschreiten der Reaktion wurde durch Gaschromatographie verfolgt. Das Gemisch wurde dann durch ein Celatomkissen filtriert, und das Lösungsmittel wurde durch Eindampfen bei einer Badtemperatur von <math>< 50^{\circ}\text{C}</math> entfernt. Das entstehende Öl wurde in Diethylether gelöst, und die Etherlösung wurde mit Wasser gewaschen, über Natriumsulfat getrocknet und eingedampft, um 22,2 g eines farblosen Öls zu ergeben. $[\alpha]^{22} = 16,7^{\circ}$ (c = 4,9, Ethanol).

Zu dem obigen Öl, das in 2-Propanol (50 g) gelöst war, wurde S-(+)-Mandelsäure (9,6 g, 0,06 mol) in 2-Propanol (50 g) gegeben. Es wurde trockener Diethylether (50 g) zugegeben, und die Lösung wurde während mehrerer Stunden belassen. Die entstehenden schweren weißen Kristalle wurden abfiltriert, und mit einem Gemisch aus 2-Propanol und Diethylether (1:1 Vol./Vol.) gewaschen und dann getrocknet, wodurch 25 g der Titelverbindung, die bei 148°C schmolz, entstanden. $[\alpha]^{22} = 38,3^{\circ}$ (c = 5,1, Methanol).

Das $^1\text{H-NMR}$ -Spektrum war in Übereinstimmung mit der obigen Struktur.

Die chirale Reinheit, wie durch HPLC bestimmt, war >99%.

Elementaranalyse:

Theoretisch: C: 73,0 H: 8,0 N: 2,8 O: 16,2

Gefunden: C: 72,9 H: 8,1 N: 3,0 O: 16,5

j2) (-)-N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylammonium(-)mandelat

Die Titelverbindung wurde aus (-)-N,N-Diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamin analog zu der in j1) oben beschriebenen Weise erhalten.

Elementaranalyse:

Theoretisch: C: 73,0 H: 8,0 N: 2,8 O: 16,2

Gefunden: C: 73,2 H: 8,1 N: 3,0 O: 16,5

Die freie Base hatte eine optische Rotation von $[\alpha]^{22} = -15,5^{\circ}$ (c = 5,0, Ethanol).

Die l-(-)-Mandelsäure hatte einen Schmelzpunkt von $147-148^{\circ}\text{C}$ und eine optische Rotation $[\alpha]^{22} = -37,9^{\circ}$ (c = 4,7, Methanol).

Die durch HPLC bestimmte optische Reinheit betrug >99%.

Pharmakologie

Die pharmakologischen Untersuchungen, die mit einer erfindungsgemäßen Verbindung und drei im Stand der Technik bekannten Verbindungen, die in der oben erwähnten WO 89/06644 beschrieben wurden, werden im folgenden beschrieben. Die folgenden Verbindungen wurden verwendet:

- (A) (+)-N,N-Diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropylamin, Hydrochlorid (WO 89/06644);
- (B) N,N-Diisopropyl-3-bis-(2-hydroxyphenyl)propylaminhydrochlorid (WO 89/06644);
- (C) (+)-N,N-Diisopropyl-3-(5-chlor-2-hydroxyphenyl)-3-(2-hydroxyphenylpropylamin, Hydrochlorid (WO 89/06644);
- (D) N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamin-(-)mandelsäuresalz (Beispiel 1 oben).

Hochgestellte Indexzahlen im folgenden Text beziehen sich auf Literaturstellen, die am Ende der Beschreibung aufgelistet sind.

Muscarinrezeptorbindungsstudien

Die Gewebepreparationen und die allgemein verwendeten Verfahren wurden an anderer Stelle für die Ohrspeicheldrüse¹, die Harnblase², das Herz³ bzw. den cerebralen Cortex³, im Detail beschrieben. Männliche Meerschweinchen (250-400 g Körpergewicht) wurden durch einen Schlag auf den Nacken getötet und ausgeblutet. Das Gehirn wurde zur Sektion des cerebralen Cortexes (lediglich die graue Substanz) auf Eis gegeben. Harnblasen, Herz und Ohrspeicheldrüsen wurden herausgeschnitten und in einen Krebs-Henseleit-Puffer (pH 7,4), enthaltend 1 mM Phenylmethylsulfonylfluorid (PMSF, ein Proteaseinhibitor), gegeben. Die herausgeschnittenen Gewebe wurden in einem eiskalten Natriumkaliumphosphatpuffer (50 mM, pH 7,4), enthaltend 1 mM PMSF, unter Verwendung eines Polytron PT-10-Gerätes (Blase, Herz, Ohrspeicheldrüse) und eines Potter-Elvehjem-Teflon-Homogenisiergerätes (Cortex) homogenisiert. Zuletzt wurden alle Homogenisate mit dem eiskalten Phosphat/PMSF-Puffer zu einer Endproteinkonzentration von $\leq 0,3$ mg/ml verdünnt und sofort in den Rezeptorbindungsassays verwendet. Protein wurde durch das Verfahren von Lowry et al. (1951)⁴ unter Verwendung von Rinderserumalbumin als Standard bestimmt.

Die Muscarinrezeptoraffinitäten der oben identifizierten nichtmarkierten Verbindungen A bis D wurden aus Konkurrenzexperimenten abgeleitet, in denen die Fähigkeit die rezeptorspezifische Bindung von (-)-³H-QNB (1-Chinuclidinyl[phenyl-4-³H]benzilat, 32,9 Ci/mmol) zu inhibieren, wie zuvor beschrieben^{3,5}, verfolgt wurde. Jede Probe enthielt 10 μ l (-)-³H-QNB (Endkonzentration 2 nM), 10 μ l einer Lösung der Testverbindung und 1,0 ml Gewebshomogenisat. Dreifachproben wurden unter Gleichgewichtsbedingungen, d.h. bei 25°C während 60 Minuten (Harnblase), 80 Minuten (Herz und cerebraler Cortex) bzw. 210 Minuten (Ohrspeicheldrüse) inkubiert. Nichtspezifische Bindung wurde in Gegenwart von 10 μ M unmarkiertem Atropin be-


stimmt. Die Inkubationen wurden durch Zentrifugation² beendet, und die Radioaktivität in den Sedimenten wurde durch Flüssigscintillationsspektrometrie² bestimmt.

Die IC₅₀-Werte (die Konzentration unmarkierter Verbindung, die zu 50% Inhibition der rezeptorspezifischen (-)³H-QNB-Bindung führte) wurden graphisch aus den experimentellen Konzentrations-Inhibitionskurven bestimmt. Die Affinitäten, die als Dissoziationskonstanten K_i ausgedrückt werden, wurden durch Korrektur der IC₅₀ mit der radioligandeninduzierten parallelen Verschiebung und den Unterschieden in der Rezeptorkonzentration unter Verwendung des Verfahrens von Jacobs et al. (1975)⁶ berechnet. Die Bindungsparameter für (-)³H-QNB (K_D und Rezeptordichten), die in diesen Berechnungen verwendet wurden, wurden in getrennten Experimentenserien¹⁻³ bestimmt. Die für die Blase, das Herz, die Ohrspeicheldrüse bzw. den Cortex erhaltenen K_i-Werte sind in der unten gezeigten Tabelle 1 dargestellt.

Funktionelle in vitro-Studien

Männliche Meerschweinchen mit einem Gewicht von etwa 300 g wurden durch einen Schlag auf das Genick getötet und ausgeblutet. Streifen glatter Muskulatur der Harnblase wurden herausgeschnitten und in eine Krebs-Henseleit-Lösung (pH 7,4) gegeben. Die Streifenpräparationen wurden vertikal zwischen zwei Haken in Thermostat-kontrollierte (37°C) Organbädern (5 ml) montiert. Einer der Haken war einstellbar und mit einem Kraftüberträger (FT 03, Grass Instruments) verbunden. In die Krebs-Henseleit-Lösung wurde kontinuierlich Kohlendioxidgas (93,5% O₂/6,5% CO₂) eingeblasen, um den pH auf einen Wert von 7,4 zu halten. Die isometrische Spannung wurde mittels eines Grass Polygraphen (Modell 79D) aufgezeichnet. Eine Ruhespannung von etwa 5 mN wurde initial an jedem Muskelstreifen angelegt, und man erlaubte den Präparationen sich während wenigstens 45 Minuten zu stabilisieren. Die Ruhespannung wurde wiederholt angeglichen, und die Präparationen wurden mehrfach während des Stabilisierungszeitraumes gewaschen.

Carbachol (Carbamylcholinchlorid) wurde als Standardagonist verwendet. Bei jedem Experiment wurde die Lebensfähigkeit der Präparationen und die Reproduzierbarkeit ihrer kontraktile Antworten initial durch drei aufeinanderfolgende Zugaben einer submaximalen Konzentration (3×10^{-6} M) Carbachol getestet. Dann wurde eine vollständige Konzentrations-Antwortkurve auf Carbachol durch kumulative Zugabe von Carbachol zum Organbad (d.h. schrittweise Zunahme der Agonistenkonzentration bis die maximale kontraktile Antwort erreicht wurde), gefolgt von Auswaschen und einer Ruheperiode von wenigstens 15 Minuten bevor eine Fixkonzentration der Testverbindung (Antagonist) zum Organbad zugegeben wurde, erzeugt. Nach 60 Minuten Inkubation mit dem Antagonisten wurde eine zweite kumulative Konzentrationsantwortkurve gegenüber Carbachol erzeugt. Die Antworten wurden als Prozent der maximalen Antwort auf Carbachol ausgedrückt. EC₅₀-Werte für Carbachol in Abwesenheit (Kontrolle) und Gegenwart des Antagonisten wurden graphisch abgeleitet und Dosisverhältnisse (r) wurden berechnet. Die Dissoziationskonstanten K_B für Antagonisten wurden unter Verwendung der Gleichung (1)⁷ berechnet, in der [A] die Konzentration der Testverbindung ist.



$$K_B = [A]/r-1 \quad (1)$$

Die K_B -Werte, die für die Verbindungen A, B und D, die oben identifiziert wurden, erhalten wurden, sind in der unten gezeigten Tabelle 1 gezeigt.

Tabelle 1

Test- verbindung	K_B nm Blase	K_i nM Blase	K_i nM Herz	K_i nM Ohrspeicheldrüse	K_i nM Cortex
(A)	3,0	2,7	1,6	4,8	0,8
(B)		10,2	6,7	2,6	1,5
(C)	2,6	2,5	0,9	2,7	0,4
(D)	4,1	4,5	0,9	4,7	0,7

Funktionelle in vivo-Studien

a) Tierpräparationen

Adulte Katzen wurden intraperitoneal mit Mebumal (42 mg/kg) anästhesiert. Nachdem die Tiere eingeschlafen waren, wurde in die Vene des Vorderfußes eine Infusionskanüle eingeführt, und der Katze wurde alpha-Chloralose verabreicht. Während des Experimentes wurde das Tier auf einen Operationstisch gelegt, der mit einem Feedback-kontrollierten elektrischen Kissen aufgeheizt wurde. Bei der Katze wurde ein Luftröhrenschnitt durchgeführt. Zur Aufzeichnung des Blutdruckes wurde ein Polyethylenkatheter in die Oberschenkelarterie eingeführt, wobei sich die Spitze in der Aorta befand und über den Dreiwegehahn mit einem Blutdruckvermittler und einem Grass-Polygraphen verbunden. Die Herzgeschwindigkeit wurde durch Verbindung eines Gerätes zum Registrieren der Fließgeschwindigkeit der Blutbewegung mit einem Treiberverstärker aufgezeichnet, der das Signal von dem Blutdrucküberträger empfing. Der Blutfluß in der zentralen mesenterialen Arterie wurde durch eine Ultraschallflußsonde um die Arterie, die mit einem Transonic-Blutflußmeter und dann mit einem Grass-Polygraphen zur Aufzeichnung des Flußes verbunden war, gemessen. Zur Infusion der Testsubstanzen, Verbindungen D und A (wie oben definiert) wurde ein Polyethylenkatheter in den Dreiwegehahn in der femoralen Vene eingeführt, und mit einer Spritze verbunden, die sich in einer Infusionspumpe befand (Sage Instrument).

Durch einen Einschnitt in die proximale Harnröhre wurde ein Katheter in die Harnblase eingeführt. Zu Beginn eines jeden Experimentes wurde dieser Katheter mit einem offenen Gefäß verbunden, das mit 38°C warmer physiologischer Kochsalzlösung angefüllt war und sich oberhalb des Tieres befand. Während dieses Stabilisierungszeitraumes entspannte sich die Blase, was zu einer Füllung der Blase mit Kochsalz unter konstantem hydrostatischem Druck führte. Nach dem Stabilisierungszeitraum wurde der Blasen-katheter mit einem Druckvermittler zur Aufzeichnung des intravesikalen Drucks verbunden. Der Blutdruck, die Herzgeschwindigkeit, der Blutfluß und der Blasendruck wurden während des ganzen Experiments gleichzeitig und kontinuierlich aufgezeichnet. Man beließ die Tiere während wenigstens 45 Minuten, um einen Gleichge-

wichtszustand in Bezug auf die kardiovaskulären Variablen vor Beginn des Experimentes zu erreichen.

Der Blasendruck wurde 8 Minuten vor dem Ende der Infusion der Testsubstanz gemessen. Die operative Präparation wurde durch intravenöse Injektion von 0,25 µg/kg Körpergewicht Noradrenalin und 0,5 µg/kg Körpergewicht Acetylcholin getestet.

b) Dosierung

Um die Dosis-Wirkungsbeziehung der Verbindung D, die oben identifiziert wurde, zu untersuchen, wurde die Substanz in Dosierungen von 0,000 (physiologische Kochsalzlösung), 0,003, 0,010, 0,030 bzw. 0,100 mg/kg mit Infusionen während 2 Minuten und einem Infusionsvolumen von 1 ml/kg verabreicht. Jede Katze erhielt alle Dosierungen und wurde so behandelt, daß wenigstens 45 Minuten zwischen den 0,003 und 0,010 mg/kg-Dosierung und 60 Minuten zwischen der 0,030 und 0,100 mg/kg-Dosierung verblieben.

c) Statistische Verfahren und Berechnung

Die Ergebnisse werden in absoluten Werten dargestellt, und als Mittelwert ± Standardabweichung berechnet.

d) Ergebnisse

(i) Blutdruck

Im allgemeinen hatte die intravenöse Verabreichung der Verbindung D einen geringen oder keinen Effekt auf den Blutdruck mit Ausnahme der Dosierung von 0,3 mg/kg. Diese Dosierung verursachte einen Anstieg von 10% für den diastolischen Blutdruck bzw. 6% für den systolischen Blutdruck.

(ii) Blutfluß

Die intravenöse Verabreichung der Verbindung D verursachte einen Anstieg des Blutflusses in der superioren mesenterialen Arterie von 8, 17 bzw. 21% für die Dosierungen von 0,003, 0,01 bzw. 0,03 mg/kg. Erneut wurde für die höchste Dosierung (0,3 mg/kg) ein 10%iger Anstieg im Blutfluß beobachtet.

(iii) Herzgeschwindigkeit

Die intravenöse Verabreichung der Verbindung D verursachte eine Abnahme von 9% bei der höchsten Dosierung (0,3 mg/kg).

(iv) Blasendruck

Wie aus Figur 4 entnommen werden kann, führte die erfindungsgemäße Verbindung D zu einer dosisabhängigen Inhibition des Acetylcholin-induzierten Effektes auf die Blase, der etwa 10 mal effizienter war als der Effekt, der aus dem Stand der Technik bekannten Verbindung A.




Literaturhinweise

1. Nilvebrant, L.; Sparf, B. Muscarinic receptor binding in the parotid gland. Different affinities of some anticholinergic drugs between the parotid gland and ileum. Scand. J. Gastroenterol. 1982, 17 (Ergänz. 72), 69-77.
2. Nilvebrant, L.; Sparf, B. Muscarinic receptor binding in the guinea pig urinary bladder. Acta Pharmacol. et Toxicol. 1983 a, 52, 30-38.
3. Nilvebrant, L.; Sparf, B. Dicyclomine, benzhexol and oxybutynin distinguish between sub-classes of muscarinic binding-sites. Eur. J. Pharmacol. 1986, 123, 133-143.
4. D Lowry, O. H.; Rosebrough, N. J.; Farr, A. L.; Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
5. Nilvebrant, L.; Sparf, B. Differences between binding affinities of some antimuscarinic drugs in the parotid gland and those in the urinary bladder and ileum. Acta Pharmacol. et Toxicol. 1983 b, 53, 304-313.
6. Jacobs, S.; Chang, K.-J.; Cuatrecasas, P. Estimation of hormone receptor affinity by competitive displacement of labelled ligand. Effects of concentration of receptor and labelled ligand. Biochem. Biophys. Res. Commun. 1975, 66, 687-692.
7. Schild, H. I. pAx and competitive drug antagonism. Br. J. Pharmacol. Chemother. 1949, 4, 277-280.

P A T E N T A N S P R Ü C H E

1. 3,3-Diphenylpropylamine der Formel I



I


worin R^1 für Wasserstoff oder Methyl steht, R^2 und R^3 unabhängig voneinander für Wasserstoff, Methyl, Methoxy, Hydroxy, Carbamoyl, Sulfamoyl oder Halogen stehen und X für eine tertiäre Aminogruppe der Formel II



II

steht, in der jedes R^4 und R^5 unabhängig voneinander für nichtaromatische Kohlenwasserstoffgruppen steht, die eine oder mehrere Hydroxygruppen tragen können und die zusammen wenigstens drei Kohlenstoffatome enthalten und in der R^4 und R^5 miteinander verbunden sein können, um einen Ring zu bilden, der kein anderes Heteroatom besitzt als den Aminstickstoff, ihre Salze mit physiologisch annehmbaren Säuren und, wenn die Verbindungen in Form optischer Isomere vorliegen können, die racemischen Gemische und die individuellen Enantiomere.




2. 3,3-Diphenylpropylamine nach Anspruch 1, dadurch gekennzeichnet, daß jedes R^4 und R^5 unabhängig voneinander eine gesättigte Kohlenwasserstoffgruppe,



insbesondere eine gesättigte aliphatische Kohlenwasserstoffgruppe, wie C₁₋₈-Alkyl, insbesondere C₁₋₆-Alkyl oder Adamantyl bedeutet und R⁴ und R⁵ zusammen wenigstens drei, vorzugsweise wenigstens vier Kohlenstoffatome umfassen.

3. 3,3-Diphenylpropylamine nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß wenigstens ein Rest aus der Gruppe R⁴ und R⁵ eine verzweigte Kohlenstoffkette umfaßt.

4. 3,3-Diphenylpropylamine nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß X für eine der folgenden Gruppen a) bis h) steht:



5. 3,3-Diphenylpropylamine nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß die HOCH₂-Gruppe in der 5-Position ist, R² Wasserstoff und R³

Wasserstoff oder Hydroxy, vorzugsweise in der 2-Position, ist.

6. 3,3-Diphenylpropylamine nach Anspruch 1, ausgewählt aus N,N-Diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropylamin, seinen Salzen mit physiologisch annehmbaren Säuren, Racemate und individuellen Enantiomere davon.


7. 3,3-Diphenylpropylamine nach einem der Ansprüche 1 bis 6 zur Verwendung als pharmazeutisch aktive Substanzen, insbesondere als anticholinerge Mittel.

8. Pharmazeutisches Mittel, umfassend ein 3,3-Diphenylpropylamin nach einem der Ansprüche 1 bis 6 und vorzugsweise einen kompatiblen pharmazeutischen Träger.

9. Verwendung eines 3,3-Diphenylpropylamins nach einem der Ansprüche 1 bis 6 zur Herstellung eines anticholinergen Medikaments.

10. Verfahren zur Herstellung von 3,3-Diphenylpropylaminen nach einem der Ansprüche 1 bis 6, umfassend die folgenden Stufen:


a) Reduktion der R⁶CO-Gruppe eines 3,3-Diphenylpropylamins der Formel III



in der R¹ bis R³ und X die oben definierten Bedeutungen haben, R⁶ Wasserstoff oder R⁷O ist, wobei R⁷ Wasserstoff, Alkyl, Alkenyl, Alkynyl oder Aryl ist, und jegliche Hydroxy-

gruppen z.B. durch Methylierung oder Benzylierung geschützt sein können oder

b) Umsetzung eines reaktiv veresterten 3,3-Diphenylpropanols der Formel IV




in der R¹ bis R³ die oben definierten Bedeutungen haben, jegliche Hydroxygruppen geschützt sein können und in der Y eine Austrittsgruppe ist, mit einem Amin der Formel V




in der X die oben definierte Bedeutung hat oder

c) Reduktion eines 3,3-Diphenylpropionamids der Formel VI




in der R¹ bis R³ und X die oben definierten Bedeutungen haben und jegliche Hydroxygruppen geschützt sein können, oder

d) N-Methylierung eines sekundären 3,3-Diphenylpropylamins der Formel VII




in der R¹ bis R³ und X die oben definierten Bedeutungen haben, und jegliche Hydroxygruppen geschützt sein können und in der Z die gleiche Bedeutung wie R¹ und R² mit Ausnahme von Methyl hat oder

e) Umsetzung eines 3,3-Diphenylpropenamins der Formel VIIIa oder eines 3,3-Diphenylpropylamins der Formel VIIIb




VIIIa



VIIIb

worin R¹ bis R³ und X die oben definierten Bedeutungen haben und jegliche Hydroxygruppen geschützt sein können und W für eine Hydroxygruppe oder ein Halogenatom steht oder


f) Umsetzung eines Diphenylpropylamins der Formel IX



IX

in der R¹ bis R³ und X die oben definierten Bedeutungen haben und Hal für Halogen steht, mit Formaldehyd oder einem Formaldehyd-Äquivalent oder

g) Oxidation der Methylgruppe eines Diphenylpropylamins der Formel X



X

00:09:38

6

in der R^1 bis R^3 und X die oben definierten Bedeutungen haben und

i) falls nötig, Abspaltung der Hydroxyschutzgruppen in den erhaltenen Verbindungen, falls erwünscht nach Mono- oder Dihalogenierung eines oder beider Phenylringe und/oder

ii) falls gewünscht, Umwandlung der erhaltenen Basen der Formel I in die Salze davon mit physiologisch annehmbaren Säuren oder umgekehrt, und/oder

iii) falls gewünscht, Trennung eines erhaltenen Gemisches optischer Isomere in die individuellen Enantiomeren, und/oder

iv) falls gewünscht, Methylierung einer ortho-Hydroxygruppe in einer erhaltenen Verbindung der Formel I, in der R^1 für Wasserstoff und/oder R^3 für Hydroxy steht.

00544

93 924 876.1

1/1




FIG. 1



Europäisches Patentamt
 European Patent Office
 Office européen des brevets



(11) EP 0 957 073 A1

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:
 17.11.1999 Bulletin 1999/46

(21) Application number: 98108608.5

(22) Date of filing: 12.05.1998

(51) Int. Cl.⁸: C07C 1/00, C07C 217/62,
 C07C 217/48, C07C 219/28,
 C07C 219/22, C07D 207/06,
 C07D 295/06, C07C 271/08,
 C07F 7/18, C07C 307/02,
 A61K 31/135, A61K 31/325,
 A61K 31/40, A61K 31/435

(84) Designated Contracting States:
 AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
 MC NL PT SE
 Designated Extension States:
 AL LT LV MK RO SI

(72) Inventors:
 • Sparf, Bengt Ph. D.
 14265 Trangsund (SE)
 • Meese, Claus O., Dr. rer. nat.
 40789 Mortheim (DE)


(71) Applicant: SCHWARZ PHARMA AG
 40789 Monheim (DE)

(54) Novel derivatives of 3,3-diphenylpropylamines

(57) The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly the invention concerns to provide novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to present drugs as oxybutynin and tolterodine, methods

for preparing thereof, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

FORMATION OF THE ACTIVE METABOLITE FROM DIFFERENT PRODRUGS BY HUMAN LIVER S 9 (%) IN 1h



EP 0 957 073 A1

Description

[0001] The present invention relates to novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. A further object of the invention is to provide novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to present drugs as oxybutynin and tolterodine, methods for preparing thereof, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

[0002] More particularly, the present invention relates to certain prodrugs of 3,3-diphenylpropylamines while avoiding on administration to a mammal a high variation in bioavailability and formation of active metabolites which can result in a substantial variation in response - too low efficacy or too much side effects - for the subjects on the suggested therapy.

[0003] In man, normal urinary bladder contractions are mediated mainly through cholinergic muscarinic receptor stimulation. There is reason to believe that muscarinic receptors mediate not only normal bladder contractions but also the main part of the contractions in the overactive bladder resulting in symptoms as urinary frequency, urgency and urge incontinence. For this reason antimuscarinic drugs have been instituted as a treatment of bladder over activity.

[0004] Among the antimuscarinic drugs available on the market, oxybutynin is currently regarded as the gold standard for pharmacological treatment of urge incontinence and other symptoms related to bladder over activity. The effectiveness of oxybutynin has been demonstrated in several clinical studies but the clinical usefulness of oxybutynin is limited due to antimuscarinic side effects. Dryness of the mouth is the most common experienced side effect which may be severe enough to result in poor compliance or discontinuation of treatment (Andersson, K.-E., 1988, Current concepts in the treatment of disorders of micturition, *Drugs* 35, 477-494; Kelleher et al. 1994).

[0005] Tolterodine is a new, potent and competitive, muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and detrusor hyperactivity. Preclinical pharmacological data show that tolterodine exhibits a favourable tissue selectivity in vivo for the urinary bladder over the effect on the salivation (Nilvebrant et al, 1997, Tolterodine - a new bladderselective antimuscarinic agent, *Eur. J. Pharmacol.* 327 (1997), 195-207), whereas oxybutynin exhibits the reversed selectivity. Tolterodine is equipotent to oxybutynin at urinary bladder muscarinic receptors and the favourable tissue selectivity of tolterodine demonstrated in the preclinical studies has been confirmed in clinical studies. Thus a good clinical efficacy has been combined with a very low number of incidences of dry mouth and antimuscarinic side effects.


[0006] A major metabolite of tolterodine, the 5-hydroxymethyl derivative is also a potent muscarinic receptor antagonist and the pharmacological in vitro and in vivo profiles of this metabolite is almost identical to those of tolterodine (Nilvebrant et al, 1997, *Eur. J. Pharmacol.* 327 (1997), 195-207). Combined pharmacological and pharmacokinetic data indicate that it is most likely that the metabolite give a major contribution to the clinical effect in most patients.

[0007] The document WO 94/11337 discloses that the active metabolite of tolterodine is suggested as a new drug for urge incontinence. Administration of the active metabolite directly to patients has the advantage compared to tolterodine that only one active principle (compound) has to be handled by the patient which normally should result in a lower variation in efficacy and side effects between patients and lower risk of interaction with other drugs.

[0008] However, the introduction of an additional hydroxy group in the tolterodine results in an increased hydrophilic property of the new compounds (3,3-diphenylpropylamines) compared to the parent compounds which normally results in a lower absorption/bioavailability. In a method to circumvent this disadvantage different prodrugs of the metabolite have been synthesized and tested for their absorption/bioavailability data.


[0009] It is an object of the present invention to provide novel derivatives of 3,3-diphenylpropylamines. It is a further object of the present invention to provide new derivatives of 3,3-diphenylpropylamines which will be more useful as prodrugs for treatment of urinary incontinence and other spasmogenic conditions that are caused by muscarinic mechanisms while avoiding the disadvantage of a too low absorption/bioavailability after oral administration of the drugs or an unfavourable metabolism.

[0010] The novel compounds of the present invention are represented by the general Formula (I)




wherein R independently signifies:

- a) R¹ represents the residues hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, benzyl or allyl; or
- b) R² represents the residues formyl, acetyl, propionyl, isobutyryl, butyryl, valeroyl, pivaloyl, benzoyl; or
- c) R³ represents the residues CH₃OCO-, C₂H₅-OCO-, C₃H₇OCO-, (CH₃)₃COCO-, benzoylacyl, benzoylglycyl, glycy, valyl, leucyl, isoleucyl, phenylalanyl, prolyl, seryl, threonyl, methionyl, hydroxypropyl; or
- d) a group consisting



of wherein R⁴ and R⁵ independently represent the residues hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, benzyl, phenoxyalkyl wherein the alkyl residue means methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and wherein R⁴ and R⁵ may form a ring together with the amine nitrogen; or


- e) a group consisting .



of wherein R⁶ and R⁷ independently represent the residues methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, benzyl, phenoxyalkyl wherein the alkyl residue means methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl; or

- f) an ester of inorganic acids such as sulfuric acid, phosphoric acid;

X represents a tertiary amino group of Formula Ia



wherein R⁸ and R⁹ signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R⁸ and R⁹ may form a ring together with the amine nitrogen, R' represents hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl, benzyl, alkyl, phenoxyalkyl wherein the alkyl residue means methyl, ethyl, propyl, isopropyl, butyl, isobutyl, if R is hydrogen R' will not represent hydrogen or methyl and

their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers.

[0011] The compounds of Formula (I) can form salts with physiologically acceptable acids, organic and inorganic. Furthermore the aforementioned compounds comprise the free bases as well as the salts thereof. Examples of such acid








addition salts include the hydrochloride, hydrobromide and the like.

[0012] When the novel compounds are in the form of optical isomers, the invention comprises the racemic mixture as well as the individual isomers as such.

[0013] Preferably each of R^8 and R^9 independently signifies a saturated hydrocarbonyl group, especially saturated aliphatic hydrocarbonyl groups such as C_{1-8} -alkyl, especially C_{1-6} -alkyl, or adamantyl, R^8 and R^9 together comprising at least three, preferably at least four carbon atoms.


[0014] According to an other embodiment of the invention at least one of R^8 and R^9 comprises a branched carbon chain.

[0015] Presently preferred tertiary amino groups X in Formula I include the following groups a) to h):




[0016] Preferred compounds according to the present invention are:

A) Phenolic monoesters represented by the general Formulae II and II'




Formula II



Formula II'

Formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 Propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 n-Butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 2,2-Dimethylpropionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 Malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl] ester
 Succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl] ester
 Pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl] ester
 Hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl] ester


B) Identical diesters represented by the general Formula III



Formula III

Formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester
 Acetic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester
 Propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-propionyloxymethylphenyl ester
 n-Butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester
 Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-isobutyryloxymethylphenyl ester
 2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester
 Benzoic acid 4-benzoyloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester


C) Mixed diesters represented by the general Formula IV



Formula IV

Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester
 Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester
 Isobutyric acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester
 2,2-Dimethylpropionic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)benzyl ester
 2,2-Dimethylpropionic acid 4-acetoxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester


D) Benzylic monoesters represented by the general Formula V



Formula V

Formic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester
 Acetic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester
 Propionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester
 Butyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester
 Isobutyric acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester
 2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester
 Benzoic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-hydroxybenzyl ester


E) Ethers and silyl ethers represented by the general Formula VI




Formula VI

2-(3-Diisopropylamino-1-phenylpropyl)-4-methoxymethylphenol
 2-(3-Diisopropylamino-1-phenylpropyl)-4-ethoxymethylphenol
 2-(3-Diisopropylamino-1-phenylpropyl)-4-propoxymethylphenol
 2-(3-Diisopropylamino-1-phenylpropyl)-4-isopropoxymethylphenol
 2-(3-Diisopropylamino-1-phenylpropyl)-4-butoxymethylphenol
 Acetic acid 2-(3-Diisopropylamino-1-phenylpropyl)-4-methoxymethylphenyl ester
 Acetic acid 2-(3-Diisopropylamino-1-phenylpropyl)-4-ethoxymethylphenyl ester
 2-(3-Diisopropylamino-1-phenylpropyl)-4-trimethylsilyloxyethylphenol
 Diisopropyl-[3-phenyl-3-(2-trimethylsilyloxy-5-trimethylsilyloxyethylphenyl)propyl]-amine
 [3-(3-Diisopropylamino-1-phenylpropyl)-4-trimethylsilyloxyphenyl]-methanol
 Diisopropyl-[3-(5-methoxymethyl-2-trimethylsilyloxyphenyl)-3-phenylpropylamine
 Diisopropyl-[3-(5-ethoxymethyl-2-trimethylsilyloxyphenyl)-3-phenylpropylamine
 (4-(tert.-Butyl-dimethylsilyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]methanol
 Acetic acid 4-(tert.-butyl-dimethylsilyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester
 4-(tert.-Butyl-dimethylsilyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenol
 Acetic acid 4-(tert.-butyl-dimethylsilyloxy)-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester
 (3-[2-(tert.-Butyl-dimethylsilyloxy)-5-(tert.-butyl-dimethylsilyloxyethyl)phenyl]-3-phenylpropyl)-diisopropylamine
 [4-(tert.-Butyl-diphenylsilyloxy)-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]methanol
 Acetic acid 4-(tert.-butyl-diphenylsilyloxyethyl)-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester
 4-(tert.-Butyl-diphenylsilyloxyethyl)-2-(3-diisopropylamino-1-phenylpropyl)phenol
 (3-[2-(tert.-Butyl-diphenylsilyloxy)-5-(tert.-butyl-diphenylsilyloxyethyl)phenyl]-2-phenylpropyl)-diisopropylamine
 Acetic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester
 Benzoic acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester
 Isobutyric acid 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester

F) Carbonates and carbamates represented by the general Formulae VII and VII'



Formula VII



Formula VII'

N-Ethylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 N-Phenylcarbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester
 N-Ethylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-ethylcarbamoyloxybenzyl ester

N-Phenylcarbamic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-N-phenylcarbonyloxybenzyl ester
 4-[2-(3-Diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenoxy-carbonylamino]-butyl]-carbamic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl ester
 Carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester ethyl ester
 Carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester phenyl ester
 Carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-ethoxycarbonyloxymethylphenyl ester ethyl ester
 Carbonic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-phenoxy-carbonyloxymethylphenyl ester phenyl ester

[0017] The compounds of formula (I) may, in accordance with the present invention be prepared by per se conventional methods. Methods for preparing substituted 3,3-diphenylpropylamines as disclosed by this invention may be synthesized according to methods as described in the document PCT/SE93/00927.

[0018] The invention will be further illustrated by the following non-limiting examples and pharmacological tests.

[0019] The following starting materials and preferred Examples illustrate the invention:

1. Experimental

1. General

[0020] All compounds were fully characterized by ^1H and ^{13}C NMR spectroscopy. The chemical shifts reported (^{13}C NMR, ppm) refer to the solvents CDCl_3 (77.10 ppm), CD_3OD (49.00 ppm) or hexadeuterio dimethylsulphoxide (DMSO- d_6 , 39.70 ppm) respectively. Thin-layer chromatography (tlc, R_f values reported) was conducted on precoated 5x10 cm E. Merck silica gel plates (60F254), spots were visualized by fluorescence quenching or spraying with alkaline potassium permanganate solution. Solvent systems: (1), ethyl acetate/n-hexane (30/70, v/v-%); (2), toluene/acetone/methanol/acetic acid (70/5/20/5, v/v-%); (3), n-hexane/acetone/diethylamine (70/20/10, v/v-%); (4), n-hexane/acetone/diethylamine (70/20/10, v/v-%); (5), ethyl acetate/n-hexane/2-propanol/triethylamine (60/40/20/1, v/v-%); (6), ethyl acetate/triethylamine (90/10, v/v-%). Gas chromatography-mass spectrometry (GC-MS): spectra (m/z values and relative abundance reported) were recorded on a Finnigan TSQ 700 triple mass spectrometer in the positive (P-CI) or negative (N-CI) chemical ionization mode using methane or ammonia as reactant gas. Hydroxylic compounds were analyzed as their trimethylsilyl ether derivatives.

2. Synthesis of Intermediates A and B

[0021] An icecooled solution of 4-bromophenol (69.2g) and cinnamoyl chloride (66.8g) in dichloromethane (150ml) was treated with triethylamine (40.6g). After stirring for 18h at room temperature the mixture was washed with water (250ml), 1M aqueous HCl, and dried over anhydrous sodium sulphate. Evaporation in vacuum left solid 3-phenylacrylic acid 4-bromophenyl ester (121.0g, 99.8% yield), m.p. 113.3 °C, tlc (1) 0.83. NMR(CDCl_3): 116.85, 118.87, 123.49, 128.38, 129.06, 130.90, 132.49, 134.02, 147.07, 149.84, 165.06.

[0022] A portion of the ester (60.0g) was dissolved in a mixture of acetic acid (60ml) and concentrated sulphuric acid (18ml) and refluxed for 2h. After cooling, the reaction mixture was poured into ice water and the product was isolated by extraction with ethyl acetate. Evaporation of the solvent and recrystallization of the residue from boiling 1 ethanol (150ml) yielded 26.3g (43.8% yield) of pure, crystalline 6-bromo-4-phenylchroman-2-one, m.p. 117.8 °C, tlc (1) 0.67. NMR (CDCl_3): 36.56, 40.51, 117.29, 118.87, 127.47, 127.89, 128.33, 129.32, 131.07, 131.79, 139.42, 150.76, 166.84.

[0023] A suspension consisting of 6-bromo-4-phenylchroman-2-one (85.0g), anhydrous potassium carbonate (46.7g), sodium iodide (20.5g) and benzyl chloride (40.6g) in methanol (350ml) and acetone (350ml) was refluxed for 3h. After evaporation of the solvents the residue was extracted with diethyl ether (2 x 300ml) and the extract was washed with water (2 x 200ml) and aqueous sodium carbonate. Drying (Na_2SO_4) and rotoevaporation left 121.8g (102.1 % crude yield) of 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropionic acid methyl ester as a light yellow oil, tlc (1) 0.77. NMR (CDCl_3): 39.22, 40.53, 51.63, 70.16, 113.10, 113.77, 126.46, 126.92, 127.88, 128.08, 128.34, 128.45, 130.31, 130.55, 134.41, 136.44, 142.37, 154.94, 172.08.


[0024] A solution of the propionate (121.0g) in 350ml of dry tetrahydrofuran was slowly added under an atmosphere of nitrogen to a suspension of lithium aluminiumhydride (7.9g) in tetrahydrofuran (350ml). After stirring at room temperature for 18h, 20% aqueous HCl was added dropwise and the product was isolated by repeated extraction with diethyl ether. The combined extracts were gradually washed with hydrochloric acid, sodium hydroxide solution, distilled water, and then dried (Na_2SO_4) to give a light yellow viscous oil (108.8g, 96.3% yield) after evaporation which gradually crystallized, m.p. 73.8 °C, tlc (1) 0.47, 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol. NMR (CDCl_3): 37.52, 39.52, 60.84, 70.54, 113.54, 113.83, 126.29, 127.30, 127.51, 129.99, 128.24, 128.38, 129.99, 130.88, 135.69, 136.40, 143.53, 155.12.

[0025] A cooled (5 °C) solution of 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropan-1-ol (108.0g) in dichloromethane (300ml) was treated with pyridine (79.4ml) and then p-toluenesulphonyl chloride (60.6g) in dichloromethane (200ml). After 18h at room temperature the solvent was removed in vacuum and the residue extracted diethyl ether. The extract was washed with hydrochloric acid, water, and dried over anhydrous sodium sulphate to give *toluene-4-sulphonic acid*, 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester as a light yellow oil after concentration under reduced pressure (140.3g, 93.6% yield), tlc (1) 0.66. NMR (CDCl₃): 21.67, 33.67, 39.69, 68.58, 70.28, 113.21, 113.76, 126.47, 127.84, 128.10, 128.25, 128.41, 128.51, 129.81, 130.26, 130.42, 132.91, 134.39, 136.41, 142.16, 155.07.


[0026] A solution of the toluenesulphonate (139.3g) in acetonitrile (230ml) and N,N-diisopropylamine (256g) was refluxed for 97h. The reaction mixture was then evaporated to dryness and the residue thus formed was partitioned between diethyl ether (500ml) and aqueous sodium hydroxide (2M, 240ml). The organic phase was washed twice with water (250ml) and then extracted with 1M sulphuric acid. The aqueous phase was adjusted to about pH 12-13 and reextracted with ether (500ml). The organic phase was washed with water, dried (Na₂SO₄) and evaporated to provide 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl-diisopropylamine as a brown and viscous syrup (94.5g, 77.9% yield), tlc (2) 0.49. NMR (CDCl₃): 20.65, 20.70, 36.70, 41.58, 43.78, 48.77, 70.24, 113.52, 126.02, 127.96, 128.20, 128.36, 129.82, 130.69, 136.34, 136.76, 144.20, 155.15.

[0027] An ethereal Grignard solution, prepared from the above amine (22.8g), ethyl bromide (17.4g) and magnesium (6.1g) under an atmosphere of nitrogen was diluted with dry tetrahydrofuran (200ml) and then cooled to -60 °C. Powdered solid carbon dioxide (ca. 50g) was added in small portions and the green reaction mixture was warmed at room temperature. After the addition of an aqueous solution of ammonium chloride (200ml, 10%) and adjustment of the aqueous phase to pH 0.95, a white solid was recovered by filtration to provide 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)benzoic acid hydrochloride (14.7g, 64.3% yield), m.p. 140 °C (dec.), tlc (2) 0.33. NMR (CD₃OD): 17.07, 18.77, 33.55, 43.27, 56.50, 71.50, 112.89, 124.10, 127.94, 129.07, 129.25, 129.34, 129.59, 129.66, 130.18, 131.60, 132.78, 137.60, 143.30, 161.11, 169.70.

[0028] The hydrochloride was converted into its methyl ester (MeOH, trace sulphuric acid, 6h reflux) and the free base thus obtained (28g) was dissolved in dry diethyl ether (230ml). This solution was slowly (2h) dropped under a nitrogen atmosphere to a suspension of lithium aluminium hydride (1.8g) in ether (140ml). After stirring for 18h, the reaction was quenched by the addition of water (4.7ml). The organic phase was dried over anhydrous sodium sulphate, filtered and evaporated to dryness to provide 4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl-methanol (26g, 98.9% yield), as an oil which gradually crystallized, m.p. 86.4 °C, tlc (2) 0.32, Intermediate A. NMR (CDCl₃): 20.53, 20.61, 36.87, 41.65, 44.14, 48.82, 65.12, 70.09, 111.80, 125.77, 125.97, 126.94, 127.55, 128.08, 128.37, 128.44, 133.27, 134.05, 134.27, 137.21, 144.84.



[0029] A solution of Intermediate A (9.1g) in methanol (100ml) was hydrogenated over Raney-nickel (4.5g) under ambient conditions. After 5h thin layer chromatography indicated complete hydrogenolysis. The catalyst was filtered off and the solution evaporated to dryness to leave an oil (6.95g, 96.5% yield) which gradually solidified, 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol, m.p. 50 °C, tlc (2) 0.15, Intermediate B. NMR (CDCl₃): 19.42, 19.83, 33.22, 39.62, 42.27, 48.27, 65.19, 118.32, 126.23, 126.55, 127.47, 128.33, 132.50, 144.47, 155.38. Hydrochloride: colourless crystals, m.p. 187-190 °C (with decomposition)



(Intermediate B)

3. Examples

a) Phenolic monoesters

aa) General Procedure

[0030] A stirred solution of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenol (Intermediate B, 1.71g, 5.01 mmol) and acid chloride (5.00 mmol carboxylic acid monochloride for compounds of Formula II, 2.50 mmol for compounds of Formula II') in 60 ml of dichloromethane was cooled to 0 °C and then triethylamine (0.502g, 4.96 mmol for compounds of Formula II, 1.05g, 9.92 mmol for compounds of Formula II'), dissolved in 10 ml of dichloromethane, was added dropwise during 5-10 min. Stirring was continued for 18h at room temperature, and then the mixture was washed successively with water (25 ml), aqueous sodium hydrogen carbonate (5%, 25 ml), and water (25 ml). The organic phase was then dried (sodium sulphate) and evaporated under reduced pressure and a low temperature. The oily residues thus formed were finally exposed to high vacuum (2-4 hrs.) to remove traces of residual solvents. The esters of Formula II or II' were obtained as viscous colourless to light yellow syrups in purities between 90% and 99% (tlc, HPLC, NMR).

bb) Salt formation (Example hydrochloride)

[0031] A cooled (0 °C) solution of 4.94 mmol amino base in 30 ml of dry diethyl ether was treated under an atmosphere of nitrogen with 4.70 mmol (monoamines of Formula II) or 9.4 mmol (diamines of Formula II') ethereal (1M) hydrochloric acid. The oily precipitation was washed repeatedly with dry ether and then evaporated in high vacuum. The residual product solidified in most cases as an amorphous foam. The highly hygroscopic solids show a wide melting range above 100 °C (with decomposition).

Acetic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R_f 0.47 (4); NMR ($CDCl_3$): 20.36, 20.68, 20.97, 36.59, 42.35, 43.83, 48.76, 64.58, 122.69, 125.61, 126.22, 126.71, 127.96, 128.34, 136.82, 138.97, 143.73, 147.77, 169.24; GC-MS/P-Cl (ammonia, trimethylsilyl derivative): 456.8 (100%), 398.4 (4%)

Propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R_f 0.52 (4); NMR ($CDCl_3$): 20.44, 20.64, 27.67, 36.67, 42.21, 43.87, 48.78, 64.70, 122.71, 125.62, 126.52, 126.78, 127.97, 128.53, 136.86, 138.82, 143.82, 147.86, 172.68; GC-MS/P-Cl (ammonia, trimethylsilyl derivative): 470.38 (100%), 398.4 (4%)

n-Butyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R_f 0.43 (4); NMR ($CDCl_3$): 13.77, 18.40, 20.43, 20.51, 20.59, 36.15, 36.82, 42.16, 43.90, 48.83; 49.20, 64.58, 122.66, 125.98, 126.17, 126.74, 127.33, 127.94, 128.33, 136.79, 138.91, 143.82, 171.88; GC-MS/N-Cl (methane, trimethylsilyl derivative): 482.3 (20%), 412.3 (100%), 340.1 (33%), 298.1 (89%), 234.7 (15%); GC-MS/P-Cl (methane, trimethylsilyl derivative): 484.5 (100%), 468.4 (62%), 394.3 (22%); GC-MS/P-Cl (ammonia, trimethylsilyl derivative): 484.4 (100%), 398.4 (3%)

Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R_f 0.43(4); NMR ($CDCl_3$): 18.99, 19.11, 20.54, 34.21, 36.88, 41.84, 43.91, 48.78, 64.61, 122.54, 125.57, 126.14, 126.81, 127.94, 128.34, 136.84, 138.84, 143.89, 147.85, 175.36;

2,2-Dimethylpropionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester, R_f 0.49 (1); NMR ($CDCl_3$): 20.46, 20.66, 26.53, 27.34, 37.12, 39.21, 41.46, 43.98, 48.81, 64.65, 122.42, 125.58, 126.16, 126.92,

128.37, 134.27, 136.92, 138.82, 143.97, 148.02, 176.97; ; GC-MS/P-CI (ammonia, trimethylsilyl derivative): 498.8 (100%), 482.5 (10%), 398.4 (4%)

5 *Benzoic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenyl ester*, R_f 0.52 (4); NMR (CDCl₃): 20.42, 20.62, 36.95, 41.72, 42.27, 48.23, 64.83, 122.74, 125.33, 127.36, 127.89, 127.97, 128.38, 129.34, 130.64, 131.15, 131.83, 136.87, 138.90, 143.82, 147.74, 164.77

10 *Malonic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl] ester*, R_f 0.38 (4); NMR (CDCl₃): 20.52, 20.62, 20.69, 36.95, 41.84, 42.82, 43.89, 48.23, 64.83, 123.37, 127.36, 127.97, 128.42, 128.38, 129.06, 131.55, 137.50, 138.90, 148.23, 148.32, 160.54

15 *Succinic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl] ester*, R_f 0.40 (4) NMR (CDCl₃): 20.54, 20.63, 20.73, 30.69, 36.91, 41.80, 43.92, 48.20, 64.81, 122.60, 127.41, 127.93, 128.39, 129.31, 131.80, 136.73, 138.92, 143.82, 148.17, 168.01

Pentanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl] ester, R_f 0.43; NMR (CDCl₃): 20.47, 20.60, 32.87, 36.93, 41.82, 43.90, 48.22, 64.81, 64.83, 122.85, 122.85, 127.39, 127.99, 128.35, 129.31, 131.84, 136.98, 138.94, 143.80, 147.40, 147.40, 169.05

20 *Hexanedioic acid bis-[2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenyl] ester*, R_f 0.43; NMR (CDCl₃): 20.64, 23.40, 34.37, 36.95, 41.84, 43.88, 48.25, 64.87, 122.88, 127.34, 127.97, 128.39, 129.33, 131.80, 136.99, 138.94, 143.82, 147.65, 168.72

b) Identical diesters

25 [0032] Identical diesters (Formula III) were prepared and worked-up as described above with the exception that 2.4 mmol of both triethylamine and acyl chloride (R¹-COCl) were used. The physical properties were similar to the bases and salts described above.

30 *Formic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-formyloxymethylphenyl ester*, R_f 0.65 (4) This diester was prepared from mixed formic acetic anhydride and intermediate B as described for other substrates previously (F: Reber, A. Lardon, T. Reichstein, *Helv. Chim. Acta* 37: 45 - 58 [1954])

35 *Acetic acid 4-acetoxy-3-(3-diisopropylamino-1-phenylpropyl)-benzyl ester*, R_f 0.76 (4); GC-MS/P-CI (ammonia): 426.3 (100%), 368.3 (22%); GO-MS/P-CI (methane, trimethylsilyl derivative): 426.4 (64%), 410.3 (16%), 366.3 (100%); hydrochloride, NMR (DMSO-d₆): 16.50, 16.76, 18.05, 20.94, 21.04, 27.02, 31.39, 41.28, 45.26, 53.80, 65.21, 123.39, 126.84, 127.61, 127.85, 128.70, 134.41, 135.49, 142.68, 148.20, 169.32, 170.42

40 *Propionic acid 2-(3-diisopropylamino-1-phenylpropyl)-4-propionyloxymethylphenyl ester*, R_f 0.82 (4); NMR (CDCl₃): 20.53, 20.73, 21.14, 27.66, 36.73, 42.10, 43.68, 48.65, 65.75, 122.65, 126.10, 127.01, 127.70, 128.34, 128.78, 133.73, 136.81, 143.76, 148.45, 172.45, 174.21; ; GO-MS/P-CI (ammonia): 454.8 (100%), 438.5 (9%), 382.4 (27%)

45 *n-Butyric acid 4-n-butyryloxymethyl-2-(3-diisopropylamino-1-phenylpropyl)-phenyl ester*, R_f 0.86 (4); NMR (CDCl₃): 13.70, 13.76, 18.44, 20.53, 20.69, 21.13, 36.14, 36.76, 37.09, 42.08, 43.73, 48.71, 65.64, 122.81, 125.97, 126.97, 127.92, 128.35, 128.77, 133.78, 136.99, 143.76, 148.41, 171.68, 173.40; ; GC-MS/P-CI (ammonia): 482.8 (100%), 396.4 (67%)

50 *Isobutyric acid 2-(3-diisopropylamino-1-phenylpropyl)-4-isobutyryloxymethylphenyl ester*, R_f 0.83 (4); NMR (CDCl₃): 18.97, 19.10, 20.64, 20.67, 34.01, 34.23, 36.98, 41.72, 43.70, 48.65, 65.61, 122.50, 126.18, 126.73, 127.92, 128.13, 128.36, 133.90, 137.01, 143.85, 148.41, 175.17, 176.81; GC-MS/N-CI (methane): 480.3 (15%); GC-MS/P-CI (methane): 482.5 (63%), 466.4 (18%), 394.3 (100%)

55 *2,2-Dimethylpropionic acid 3-(3-diisopropylamino-1-phenylpropyl)-4-(2,2-dimethylpropionyloxy)-benzyl ester*, R_f 0.96 (4); NMR (CDCl₃): 20.44, 20.75, 27.09, 27.24, 37.18, 38.68, 39.15, 41.25, 43.66, 48.20, 65.50, 122.36, 126.32, 127.22, 127.48, 127.83, 128.29, 133.99, 136.98, 143.87, 148.37, 176.70, 178.10; GC-MS/P-CI (methane): 510.5 (76%), 494.5 (21%), 408.4 (100%)